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 i 
Abstract 
This thesis is focussed on developing new methods and outcomes to assess respiratory 
function that require little or no volitional effort on behalf of the participants being 
tested. Specifically to attempt to detach the behaviour of the patient from the accuracy 
of the test of respiratory function, resulting in techniques that are simpler and easier to 
administer and undertake for both assessor and participant. It aims to develop methods 
that reduce the involvement of the participant during assessment of respiratory 
function. The human body’s way of controlling respiration has evolved into a 
sophisticated system that optimises breathing pattern to maintain the most efficient 
homeostatic action of the respiratory system. Eliciting and assessing this automatic 
response is the key to removing the action of participation from respiratory function 
testing. The focus must therefore be on developing non-invasive, sub-maximal 
techniques that allow participants to enter into a steady state of respiration and how 
this can be assessed. 
 
Two techniques were investigated; Respiratory Endurance (as the inspiratory work of 
breathing) and Tidal Breathing Flow Profile, and these were successfully applied in 
99 adult participants (68 healthy controls and 31 COPD patients) and 75 children (48 
clinical group and 27 healthy controls) who completed 467 respiratory endurance 
trials whilst seated and exercising, and 249 relaxed tidal breathing trials. 
 
The difficulties with lung function assessment are well established and have been 
described in this thesis. Much recent emphasis has been put on developing existing 
devices and protocols rather than developing new techniques and approaching these 
difficulties from alternative viewpoints. This thesis has described the development of 
innovative techniques to assess the function of the respiratory systems that aim to 
overcome the issues associated with maximal testing. It was shown that these 
techniques are easy to undertake for a range of participants, simple to analyse and are 
able to reliably differentiate between health and disease, suggesting that they could 
become a useful adjunct to existing methods of respiratory assessment 
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Chapter 1 - Introduction 
1.0 Study Aims and Overview 
1.1 Structure and Function of the Lungs 
1.2 Control and Regulation of Ventilation 
1.3  Muscles of Respiration 
1.4 Respiratory Homeostasis 
1.5 Existing Techniques to Assess Respiratory Function 
1.6 Issues Affecting Respiratory Function Testing 
1.7 Initial Research Focus 
1.8 Respiratory Muscle Testing 
1.9 Fatigue Versus Endurance 
1.10 Maximal Versus Sub-maximal 
1.11 Invasive Versus Non-Invasive 
1.12 Work of Breathing 
1.13 Development of Research Question(s) 
 
1.0  Study Aims and Overview 
Breathing is truly a strange phenomenon of life, caught midway between the 
conscious and unconscious (Richards 1957) and is reactive to voluntary and 
involuntary control, making assessment of the respiratory system a complex task. 
The function of the respiratory system can be assessed using a variety of methods that 
represent the functional capability as part of the overall physiological status of an 
individual. Nowhere else in medicine does the patient need to be considered, whole 
and entire, as in the field of respiration (Richards 1957). The ability to measure 
respiratory function parameters has been available for clinical use for approximately 
the last 40 years (ARTP 2006), yet the respiratory muscles and the mechanics of 
breathing have engaged the interest of the great anatomists and physicians (Rankin & 
Dempsey 1967) from the time of Galen, da Vinci and beyond (Fig 1.1). 
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Fig 1.1: The Internal Organs – Leonardo da Vinci 
The incidence of respiratory disorders due to degenerative muscle conditions, obesity 
and lung diseases such as Chronic Obstructive Pulmonary Disease (COPD), asthma 
and chronic bronchitis is gradually increasing in the modern world (Ratnovsky et al 
2008). The use of suitable measures of respiratory function is therefore important not 
only for the clinical treatment of patients, but to also accurately assess disease 
prevalence which in turn informs healthcare policy. Existing methods such as 
spirometry have been the focus of much attention and research, and are now 
established as ‘gold standard’ measurements and rightly so. This thesis does not 
contend that this should not be the case, or that other more suitable techniques exist. 
However it is proposed that in certain circumstances and situations, principally when 
these existing methods cannot be correctly employed, that there exists a potential for 
new techniques to be developed to overcome such situations so that respiratory 
function can be adequately assessed. 
 
Unlike other techniques which measure other physiological functions such as blood 
pressure or ECG, the majority of respiratory measurements rely on substantial levels 
of volitional cooperation from a participant to attain acceptable results. Even with a 
highly experienced respiratory physiologist with correctly functioning and calibrated 
equipment, without the cooperation of the participant to follow instruction, a correct 
result will not be achieved. It may be argued that it is the skill of the respiratory 
physiologist to overcome any reluctance to participate by a patient and that therefore 
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correct technique can always be achieved. Calverley (2009) describes spirometry as 
‘in many senses effort independent, providing the subject makes a reasonable 
attempt’. In essence Calverley is suggesting that spirometry is effort independent as 
long as a participant tries hard enough, which is a misnomer. This encapsulates the 
major issue with respiratory measurement in that many who practice it expect 
everyone participating to 1) want to undertake it and 2) try to complete it as well as 
possible. While they may agree to the former they may not, or cannot, do the latter. 
 
While most children above the age of 7–8 yrs can successfully complete the 
respiratory function tests available for adults, assessing younger children is more 
involved, due to the lack of suitable equipment and the complexity of undertaking 
such measurements (Merkus et al 2005), although it has been shown that even pre-
school children are able to successfully complete spirometry (Eigen et al 2001). 
Techniques to improve the feasibility of respiratory function testing in children 
include creating a playful environment, adaptation to a shorter attention span and 
‘considerable patience’ (Gappa et al 2006). Again, while it can be argued that with 
sufficient training, practice and time, accurate and reliable results can be performed, 
this is so that full cooperation can be obtained, not that accurate results can be 
achieved without it. The natural extension to this argument is to the example of 
infants, where many standard respiratory function tests cannot be undertaken as they 
cannot follow instruction. This indicates that above all, full cooperation is vital for 
correct and accurate completion of standard respiratory function tests.  
 
It is not just children where there may be issues with successfully completing 
respiratory tests. Groups such as the elderly, individuals with learning disabilities or 
chest disease patients experiencing acute exacerbations of their symptoms, may 
struggle to follow instruction and may also not be able to always complete specific 
respiratory tests. Indeed patients may be less coordinated and motivated than healthy 
subjects (Romer & McConnell 2004). 
 
Furthermore respiratory measurement also involves considerable effort, Enright & 
Lehman (2009) describe how most ‘diagnostic tests require little or no maximal 
activity by a patient in order to obtain good quality results, conversely spirometry  
requires a rapid sequence of three unusually athletic-type breathing manoeuvres’. 
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Accurate assessment of maximal inspiratory pressure (MIP) can require up to 20 
repeated maximal tests (Wen et al 1997). What other forms of human diagnostic 
testing require such repetition and maximal effort on behalf of the participant as that 
associated with respiratory testing? 
 
This thesis is focussed on developing new methods and outcomes to assess respiratory 
function that require little or no volitional effort on behalf of the participants being 
tested. Specifically to attempt to detach the behaviour of the patient from the accuracy 
of the test of respiratory function, resulting in techniques that are simpler and easier to 
administer and undertake for both tester and participant. 
 
Chapter 1 reviews how breathing is regulated, describes the respiratory muscles and 
outlines approaches to measuring respiratory function. 
Chapter 2 syntheses the existing literature in relation to Respiratory Endurance and 
Tidal Breathing Profile Analysis (TBPA) 
Chapter 3 describes the methodology used in subsequent chapters 
Chapter 4 outlines the development of a 6-minute protocol to assess Respiratory 
Endurance  
Chapter 5 tests the repeatability and reliability of these measures of Respiratory 
Endurance and TBPA 
Chapter 6 assesses how measures of Respiratory Endurance react during exercise 
Chapter 7 measures Respiratory Endurance and TBPA in COPD  
Chapter 8 measures Respiratory Endurance and TBPA in Children 
Chapter 9 outlines a new method of resistive load detection in health and disease 
Chapter 10 summarises the work in this thesis 
Chapter 11 provides a conclusion to the work in this thesis and future directions of 
research. 
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1.1  Structure and Function of the Respiratory System 
The principal function of the human respiratory system is the exchange of the 
respiratory gases O2 and CO2, which maintains adequate levels of O2 in the arterial 
blood so that the metabolic demands of the body can be met (Braman 1995). This 
process can be described as ventilation  The respiratory system (Fig 1.2) consists of 
the lungs, airways, chest wall, respiratory muscles and rib cage, and the parts of the 
central nervous system that regulate breathing (Cloutier 2007). 
 
The lungs, located within the thoracic cage, are the organs of ventilation where the 
exchange of gas takes place. Ventilation consists of rhythmic changes in lung volume 
and during spontaneous breathing the lungs passively follow the changes in the 
contours of the thorax produced by the contraction of the respiratory muscles (Nunn 
1993). Breathing, like cardiac activity must be sustained at an adequate level to meet 
the demands placed upon it throughout life (Celli 1989). 
 
 
Figure 1.2: Structure of the lungs (downloaded 
www.northhertsradiologygroup.co.uk) 
 
The movement of gas in and out of the lungs, or ventilation, is performed by the 
respiratory muscles (Ratnovsky et al 2008) which generate a pressure gradient so that 
on contraction of the inspiratory muscles, a negative pressure is generated and gas 
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flows into the lungs. During exhalation the inspiratory muscles relax, the pressure 
inside the chest and airways increases and gas flows passively out of the lungs (Fig 
1.3). To promote the flow of gas the architecture of the respiratory tree is such that air 
flows with very little resistance, although this can be increased in many disease states 
(Zechman et al 1957).The respiratory muscles therefore perform the crucial function 
of sustaining ventilation (Moxham 2000) by generating the pressure gradient 
necessary for the movement of gas. 
 
 
Fig 1.3: Respiration (Copyright Encyclopaedia Britannica 2006) 
 
As ventilation of the lungs eliminates CO2 from the body and promotes the addition of 
O2 to the blood it thereby controls the partial pressures of O2 (PaO2) and CO2 (PaCO2) 
as well as the pH of arterial blood. When the respiratory system is disrupted by a 
change in PaO2 or PaCO2, the change is sensed by receptors resulting in a change in 
the breathing pattern to maintain homeostasis (Braman 1995). The control of 
breathing, while able to be temporarily overcome by conscious control for example 
breath holding or when talking or singing, is a powerful automatic mechanism that 
will take ultimately involuntary control to preserve homeostasis (Section 1.5).  
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1.2  Control and Regulation of Ventilation 
Although breathing is a rhythmic process with no intrinsic driving system, respiration 
requires external neural drive to maintain adequate ventilation. Ventilation is 
regulated by the levels of CO2 and O2 and the pH of the blood and has been reviewed 
fully elsewhere (Braman 1995), and can be summarised as comprising of three 
components; the control centre; the sensors; and the effectors organs (Fig 1.4). Like 
every control system it needs various components for it to function control, these 
include a control variable, a desired value for that variable, a measured value for that 
variable, sensors to detect the measured variable, effectors to change the system to 
maintain the desired variable and a control system. Both the rate and depth of 
breathing are controlled to maintain PaCO2 close to 40mmHg, even during periods of 
activity, rest or sleep, arterial PaCO2 is held at 40 ±2-3mmHg (Cloutier 2007).  
 
Figure 1.4: The Control of Respiration 
 
The respiratory control centres are located in several areas of the brainstem, the most 
important being the medulla oblongata where respiratory rhythm originates (Nunn 
1993). The rhythmicity is generated within specific areas of the medulla oblongata, 
the dorsal respiratory group (DRG), ventral respiratory group (VRG) and Botzinger 
complex. Neurons in the cerebral cortex also contribute and can override the 
automatic control system for voluntary respiratory efforts such as breath holding 
(Braman 1995) although these can only be sustained for short periods of time. 
 
The sensors that control breathing consist of chemoreceptor’s (central and peripheral) 
and the mechanoreceptors which all function to maintain homeostatic levels of arterial 
PaO2 and PaCO2. Central chemoreceptor’s in the medulla oblongata react to changes 
in CO2 and pH in the cerebrospinal fluid (CSF), whereas peripheral chemoreceptor’s 
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in the aortic arch respond to changes in O2, CO2 and pH (Richardson 2003). The 
mechanoreceptors are located within the airways and chest wall such as within the 
intercostal muscles and diaphragm and give protective reflexes affecting 
bronchomotor tone. Of these sensors it is the central chemoreceptors that are the most 
important stimulus of breathing, detecting change in the CSF by way of hydrogen ion 
concentration due to increases in PaCO2. Ventilation increases almost linearly with 
changes in hydrogen ion concentration thus CO2 in the blood regulates breathing by 
way of its effect on the pH of the CSF fluid (Cloutier 2007). Changes in arterial pH 
take longer to influence the CSF as the hydrogen ions cross the blood brain barrier too 
slowly to affect the central chemoreceptors. 
1.3  Muscles of Respiration 
Ventilation requires a coordination of the respiratory muscles which create change in 
the shape of the thoracic cage creating the necessary pressure gradient so that gas 
moves in and out of the lungs. While the complexity of some of the movements and 
muscle insertions is such that the mechanical action of individual muscles can hardly 
be determined with precision (Rankin & Dempsey 1967), the respiratory muscles can 
be divided into two groups. Those that are active on inspiration, performing most of 
the work of breathing at rest, and the expiratory muscles which are largely inactive 
only being used when exhalation becomes active such as during exercise or other 
situations when the ventilatory system is stressed (Celli 1989). Many of the 
respiratory muscles are involved in other motor functions, including coughing, 
sneezing, retching swallowing and postural adjustments of the trunk and chest wall 
(Rowley et al 2005). 
 
The respiratory muscles can be broadly categorised as a ventilatory pump and are 
centred around the diaphragm (Celli 1989), the dome shaped skeletal muscle that 
contracts downwards and outwards like a piston increasing the size of the thoracic 
cavity (ARTP 2006) creating the negative pressure gradient required for inspiration. 
The respiratory muscles are skeletal muscles and ability of the force of contraction 
increases on being stretched and decreases on being shortened, thus the force of 
contraction increases with increasing lung volume (Cloutier 2007). As diaphragmatic 
function becomes compromised, such as when ventilation or resistance to breathing is 
increased, additional inspiratory muscles and eventually expiratory muscles are 
recruited to provide the work of breathing (Nunn 1993). 
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The diaphragm is the most important inspiratory muscle, with motor innervations 
solely from Phrenic nerves (C3, 4, 5) (Nunn 1993). Like other skeletal muscle it is 
composed of three fibre types and corresponding motor types which vary in their 
physiological and histochemical properties, slow twitch, fast twitch oxidative and fast 
twitch glycolytic, with an obvious trade off with sustained increased ventilatory effort 
and fatigue susceptibility of fast twitch motor units. Therefore it is not only important 
to determine maximal strength of respiratory muscle but also the endurance 
capabilities (Belman & Sieck 1982B). It has been shown that the diaphragm is able to 
remodel in response to chronic overload, consisting of fibre type transfer and 
increased oxidative capacity (Dempsey 2006A).The accessory muscles of respiration 
include the Intercostals, abdominal muscles, Scalenes and Sternocleidomastoids 
(Rankin et al 1967; Ratnovsky et al 2008). 
1.4  Respiratory Homeostasis 
Homeostasis is the physiological process by which the human body maintains the 
internal systems of the body in equilibrium despite variations in external conditions 
(Martin 2004). As discussed previously (Section 1.3) the control of breathing has 
evolved into a highly sophisticated, negative feedback system which is able to 
accurately match the level of ventilation with the requirements of the body. 
Individuals appear to select one particular breathing pattern among the infinite 
number of possible combinations of ventilatory variables and airflow profiles 
(Benchetrit 2000) that enables the work of breathing to be minimised (Cloutier 2007). 
This process is an automatic unconscious one, in that when left alone individuals will 
find the most efficient breathing pattern for the ventilation level required. Even with 
additional stress or loads if these are not immediately fatiguing and remain constant 
the respiratory control system will adopt the most efficient pattern of breathing to 
accommodate. Although in healthy subjects the pattern of breathing can vary they can 
be approximately described as normal values (Fig 1.5). 
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Table 1.1: Normal Breathing Patterns -Values of Healthy Individuals (adapted 
from Cloutier 2007 
Parameter Value 
Respiratory Rate - fR 12 (bpm-1) 
Tidal Volume – VT 0.5 (L-1) 
Minute Ventilation - EV = fR x VT 0.5 x 12 = 6(L.min
-1) 
Total Lung Capacity – TLC 6 (L) 
 
1.5  Existing Techniques to Assess Respiratory Function 
Respiratory function measurements are made to obtain objective information about 
the health and structure of the airways and/or lungs. Many standard techniques exist 
that assess respiratory function and are used to quantify the health and ability of the 
lungs (BTS 1994). The assessment of respiratory function is now a routine part of 
clinical practice with many specialised laboratories in the UK with international 
guidelines being established for the standardisation of spirometry (Miller et al 2005). 
Clinically, forced expiratory volumes measured with spirometry (Section 3.4) is the 
key tool in lung function testing (Miller 2009) and can be used to differentiate 
between health and disease, and to assess disease severity (Section 7.1) 
  
Methods of testing the respiratory system are invaluable as screening tests of general 
respiratory health in the same way that blood pressure provides important information 
about general cardiovascular health (Miller et al 2005) and for the use in clinical 
management of respiratory disease. For example spirometry is used within 
international guidelines to assess disease severity such as those for COPD (Gomez 
2002) and subsequent onset of medical treatment. 
1.5.1  Spirometry 
Spirometry is the most commonly performed respiratory function test, although alone 
it cannot define the full extent of respiratory disease (ARTP 2006). Originally 
assessed using water sealed spirometers that can be precisely calibrated by the 
displacement of water (Nunn 1993) modern versions of the device use sophisticated 
electronics to integrate air flow with time to give lung volumes. Spirometry involves 
making a series of maximal manoeuvres (normally 3) that reflect a complex, dynamic 
relationship between patient effort, muscle strength, compliance and elastic recoil of 
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the lungs as well as airway resistance. Standard pulmonary function tests such as 
spirometry and static lung volumes require a certain level of respiratory muscle 
strength (Rochester 1988) and coordination to be completed successfully. 
1.5.2  Maximal Static Pressures 
The assessment of maximal pressures has been reviewed elsewhere (Black & Hyatt 
1969), and are used to represent the strength of the respiratory muscles. In clinical 
practice respiratory muscle force is indirectly measured through the pressure 
generated at the mouth during inspiration (MIP or PI,max) or expiration (MEP or 
PE,max) and is expressed as kilopascal (kPa) or cm water (cmH2O) (1 kPa=10.2cm 
H2O) and represent pressure changes generated against atmospheric pressure 
(Troosters et al 2005). Up to twenty attempts may be needed to obtain an acceptable 
result although a respiratory warm up may reduce MIP variability (Volianitis et al 
2001), reducing the need for so many attempts. Furthermore because maximum 
respiratory pressures are indices of maximal strength they are highly effort 
independent and require well-motivated participants (McConnell 2007). MIP tests are 
tiring and subjects should be allowed several minutes rest between maximal efforts, 
despite careful coaching some subjects simply are unable to coordinate adequately to 
perform MIP and MEP manoeuvres (Rochester 1988). 
1.6  Issues Affecting Respiratory Function Testing 
When completed correctly spirometry is the gold standard method for assessing 
respiratory function. The main issue when assessing respiratory function is that of 
error in the result. This is important as results obtained are used to inform clinical 
decisions or act as key outcomes in research studies. Reducing or removal of the error 
is the key aim in maintaining the accuracy of respiratory measurement. Sources of 
error can include: 
1.6.1  Equipment 
Accurate measurement and assessment of respiratory function can require expensive, 
highly technical equipment that does not react well to being moved. More portable 
devices have been developed but there can be a decrease in accuracy. Respiratory 
devices like all diagnostic equipment require frequent calibration to maintain 
accuracy. 
1.6.2  Staff 
Fully trained and experienced clinical respiratory physiologists are required to 
conduct testing to gain accurate results. Individuals that only occasionally conduct 
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respiratory assessments will not have the same level of expertise or experience as 
those working in specialist centres performing testing on a regular basis. 
1.6.3  Environment 
The need for highly specialised centres means that most respiratory function testing is 
centred on units based in large hospitals. Testing away from these sites with 
equipment and staff, can mean accuracy falls. Wensley & Silverman (2001) report a 
steady decrease in spirometric values made at home in asthmatic children even over a 
relatively short 4 week period. Other studies of peak expiratory flow again in 
asthmatic children have found that many of the home recordings were in fact ‘self-
invented’ i.e. not blown  but a value recorded anyway in a diary (Kamps et al 2001). 
1.6.4  Participant  
As has already been argued (Section 1.1) it is the participant that has the biggest effect 
on sources of error, principally because the individual conducting the test has no 
direct control over the actions of the participant. There is also a learning effect that 
accompanies all volitional tests of respiratory function (Eastwood et al 1998). 
1.7  Initial Research Focus 
The focus of this thesis is to develop new methods of assessing respiratory function 
that can reduce the influence of patient behaviour that can affect test outcome. While 
this cannot totally be removed; participants must still consent to take part/ breathe 
through a device for example, it is the removal of active participation which is the 
goal, much like other diagnostic tests such as blood pressure or an ECG for example. 
 
This thesis aims to find a new way of assessing respiratory function based around 
existing work on expiratory flow profiles (Colsanti et al 2004) as a review of the 
literature (Section 2.3) suggests that this may be a way of assessing respiratory 
function without the need for full participation in respiratory manoeuvres. 
 
Additionally this thesis will focus on testing of the endurance of the respiratory 
system. As breathing is a continuous process, measures of respiratory strength (MIP) 
appear inappropriate for assessing endurance, provoking the question what is 
respiratory endurance  and can techniques be developed that accurately measure it? 
These aims can be addressed as part of two themes:  
1) The Participant: How well do participants complete any new methods?  
2) The Test: How well do these new methods represent respiratory function? 
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1.8  Respiratory Muscle Testing 
Over the last twenty years efforts have been made to develop techniques to assess 
respiratory muscle function (ATS 2002A) however the ability to evaluate the 
respiratory muscles is limited because of their inaccessibility (Clanton & Diaz 1995) 
making them difficult to assess, and the techniques employed are still relatively 
primitive (Nava 1998). All-inclusive functions of the respiratory muscles is an 
important index in diagnosis and follow up treatment of breathing problems, due to 
respiratory weakness (Ratnovsky et al 2008). 
 
Previously, measures of respiratory function have been indirectly used to assess the 
respiratory muscles on the basis that some indices are affected in part by the 
respiratory muscles (Romer & McConnell 2004). However unlike lung function 
which can be predicted with reasonable accuracy on the basis of stature, gender and 
age, (Coates 1993) respiratory muscle function shows much less predictability, 
making one-off measurements largely meaningless unless there is underlying gross 
weakness (McConnell 2007). 
 
With few exceptions respiratory muscle function testing involves the whole 
respiratory pump system (Celli 1989). At advanced stages of obstructive airway 
disease, thoracic resistive diseases or neuromuscular disorders, respiratory failure may 
occur due to either, increasing the work of breathing beyond the muscle endurance 
capacity or a weakening of the muscle that cannot sustain the work of normal, quiet 
breathing (Ratnovsky et al 2008). Failure of the lung parenchyma leads to 
hypoxaemia, although acute hypercapnia may ensue if there insufficient functioning 
gas exchange tissue to eliminate CO2. Failure of the ventilatory pump and in 
particular a dysfunction of the respiratory muscles leads to hypercapnic respiratory 
failure (Nava 1998). Failure of the respiratory muscles can also lead to dyspnoea1. 
1.8.1  Respiratory Muscle Strength 
Not only is there a wide natural variation in muscle strength between individuals 
(Moxham 2000), there is also a much greater degree of intra subject variability in 
maximal respiratory pressures than in other pulmonary function tests (Rochester 
                                               
1 As the spelling of dyspnea/dyspnoea varies due to the American/British origin of an author I will use 
irrespective of the original spelling the British version ‘Dyspnoea’ as given in the Oxford Concise 
Medical Dictionary (Martin 2004) 
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1988). Respiratory muscle strength can be assessed using pressure measurement at the 
mouth although this only estimates global performance of respiratory muscles 
(Ratnovsky et al 2008). However these maximal respiratory muscle pressures can also 
be recorded within the pleural and abdominal cavities with balloon catheters inserted 
via the nose and the pharynx into the oesophagus for pleural pressure and into the 
stomach for abdominal pressure (Rochester 1988) although invasive testing has 
inherent risks (Section 1.12). Strength is determined by muscle fibre density, the 
pattern of innervation, the pre contraction length and the velocity of muscle fibre 
shortening. Endurance depends on all these properties but also upon other properties 
such as mitochondrial mass, myoglobin content, capillary density, arterial 
oxygenation and the level of cardiovascular fitness (Aldrich 1985). 
1.8.2  Respiratory Muscle Endurance 
Though in normal humans there are only a few occasions when the reserve of 
respiratory muscle function is utilised sufficiently to cause fatigue, there are certain 
groups of patients where the endurance properties of the respiratory muscles may be 
critical to survival or necessary for adequate exercise tolerance (Clanton 1995). With 
the increased use of pulmonary rehabilitation programmes it is necessary to monitor 
endurance performance rather than strength and valid measures of endurance are 
needed to assess the outcomes of such interventions (Powell & Williams 2009).  
Despite intense investigation the importance of respiratory muscle endurance in the 
failing patient or the obstructed patient during exercise is still relatively inadequate, 
just as important are the development of better techniques for evaluating respiratory 
muscle endurance and work capacity in chest disease patients (Clanton 1995).  
1.9  Fatigue Versus Endurance 
Endurance is a term that when applied to skeletal muscle is synonymous with 
resistance to fatigue (Clanton 1995). To be explicit, endurance and fatigue do not 
represent the same concept and to use the terms in this way is incorrect.  
 
Failure or fatigue is a definite point that can be easily identified and measured. 
Respiratory muscle fatigue can be described as occurring when respiratory endurance 
is exceeded (Nava 1998).  The inability to sustain adequate ventilation at rest is an 
extreme example of respiratory muscle fatigue (Belman & Sieck 1982B).  
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Muscle endurance is the ability to sustain a specific muscular task over time (ATS 
2002A). The undefined time component is the most important aspect as, unlike 
exercise endurance which when exceeded merely results in the cessation of the 
exercise, exceeding respiratory endurance resulting in fatigue can result in the 
cessation of breathing.  
 
Therefore in the context of respiration, respiratory endurance refers to the ability of 
the respiratory muscles to sustain respiration indefinitely. The use of ambiguous terms 
such as fatigability (Belman & Sieck 1982B) can been seen in the wider literature and 
makes the differential between endurance and fatigue difficult. In those articles 
identified in the literature synthesis (Section 2.2.5) that attempt to make a definition, 
endurance is often framed as a property that affords resistance to fatigue. 
 
Although they appear related, endurance cannot be accurately predicted from 
estimates of maximal ventilatory pressures, capacity or strength (ATS 2002 A). 
Endurance should be viewed as a continuous ongoing process, whereas fatigue is the 
definite point when the ability to endure has failed. Endurance (from the Latin duro or 
durare - to make hard, last out, to survive) is best defined as the ability to resist 
fatigue or exhaustion (from fatigo or fatigaio – to weary, tire or to be overcome) 
(Morwood 1994). The two terms are not interchangeable. 
1.10  Maximal Versus Sub-Maximal / Incremental Versus Constant 
While a measure of fatigue provides valuable information about an individual’s 
maximum capacity, it does not measure the clinically important ability of the 
respiratory system to endure sub-maximal loads such as those experienced during the 
physical activities of daily life. In terms of physical exercise testing, within the latest 
ATS/ACCP statement on cardio respiratory testing it states ‘while incremental 
protocols are widely used in clinical practice, constant work rate protocols are gaining 
popularity because of their clinical ability, particularly for assessing response to 
therapy and other interventions’ (ATS/ACCP 2003).  
 
To assess the endurance of the respiratory system, constant loading of the respiratory 
muscles may be more appropriate since pathologies such as airway narrowing or 
obstruction, chest wall restriction, or muscle weakness are constant rather than 
progressing ‘loads’ (Rohrbach et al. 2003). While breathing against a resistance, 
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mechanisms of load compensation induce adaptations in the pattern of breathing 
proportional to the applied load (Calabrese et al. 1998) and these changes act to 
maintain ventilation at the most optimum or efficient level (Zechman et al. 1957).  
 
Incremental tasks reflect the strength rather than the endurance of the respiratory 
muscles (Eastwood et al. 1994). Completing a test to fatigue/exhaustion will result in 
a participant being unable to achieve a level of optimum efficiency as they will have 
to continually adapt to the increased load being placed upon them. They will feel a 
significant level of distress and discomfort and it requires a high degree of co-
operation to reach such a maximal point. 
 
Such maximal tests are volitional in nature, requiring participant motivation, which 
make it difficult to establish whether it is a respiratory impairment or inadequate 
effort that is responsible for poor test performance (Moxham 2000). Sustained and 
incremental load protocols define the point of respiratory fatigue/exhaustion when a 
participant can no longer continue. This is not a measure of respiratory endurance. 
Endurance assessment protocols that allow participants to adapt to the most efficient 
homeostatic breathing response would represent the best measure of endurance.  
1.11  Invasive Versus Non-Invasive Testing 
Any form of invasive testing involves some form of inherent risk to the patient. It 
requires a ‘step-up’ in terms of clinical environment, equipment and personnel 
required to safely undertake procedures. In addition invasive techniques require a 
fully cooperative and willing subject. Measurement of oesophageal and gastric 
pressures aid the study of diaphragm, although these remain a research tool (Celli 
1989) perhaps due to their unsuitability for widespread use in clinical practice. Direct 
measurements of respiratory muscle activity are still considered basic physiology and 
are not utilised in clinical settings (Ratnovsky et al 2008). 
 
As a key aim of this thesis is on developing new methods of assessing respiratory 
function that require little or no volitional effort on behalf of the participants, invasive 
testing methods would be contrary to this. Furthermore if any new methods are to be 
developed an additional aim would be to use them in the sub-clinical and home 
environment where it would be inappropriate to undertake protocols that incorporate 
some form of invasive procedure. 
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1.12  Work2 of Breathing 
During inspiration the muscles of breathing work against three main types of forces; 
1) the elastic forces developed in the tissues of the lung and thorax when volume 
change occurs; 2) flow resistive forces that depend on frictional resistance to airflow; 
and 3) inertial forces which depend on the mass and acceleration of tissues and gases 
(Rankin & Dempsey 1967). Work of breathing is the change in volume times the 
pressure exerted across the respiratory system and is composed of elastic and non 
elastic components, and is elevated in individuals with chronic pulmonary disease 
(Cloutier 2007).  
 
When expiration is passive during quiet breathing, the work of breathing is performed 
entirely by the inspiratory muscles. Approximately half of this work is dissipated 
during inspiration as heat in overcoming frictional forces opposing inspiration, the 
other half stored as potential energy in the deformed elastic tissues of lung and chest 
wall (Nunn 1993). Inspiratory work is consistently larger than expiratory work; with 
the inspiratory muscles developing a higher rate of flow and therefore a higher 
pressure that accounts for the additional work during inspiration (Cain & Otis 1949). 
Patients with severe COPD must expend many times more energy to breathe than 
normal subjects, even at rest their respiratory muscles must work harder than normal 
in order to compensate for airway obstruction present (Aldrich 1985). 
 
Work of breathing may be studied by measuring either the total energy required by 
the respiratory muscles or the mechanical work done by them (Rankin & Dempsey 
1967). The complete assessment of the work of breathing is complex as quantifying 
movement and distortions of the chest wall are difficult to quantify and as such work 
of breathing measured at the mouth is not a direct measure of the work of breathing. 
However ‘measuring the work performed against an external load can provide 
sufficient information for purposes of respiratory endurance testing’ (ATS 2002 A). 
                                               
2 Work of breathing is equal to the product of the mean volume and the mean change in pressure 
whereas power is a measure of the rate at which work is being performed. The term work of breathing 
is widely used but power is the correct term (Nunn 1993 Pp124) 
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1.13 Summary & Development of Research question(s) 
 
 
This thesis aims to develop methods that reduce the involvement of the participant 
during assessment of respiratory function. While using invasive techniques may be 
able to accomplish this, by their very nature they do not lend themselves to 
widespread use, with the inherent problems of invasive procedures and do not match 
with the simple approach to respiratory measurement set out at the start of this thesis 
(Section 1.1). The human body’s way of controlling respiration has evolved into a 
sophisticated system that optimises breathing pattern to maintain the most efficient 
homeostatic action of the respiratory system. Eliciting and assessing this automatic 
response is the key to removing the action of participation from respiratory function 
testing.  The focus must therefore be on developing non-invasive, sub-maximal 
techniques that allow participants to enter into a steady state of respiration and how 
this can be assessed. 
 
Therefore the initial research questions are: 
1. Using the concept of endurance as being a constant function, can respiratory 
endurance be accurately measured? Specifically what other techniques have been 
 In Summary……. 
In this chapter I described and summarised the respiratory system and the concepts of respiratory 
endurance and fatigue. 
The Participant 
 The human respiratory system will always if allowed, adopt the most efficient breathing 
pattern for the work imposed upon it. 
 Full cooperation from a motivated participant is required to successfully complete most 
respiratory tests. 
 Not all participants can successfully complete all standard lung function tests. 
The Test 
 Endurance and fatigue are individual concepts that cannot be used interchangeably. 
 Fatiguing test protocols cannot measure respiratory endurance. 
 Using the homeostatic response of the breathing control system can allow resting 
breathing patterns to be achieved. 
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described to assess respiratory muscle endurance and do they follow the concept of 
endurance as a constant sub-maximal state? 
2. Can the work of Colsanti et al (2004) be used as a sub-maximal technique to 
accurately predict lung volumes, specifically FEV1? 
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Chapter 2 - Review of the Literature 
 
2.0  Introduction and Overview 
2.1  Conceptual Framework for Research Synthesis Process. 
2.2  Review of Respiratory Muscle Endurance (RME) 
2.3  Review of Peak Tidal Expiratory Flow (PTEF) Measurement 
2.4  Summary & Conclusions 
 
2.0  Introduction and Overview 
This chapter reviews the literature in relation to respiratory endurance assessment and 
tidal breathing profile analysis that form the general focus of the thesis, the sub-
maximal, non-invasive assessment of respiratory function. It begins with an overview 
of the syntheses of the literature and the conceptual framework behind it. The first 
section (2.2) details a review of non-invasive techniques available for measuring 
Respiratory Muscle Endurance (RME). The second section (2.3) reviews the 
technique of using tidal breathing airflow profile to predict FEV1 called Tidal 
Breathing Profile Analysis – TBPA (described later in section 3.2). TBPA has been 
developed by only one group (Colsanti et al 2004), the review of the literature for this 
topic therefore looks at the basis of generating the airflow data and the main 
parameter calculated, Peak Tidal Expiratory Flow (PTEF). These results are then 
summarised and used to inform the future work of the thesis.  
2.1  Conceptual Framework for Research Synthesis Process. 
Research is rarely conducted in an intellectual vacuum and it therefore needs to be 
securely grounded and explored within the context of the existing base of knowledge. 
This results from the previous work of other research studies within the same or 
similar field(s). It is not always clear what a review of the literature implies, most 
frequently it relates to the gathering of existing work, whereas a synthesis of the 
literature or research explicitly implies some form of critical appraisal and evaluation 
that denote an active process rather than a collation of information. Davies (2004) and 
Depoy & Gitlin (1994) both list the major reasons why a critical synthesis of the 
literature is important that can be summarised as; identifying the context in which the 
topic is being explored, outlining what is known about the topic, reviewing the level 
and relevance of relevant theory and knowledge development, and formulating the 
rationale for the selection of research strategy. 
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Cooper (1998) gives a framework for the process of synthesis namely, problem 
formulation stage, data collection/literature review, data evaluation, analysis and 
interpretations, and public presentation. However, Polit & Beck (2008) illustrate a 
more in-depth example of this process, this conceptualisation provides a more detailed 
approach that actively encourages feedback mechanisms into the overall strategy and 
more importantly, active reflection on the part of the reviewer or synthesiser. This 
synthesis of current research will apply this model emphasising the use of feedback 
mechanisms, for example cross referencing publication lists in ‘new’ articles with 
those currently held to ensure all relevant articles are located – and developing new 
search strategies such as related search terms and locations for possible articles.  
2.2  RME: Original Research Question 
Using the concept of endurance being a constant function, can respiratory endurance 
be accurately measured? Specifically what other techniques have been described to 
assess respiratory muscle endurance and do they follow the concept of endurance as a 
constant sub-maximal state? 
2.2.1  Redefinition of the Research Question. 
To facilitate the synthesis of the existing literature in the context of developing a 
synthesis rather than a simple review of the literature it was necessary to adapt the 
original research question to meet the needs outlined in section 2.1. The original 
question needed to be adapted to become more specific and to identify its key 
components and definable ways of answering these; 
1. What is RME? 
- What does it represent? Practically and physiologically  
2. How has RME been defined? 
- What issues or difficulties can be identified? 
3. How has RME been measured? 
- In what groups of individuals? 
- In what environments? 
- With what devices and protocols? 
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2.2.2  Formulation of Search Strategy 
The search strategy was as follows: 
 
1. Search term ‘Respiratory Muscle Endurance’ 
2. Format of literature Original research studies published in peer reviewed academic 
journals and books (symposiums) 
3. Location of sources Scientific Journal Databases - ZETOC, EMBASE,  
MEDLINE, PubMed.  
Relevant academic journals (see Section 2.2.3) 
4. Selection criteria Articles were identified by the appearance of the search term 
in either the article title or the body of any abstract 
5. Inclusion/Exclusion 
criteria 
Described a non-invasive method of assessing RME 
Related to human physiology 
In English 
Full Article, not personal communication or conference 
abstract 
Available to reviewer as either paper or electronic copy 
6. Other Sources Relevant Academic Journals  
Figure 2.1: RME search strategy 
 
Key respiratory journals and other scientific journals that had published papers 
identified in this review and that were available to the reviewer (Table 2.1) were 
regularly checked for relevant recent articles using selection criteria listed above 
(Appendix 2.1). 
2.2.3  Results of Article Search 
Initial searching with the ‘Respiratory Muscle Endurance’ search term yielded sixty-
two articles that fulfilled the inclusion/exclusion criteria. However on initial appraisal 
of these articles it became apparent that alternate terms were being used to describe or 
represent RME, in many circumstances interchangeably. The most common 
alternative term that was used was Inspiratory Muscle Endurance (Scherer et al 2000; 
Koppers et al 2006A, 2000B; Chang et al 2005; Morrison et al 1989 A; Weiner et al 
1998A 1998B; Tobin et al 2002; van der Esch et al 2004; and Walsh et al 1996). 
However Ventilatory Muscle Endurance (Eastwood et al 2001; Morgan et al 1987) 
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and Breathing Endurance (Stuessi et al 2001) were also cited. (Further discussion and 
critique of terms follows in section 2.2.5) 
 
The initial search was therefore repeated using the following key terms 1) Inspiratory 
Muscle Endurance 2) Ventilatory Muscle Endurance and 3) Breathing Endurance.  In 
total 110 journal articles were identified (Table 2.2). Each article was critically 
appraised for; terms and definitions used; study design; sample size; subject group; 
assessment method; and assessment results. The results were then tabulated 
(Appendix 2.2). 
2.2.4  Range of Academic Journal Sources and Year of Publication 
Articles appeared in a range of journals across a variety of academic disciplines 
including respiratory medicine, applied physiology, sports medicine, cardio-vascular 
disease, and paediatric sciences, indicating the wide interest in respiratory endurance 
within the scientific community. Chest, the journal of the American College of Chest 
Physicians was responsible for publishing the largest number of journals that fulfilled 
the synthesis inclusion criteria (Fig 2.2). 
 
Search databases used for this review varied in the chronological length of their 
search, ZETOC (from 1993), EMBASE (from 1974) and MEDLINE (from 1949), 
PubMed indexes MEDLINE so shares a similar earliest available record. The earliest 
article that fulfilled study criteria was published in 1976. In the past 20 years there has 
been a regular publication of relevant papers at 4.5 per year (Fig 2.3). 
2.2.5  A Clear Description of Respiratory Endurance 
The variation in the terms applied to non-invasive respiratory endurance measurement 
has been highlighted (Section 2.2.3). Not only do studies refer to RME, Inspiratory 
Muscle Endurance (IME), Ventilatory Muscle Endurance (VME) and Breathing 
Endurance (BE), it is not unusual for these terms to be used interchangeably; RME & 
IME (Chang et al 2005; Inzelberg et al 2005; Morrison et al 1989 B; Sette et al 1997; 
Tobin et al 2002; Walsh et al 1996; and Weiner et al 1998B), RME & VME (Martin et 
al 1986; and Eastwood et al 2001) and RME & BE (Williams et al 2002). 
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Table 2.1: Relevant Academic Journals Reviewed 
Respiratory Applied Physiology Sport & Exercise 
Thorax Journal Applied Physiology Medicine Science in Sport Exercise 
Chest European Journal Applied Physiology British Journal Sport Medicine 
Chronic Respiratory Disease  International Journal Sport Medicine  
Respiratory Medicine  Journal Science Medicine Sport  
European Respiratory Journal  Journal Sport Science  
Respiration   
Respiratory Physiology & Neurobiology   
American Journal Respiratory Critical Care Medicine  
 
Table 2.2: Search Terms and Number of Articles Located 
 Respiratory Muscle 
Endurance 
Inspiratory Muscle 
Endurance 
Ventilatory Muscle 
Endurance 
Breathing Endurance Journal 
search 
Total articles 62 44 20 8 2 
Invasive method 3 8 - 1 - 
Commentary 3 - - - - 
Review 5 3 2 - - 
Total 50 33 18 7 2 
Grand  Total 110     
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Figure 2.2:  Scientific Journals Publishing Papers in this Review 
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Figure 2.3: Chronological Output of Papers 
 26
This variation is most probably due to the complexity of ‘endurance’ and what it 
involves (see Section 1.9). The common use of the term IME could be due to the fact 
that at rest expiration is a passive process and the work of breathing is performed by 
the inspiratory muscles (Nunn 1993). Whereas VME relates to the methods that utilise 
increased levels of ventilation as their indices of endurance. Despite these factors the 
range of terms and their interchangeable use as it appears in the scientific literature 
represents poor scientific practice and such variation and disparities should be a focus 
particularly on behalf of journal publishers and reviewers when assessing future work. 
 
This poor use of terminology is further compounded by the infrequent use of clearly 
stated definitions. Of the 110 articles identified only 15 explicitly defined a measure 
of endurance (Table 2.3). These definitions were either; loose or simplistic 
descriptions of endurance; standard physiological measures that were used as indices; 
or were based on the modality of the test employed. None attempted to explicitly 
define endurance in biological or physiological terms. 
 
In addition the majority of articles that relate to non-invasive methods of assessing 
respiratory endurance include the term ‘muscle’ i.e. respiratory muscle endurance, 
inspiratory muscle endurance etc. Therefore these articles suggest or imply that the 
technique or method they employ is capable of measuring the capabilities of the 
respiratory muscles. However when measurements are made at the mouth as non-
invasive tests must do by definition, it is difficult to directly assess the respiratory 
muscles per se, or to isolate their action from that of other respiratory system 
components. More accurately it is the function of the entire respiratory system that is 
being assessed, including elastic recoil of the lungs and the chest wall structure, in 
combination with the respiratory muscles.   
 
Therefore when measuring endurance non-invasively at the mouth it is inaccurate to 
refer to the respiratory muscles with respect to any definition. A term that regards the 
respiratory system as a whole would be more accurate and therefore more preferable. 
It could be suggested ‘Respiratory System Endurance’ or ‘Respiratory Endurance’ as 
a preferable term. In the rest of this synthesis however, when assessing individual 
articles the term that the article authors use will be used accordingly.  
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Table 2.3: Fifteen Given Definitions of Endurance 
 
A uthor  Term  used  Sta ted Definit io n 
(descriptive)  
Author  Term  used  Stated  D efinition (re lating to  test) 
Scherer et 
al. 200 0  
1 . Respiratory 
mu scle 
endurance (RET)  
2 . Inspiratory 
mu scle 
endurance  
RET = su stained ventila tion  
R MT  
Fiz et  al. 
1998 
Respiratory 
Mu scle 
E ndurance  
 
 
1. IME = maximum tolerated loa d for  a 
2min incremental Martyn test ( C max ) 
 
2.time o f su stained breathing against an 
inspira tory pressure load equi valent to 
80%  o f C max  
M ueller et 
al. 200 6  
Respira to ry 
M uscle 
E ndurance  
RET=exhaustiv e normoc apnic 
h yp erp noea  
R MT  
McElvaney 
et al. 198 9  
Respiratory 
Mu scle 
E ndurance  
RME = time(tlim) that the maxi mum load 
(ascertained in an incrementa l  test) could 
be tolerated  
Bousanna 
et al. 2001  
Respira to ry 
M uscle 
E ndurance  
RME = is th e property of 
respiratory m usc le that affords 
resistan ce  to fatigue  
Wirnsberge
r et  al. 19 97  
Respiratory 
Mu scle 
E ndurance  
RME time = max time (sec) subj ect 
susta in brea thing against insp iratory 
pressure load=70%  of individua l PI,max  
Supinski et  
al. 198 5  
Respira to ry 
M uscle 
E ndurance  
Suggested that RM E is 
d etermined in part by the  
b alance  be tween energy 
consumption and en ergy 
availability  
Kochelin et 
al.200 5  
Respiratory 
Mu scle 
E ndurance  
RME = max time Tlim a  subject is ab le to 
susta in a specific sub maximal  muscle task  
N ickerson 
&  Keens 
198 2  
V entilatory 
M uscle 
E ndurance  
E ndurance  is the prop erty that  
affords resistance to  fa tigue  
Chang et al. 
2005 
Inspiratory 
Mu scle 
E ndurance  
Respiratory 
Mu scle 
E ndurance  
Fatigue  Resistance  Index = FRI  
Keens et al. 
197 7  
V entilatory 
M uscle 
E ndurance  
V ME T 
‘muscle endurance is correlate d  
w ith  resistance to fatigue’  
Mo rrison et  
al. 1989 
(A1 69) 
Respiratory 
Mu scle 
E ndurance  
RMEMSVC = Maximal Sustainable 
ventila tory capacity = is the highest 
ventila tion that can be sustai ned for 15 
min.  
F orte et al. 
199 7  
V ent ilatory 
M uscle 
E ndurance  
E ndurance  o f th e Inspiratory 
musc les can b e measured as the  
capacity to su sta in  inten se 
b reathing tasks  
Bousanna 
et al. 200 3  
Respiratory 
Mu scle 
E ndurance  
RME= correspon ds to length of time resp’ 
load  can be sustained b efore f a tigue 
develops suff iciently to cau se  task failure  
   Kerr & 
Schultz 
1996 
Inspiratory 
Mu scle 
E ndurance  
End urance def’  by length time load can be 
endured before pro cess of fati gue develops 
sufficiently  to  cause task fa ilure  
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2.2.6  Design and Quality of Studies 
The sample sizes of participants varied widely ranging from 4 (Boutiller & Piko 1992) to 160 
(Chen & Kuo 1989A). In terms of methodological design, studies were found to be; cohort 
(N=81); matched control (n=16); healthy matched controls (n=11); or double blinded 
randomised control (n=2).  
 
There were many examples of poor scientific rigor in articles identified in the review. Some 
studies were clear and frank about methodological issues associated with assessing 
respiratory muscle endurance, Martin et al (1986) described how ‘the major weakness of the 
study is the assessment of ventilatory muscle endurance’ primarily due to the arbitrary nature 
of their measure of endurance. 
 
The most common examples of poor scientific rigor include; not describing the gender of 
subjects (Mador et al 2005; Koessler et al 2001; Nava et al 1992; Orenstein et al 1981); little 
or no detailed methodology of the technique used to assess endurance (Laghi et al 2005; 
Sonne & Davis 1982; Cimen et al 2002; Weiner et al 1993; Levine et al 1986); not clearly 
defining outcome measures (Wanke et al 1994; and Martin et al 1986); that while assuming 
that maximal ventilatory capacity is a measurement of RME (the accuracy of this assumption 
is discussed later in section 2.2.9), that this assumption is not stated in method or results 
sections (Sairikaya et al 2003; Belman & Mittman 1980; Forte et al 1997; Cimen et al 2003; 
Morgan et al 1987; Warren et al 1989); and poor reporting of results, such as not quantifying 
absolute figures returned and the use of graphs instead of tables (Boussana et al 2001; Holm 
et al 2004; Chatham et al (1996); Weiner et al 1998B; Johnson et al 1996 B; O'Donnell et al 
1998; Scardella et al 1993). 
2.2.6.1 ‘The effect of inspiratory resistive training on exercise capacity in 
optimally treated patients with severe chronic airflow limitation’ - 
McKeon et al (1986). 
A paper that stands out as a poor example and requires further appraisal is that of McKeon et 
al (1986) which is a study based around the use of an inspiratory training device. This study 
was designed to assess the effect of inspiratory resistive training on exercise capacity in 
patients with severe chronic airflow limitation. There is no mention of IME in the 
introduction, method or results sections of the article. It does not define what IME is, how it 
was measured or how it was seen to change. This makes the claim in the first sentence of the 
discussion all the more extraordinary: 
 29
‘There was no significant increase in maximum inspiratory pressure in the 10 trained 
subjects, but IME improved’. 
 
The training protocol was based on breathing through a device with fixed orifices that could 
be made progressively smaller. In the discussion the authors then allude to an ability to 
‘tolerate smaller apertures to be an indication of improved IME’. It is on this basis that 
‘subjects in the study could be considered likely to have improved their IME’. It is clear that 
this study lacks any clear rationale for, or a definition of, endurance and the poor scientific 
standards of the article are further compounded by non-reporting of the subjects’ gender. 
 
The way that this influences the development of future research can be seen in the resulting 7 
citations this article received by subsequent authors of further original studies (Harver & 
Mahler 1989; Lake et al 1990;Guyatt et al 1992), systematic reviews and meta-analyses( 
Smith et al 1992; Pardy & Rochester 1992, Geddes et al 2005; Geddes et al 2008). This 
second review by Geddes et al (2008) prompted the author of this thesis to write a letter to the 
publishing editor outlining many of the points made already in this thesis, which was 
successfully accepted for publication (Powell & Williams 2009). 
 
Geddes and co workers responded to the concerns raised surrounding the issues identified 
here within the topic of RME assessment (Geddes et 2009), stating that ‘many authors 
performing clinical research perceive these tests (of endurance as outlined in the review) to 
be estimates of RME’ (emphasis added). This didn’t really answer the concerns raised, 
indeed the use of the terms ‘perceive’ and ‘estimate’ actually reinforce the issues that are felt 
to be present in that there is no direct measurement of respiratory endurance. Geddes and co-
workers did however agree that a standardised test protocol was needed for assessment of 
RME. 
2.2.7  Inspiratory Muscle Training Studies 
The premise that function of the respiratory muscles can be independently trained and 
adapted has driven a great deal of clinical and commercial interest, especially as breathing 
may be regarded as a form of muscular exercise (Rankin & Dempsey 1967). Although the 
lung airway and vascular structures seem to be resistant to the stimulus of physical training, 
as while it is not uncommon for elite endurance athletes to have large lung volumes and flow 
rates this is more likely due to why they are an elite athlete, than as a result of the training 
associated with it (Dempesy 2006A). 
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Regardless, the notion that the endurance capabilities of patients with chest disease can be 
easily increased by relatively simple exercises that can be conducted without clinical 
supervision has been a focus for many in the respiratory field. However as has been set out up 
to this point there appears to be no common consensus on a definition of respiratory 
endurance, let alone any reliable non-invasive assessment technique. For respiratory training 
studies there appears to be no clear method to assess the efficacy of the outcome of any 
intervention in terms of respiratory endurance. Even though two double blind randomised 
control trials were identified in the review, such complex study design is of no use if the 
outcome measures applied do not represent the intended outcomes. 
 
In all, forty-three articles identified were inspiratory muscle training studies and it was not 
unusual for these studies to use the same device and/or technique to measure respiratory 
endurance as that that was used for the training intervention (Mueller et al 2006; Mador et al 
2005; Rassler et al 2007; Chatham et al 1996; Johnson et al 1996 A; Klefbeck et al 2000; Ries 
et al 1988). This questions how much potential changes in endurance were due to true 
physiological change or because subjects became conditioned to the device in question due to 
the learning effect that accompanies all volitional tests of respiratory function (Eastwood et al 
1998).  
2.2.8 Different Methods of Assessing Respiratory/Inspiratory/ 
Ventilatory Endurance 
A range of different approaches to assessing the endurance of the respiratory system were 
identified (Fig 2.4), all of these represented maximal protocols that either resulted in fatigue 
(B, C1) or could only be maintained for a short period (A, C2). Apart from maximal 
ventilatory tests (detailed in section 2.2.9) these techniques use various forms of external 
loads to increase the rate of respiratory work to maintain adequate ventilation. These methods 
of endurance to external loads can be summarised as either flow resistive loads for example 
when using a fixed orifice, elastic loads, or threshold loads in which a finite pressure is 
required to allow flow to occur (ATS 2002 A). Resistive threshold pressure loading (described 
in section 2.2.10) is the most commonly used technique, based on a device designed by 
Nickerson & Keens (1982) (Section 2.2.14.1). 
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Figure 2.4: Methods of Assessing Respiratory/Inspiratory/Ventilatory Endurance 
identified in review (number of trials); (A) Maximal Voluntary Ventilation  – 25; (B) 
Incremental Test to fatigue - 42; (C1) Sustained test to fatigue – 34; (C2) Sustained test at 
highest possible load for set time  - 18. (Note: some articles used more than one method). 
  
2.2.9  Maximal Ventilatory Ventilation (MVV) 
The goal of ventilatory endurance testing is to define the maximum ventilation capacity 
(L.min-1), when over a short period ≤ 15sec this is described as Maximal Voluntary 
Ventilation (MVV). It is difficult for a truly maximal level of ventilation to be maintained 
beyond a short time and sustained ventilatory tests have been developed which use a 
percentage of a 15 second MVV test as a target ventilatory rate. This can be defined as 
Maximal Sustained Vital Capacity (MSVC) or Sustained Vital Capacity (SVC) can be for a 
period of up to 12-15 minutes (Levine et al 1992; Di Marco et al 1985). 
 
MVV is the oldest method of measuring ventilatory and respiratory muscle endurance 
(Rochester 1988), and has been widely used as a test of ventilatory function (Freedman 1970) 
and breathing capacity. ATS (2002 A) describes this ventilatory test as ‘a measure of both 
inspiratory and expiratory muscle endurance’, undoubtedly due to the simplicity of the test 
and what it represents. It is though a somewhat ‘blunt instrument’ that should lead on to more 
specific tests in the presence of poor performance (McConnell 2007).  
 
C1/2 
Time 
A 
B 
Intensity 
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MVV gives a fatigue index of the respiratory muscles as the progressive decline in flow rate 
is due to muscle fatigue. Zocche et al (1960) considered that fatigue of the respiratory 
muscles was the main cause of attenuation of ventilatory capacity during sustained 
hyperventilation. By measuring the point of fatigue as already argued (Section 1.9) this 
represents the point when the endurance capability of the respiratory system fails and 
therefore it is incorrect to use it as an index of respiratory endurance. Additionally, a common 
occurrence was for studies to report MVV results and refer to this as a marker of endurance 
or not even make such a connection assuming that this is an accepted technique (Section 
2.2.6). 
 
MSVC that is assessed for significant periods is a more accurate picture of endurance as it 
does not result in fatigue or cessation of test. However maximal ventilation involves 
significant cooperation on behalf of a subject which is not in concurrence with the aims of 
this thesis. Further more ventilatory levels during maximal aerobic exercise rarely get close to 
levels of MVV. This would mean that it would be difficult to undertake a clinically relevant 
task that would elicit the same physiological response so the utility of the MSVC is 
questionable. 
2.2.10   External Resistive Loading 
As resistance is added to the flow of air during respiration, an increased inspiratory and 
expiratory effort is required to maintain adequate ventilation (Cain & Otis 1949). Resting 
breathing patterns can be altered to overcome this resistance and such strategies are 
successful. However when increased ventilation is required for example during physical 
exercise these cannot be used to compensate. Examples here are of the obstructed airways in 
chest disease and the use of purse lipped breathing and lung hyperinflation by patients.  
 
To date all devices that used external resistive loading were constrained by the issue of a 
fixed orifice or load that could at best be adjusted between breaths. This meant that all these 
devices were constrained by the ability of a subject to alter their breathing pattern. The RK 
device outlined subsequently (Section 3.1) is the first device that is able to continuously alter 
its internal diameter during a breath so that strategies to overcome the resistance are 
unsuccessful and subjects are required to increase their work of breathing or cease breathing 
through the device. 
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2.2.11   Threshold Pressure Loading 
When an external mechanical load is applied to the airway opening, the respiratory muscle 
must generate an additional pressure to overcome the impedance of the load (ATS 2002 A). 
Threshold Pressure Loading (TPL) is based on the initial work of Nickerson & Keens (1982) 
and many commercial devices that are based on similar principles have been developed. The 
device consists of a plunger which must be moved to allow for air flow to take place. The 
resistance of the plunger can be controlled either by a metal spring or by adding weights. 
These are basic mechanical devices with few moving parts which make them easy to use and 
setup.  As TPL often follows a maximal protocol an operator has to closely monitor the 
subject to ensure correct techniques i.e. maintain a seal around mouthpiece. While calibration 
of the resistive load is easy with weights, devices that use springs are more difficult to 
calibrate with inspiratory pressure manometers connected to the device. 
 
As reviewed (Section 2.2.14.1) Nickerson & Keens (1982) originally outlined a sustained 
test, however the work of Martyn et al (1987) has now superseded this and all TPL studies 
now use incremental test protocols that result in fatigue. In patients with respiratory disease 
when fatigue may occur quickly discontinuous protocols have been developed when there are 
short rest periods in between the incremental stages of the trial (Larson et al 1999; Covey et 
al 2001). The outcome of these trials depending on the sophistication of the device used 
either use time taken for fatigue to occur, expressed as endurance time or if connected to a 
pressure manometer the inspiratory pressure needed to move the plunger at fatigue expressed 
as peak mouth pressure. 
 
As has been previously discussed (Section 1.9) methods that result in fatigue do not represent 
endurance and therefore TPL protocols that result in fatigue cannot be used to measure 
respiratory endurance. However the ATS (2002 A) describe incremental TPL as the most 
useful method to assess respiratory endurance and it was found to be the most commonly 
used technique in this literature synthesis. 
2.2.12  Controlling Breathing Pattern During the Respiratory Endurance 
Test 
A wide variation exists in methods of controlling breathing, even within tests of respiratory 
endurance that use the same technique. With Incremental PTL previous studies have taken 
different approaches to breathing pattern. Specifically the variation in Respiratory Rate (fR) 
and the time of inspiration (tI) regards to the total breath time (tTot), expressed as tI/tTot. 
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These include not stating a fR or tI/tTot (Laghi et al. 2005), controlling both fR and tI/tTot 
(Koppers et al. 2006A; Nava et al. 1992); allowing subjects to self-select fR but using a pre 
selected tI/tTot (O'Kroy and Coast. 1993); and controlling fR while subjects freely select tI/tTot 
(Morrison et al. 1989 A). Attention should also be drawn to the preselected tI/tTot’s that have 
been used, while they can vary, more often they are fixed at 0.5, not at a more ‘natural’ 0.4. 
The reason for these differences is not apparent from any methods described, but is probably 
due to the availability of standard commercial (i.e. symmetrical) metronomes, those 
principally designed for musicians, rather than a belief that a tI/tTot of 0.5 reflects the most 
appropriate breathing pattern. 
 
In terms of making any new method of respiratory endurance simpler to complete it would be 
more preferable to not have to control breathing rate, however this must be in context of the 
outcome of any test and the effect varying fR may have. 
2.2.13  Does a Gold Standard Exist? 
Hart et al (2002) describe their method as a reliable endurance test but this requires the 
insertion of a balloon catheter for measuring oesophageal pressure. This technique is seen as 
reliable as it measures changes in intrathoracic pressures which are seen as more accurate and 
representative of chest wall mechanics. However as previously described (Section 1.11) 
invasive testing is a highly specialised technique and carries with it an inherent risk. As such 
it is not suitable for use outside a laboratory without specialist equipment and trained staff. 
Furthermore this technique uses an incremental protocol which results in fatigue and as has 
been argued, fatigue is not equivalent to endurance. 
 
Many different methods were identified in this synthesis and can be categorised into 4 main 
types (Section 2.2.8) yet very few of the papers identified in this review either used identical 
protocols or compared their techniques with other studies. This therefore makes it difficult for 
comparisons to take place between techniques. 
 
Geddes et al (2009) describe how it would appear that respiratory muscle tests are selected 
based on whether they can estimate the desired outcome, are straightforward to perform, are 
not unduly challenging, and are accessible, reliable, and preferably non-invasive. That is, 
tailored to the particular demands of a research question, not because of a clear rationale why 
it would be the best measure of respiratory endurance. As such it is difficult to see how a 
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comparison with a gold standard and techniques developed within this thesis could take 
place.  
2.2.14  Key Historical Articles 
There are three studies that were frequently referred to by other articles in this synthesis. The 
most cited was Nickerson & Keens (1982) (cited 54 times), this article fulfilled 
inclusion/exclusion criteria and appears in this synthesis. Also cited frequently (n=30) was 
Martyn et al (1987) who built on the work of Nickerson & Keens, however none of the search 
terms for this review appear in the title or abstract with the authors referring to ventilatory 
muscle performance and not mentioning endurance and it is therefore not included. Both 
these articles utilised a TPL device. The study by Leith and Bradley (1976) (cited by 33 
articles) refers to maximal ventilatory flow measurement as an index of endurance. 
 
For such widely cited articles that a great deal of subsequent research studies were based 
upon, it is surprising that only small cohorts of subjects were studied; Nickerson & Keens - 7 
(wide age range: 5-75 years); Leith & Bradley -12 (healthy adults, age: 20-40 years); Martyns 
et al - 14 (healthy adults age: 21-44 years).  
 
Furthermore in terms of making a clear definition of endurance Nickerson & Keens,  and 
Leith and Bradley clearly do so; ‘Endurance is the property of a muscle that affords 
resistance to fatigue’; and  ‘(Ventilatory Muscle) endurance is the capacity for sustaining 
high levels of ventilation for relatively long periods’ respectively. Martyns et al while not 
clearly defining respiratory endurance described the innate difficulty and tests that had been 
previously used; ‘measurements of (ventilatory muscle) endurance are more difficult and two 
general types of test have been used; voluntary hyperpnoea and inspiratory threshold 
loading’.  
2.2.14.1 ‘Measuring ventilatory muscle endurance in humans as sustainable 
inspiratory pressure’ – Nickerson & Keens. 1982 
Nickerson & Keens constructed a plunger device (Fig 2.5) that has been widely used and 
replicated in the many articles that cited them. Their protocol set the plunger device at a 
proportion of MIP by the addition of weights to the plunger. These weights would be adjusted 
until the maximum load that could be sustained for 10 minutes is identified.  The inspiratory 
pressure needed to overcome the weighted plunger is used as the test outcome and is referred 
to as the sustainable inspiratory pressure (SIP).  This technique relies on correctly measured 
MIP which as described previously would require up to 20 separate MIP measurements to 
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ensure that a maximum value had been achieved. While this may work well in the laboratory, 
such an involved protocol may not transfer that well into a clinical or home setting. 
Interestingly Nickerson & Keens identified a 10% increase in MIP and SIP at a two week 
retest. This raises possible issues of learning with this form of respiratory measurement? 
 
Nickerson & Keens identified that endurance cannot be assessed by strength and that 
endurance is the property of a muscle that affords resistance to fatigue. They identified 
previous techniques which used the highest volume of isocapnic hypopnoea that could be 
sustained for a given time. Such techniques dependence on flow rate made it difficult to 
compare between health and disease preventing it from being easily used and interpreted 
clinically. The non-fatiguing protocol they described, although requiring maximal subject 
cooperation was closer to a test of endurance than maximal fatiguing tests. 
 
In conclusion more so than the technique they describe, the point that Nickerson & Keens 
make about endurance being dichotomous with fatigue is probably their greatest contribution 
to the field of respiratory endurance measurement. Unfortunately it would appear that this has 
since been ignored by subsequent researchers.  
2.2.14.2 ‘Measurement of inspiratory muscle performance with 
incremental threshold loading’ - Martyns et al 1987 
Martyns et al. were concerned with the learning effect that was identified with Nickerson & 
Keens’s method. They showed that using the Nickerson & Keens protocol and device, SIP 
was increased by 25% when measured twice. Therefore they chose to use incremental loads 
and ‘developed a test similar to a progressive test’. Outcome was defined as peak mouth 
pressure at the greatest load achieved (PmPeak). In effect Martyns et al used the device of 
Nickerson & Keens but applied a totally different protocol. As argued previously an 
incremental test resulting in fatigue does not measure endurance, and Martyns et al seem to 
ultimately acknowledge this by referring to how their incremental technique is a simple 
assessment of ventilatory muscle performance rather than endurance. 
 
Interestingly Martyns et al identify how subjects vary their pattern of breathing and that 
breathing strategies influence the measurement of SIP. They contend that by incrementing a 
load subjects were able to vary their breathing pattern to maximise their performance in the 
test. They do not say whether this could also have a negative effect on test performance. 
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In conclusion this paper was responsible for the development of an incremental (fatiguing) 
protocol and many subsequent studies make clear how they use a modified Nickerson & 
Keens protocol which directly or indirectly relates to the work of Martyns et al.  
 
 
Figure 2.5: Illustration of Nickerson &Keens (1982) weighted plunger device  
 
2.2.14.3 ‘Ventilatory, muscle strength and endurance training’ – Leith and 
Bradley (1976) 
Leith & Bradley used a standard measurement (15 sec MVV) as their test of endurance. As 
stated previously MVV has been widely used as a marker of ventilatory function (Section 
2.2.9). Yet it appears from articles that Leith & Bradley cite that it is only around the time 
their article was published that MVV and endurance come together as a common theme. Of 
the articles they (Leith & Bradley) cite only Tenney and Reese (1968) also express their 
findings in terms of endurance time. Indeed many articles that Leith & Bradley cite discuss 
maximal ventilatory tests within a fatigue context. 
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As have been described with other training studies (Section 2.2.7) they developed a piece of 
equipment for respiratory training (Fig 2.6) that was also used to assess endurance which 
raises issues of training effect on the endurance measurement. They measured (ventilatory 
muscle) endurance as time to exhaustion during partial re-breathing in a system which 
permitted regulation of inspired O2 and CO2 levels and which provided a ventilatory target 
(although it is not clear from their method what this target was). They also describe the need 
for repeated trials so the subjects could learn the test, suggesting that substantial amounts of 
training would be needed to ensure a repeatable/reproducible test outcome. 
 
With the large number of citations for this article and lack of evident use of endurance 
terminology before it, it is not unreasonable to speculate that it is the starting point for the use 
of maximal ventilatory tests as indexes of respiratory or more commonly ventilatory 
endurance (see Section 2.2.9). Leith & Bradley describe how previous studies have described 
and measured (ventilatory muscle) endurance as the capacity for sustaining high levels of 
ventilation for relatively long periods. However as they describe a protocol resulting in 
exhaustion this cannot be used to represent endurance.  
 
 
 
Fig 2.6: Leith & Bradley (1976) Endurance Training/Measurement Device
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2.2.15  Research Questions to Answer   
1). What is RME? 
Respiratory muscle endurance represents the ability of the respiratory muscles to continue to 
drive the internal pressure gradients within the lung needed to maintain ventilation 
indefinitely. In practical terms when assessing the respiratory system non-invasively, the 
action of the respiratory muscles cannot be isolated from the other components of the 
respiratory system, therefore in this context the term ‘muscle’ should be removed from any 
definition. 
 
2). How has respiratory endurance been defined? 
Currently there is no established definition of respiratory endurance, and not all studies 
clearly state one. In those that do any definition is based on the methodology rather than an 
underlying physiological parameter. Furthermore endurance is often framed with a fatigue 
context. Fatigue is difficult to define but certainly involves a large psychological component, 
probably a reaction to the unpleasant sensation of excessive ventilation (Shephard 1966). 
Furthermore fatigue represents the point at which endurance fails or ends. The two terms, 
fatigue and endurance, are not synonymous. 
 
While a measure of fatigue provides valuable information about an individual’s maximum 
capacity, it does not measure the clinically important ability of the respiratory system to 
endure sub-maximal loads such as those experienced during the physical activities of daily 
life. It is the consideration of the difference between maximal diagnostic testing and sub-
maximal functionality testing of the respiratory system that is pertinent, as both are important 
and valid. A definition that regards the respiratory system as a whole would be more accurate 
and therefore ‘Respiratory System Endurance’ or ‘Respiratory Endurance’ would be a more 
preferable term. 
 
3). How has respiratory endurance been measured? 
Many techniques have aimed to assess respiratory endurance but cannot be said to do either 
due to their inability to correctly define endurance or use of a protocol that results in fatigue. 
Techniques that use a sub-maximal, constant state testing in methodological terms, would be 
the most applicable when assessing respiratory endurance. The methods identified in this 
review have been used in a wide range of subject groups including paediatrics, elderly, chest 
disease, muscle wasting disease, during exercise and at rest in healthy controls. Mostly they 
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have been used in small studies within clinical or laboratory environments and none have 
been used to test respiratory endurance within the home environment for example. Often 
these methods were used to assess the outcome of respiratory training studies although due to 
their intimate connection with the training intervention, it would be difficult to assess the 
efficacy of an outcome due to the potential for learning effect. 
2.2.16 Proposals for Future Research Within Respiratory Endurance 
Testing 
From the syntheses of the existing research the following areas for future research are 
proposed. 
 
1) What form should a sub-maximal protocol follow? 
- Paced versus unpaced breathing 
- Load intensity 
- tI/tTot ratio 
- Metronomic control of breathing pattern 
2) How repeatable and reliable is any such protocol/technique? 
3) What effect does physical exercise have on the outcomes of the protocol? 
4) Can the protocol be used to distinguish between health and disease? 
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2.3 Tidal Breathing Profile Analysis - Developing the Research Question 
The ability to measure respiratory function during tidal breathing regardless of the age or 
respiratory state of a participant would be particularly advantageous especially in those 
individuals when it is difficult or not possible to perform forced expiratory manoeuvres 
(Lodrup-Carlsen. 2000). For example as COPD severity increases it becomes hard for 
patients to cooperate as they get older, suffer from more co-morbidities and experience more 
exacerbations of their disease symptoms (Soriano & Miravitlles 2009). 
 
As such there has been interest in the development of techniques that use a passive non-
volitional protocol which have mainly focussed on the shape of the expiratory flow curve as 
an index of airway obstruction. Colsanti et al (2004) have taken this technique further and 
developed algorithms that can be used to predict airway obstruction incorporating parameters 
derived form expiratory airflow curves. This technique is described in detail later (Section 
3.2), and has been reviewed in editorials (Bates et al 2000) but has not been studied by others. 
Therefore it is only possible to  review existing studies that have studied parameters derived 
from the resting tidal expiratory airflow curve most notably PTEF and the time taken to 
achieve this (tPTEF). 
2.3.1  Redefinition of the Research Question. 
To facilitate the synthesis of the existing literature in the context of developing a synthesis 
rather than a simple review of the literature it was necessary to adapt the original research 
question to meet the needs outlined in section 2.1. The original question needed to be adapted 
to become more specific and to identify its key components and definable ways of answering 
these; 
 
1) In terms of PTEF what is the best technique or protocol to use to accurately collect this 
parameter? 
2) What type of participants has it been collected in and how well was this 
tolerated/undertaken?  
3) Can differences be observed using resting tidal profiles in groups with different lung 
function? 
4) How reliable a technique is it to accurately represent airway obstruction? 
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2.3.2  Formulation of Search Strategy 
1. Search term Peak Tidal Expiratory Flow – ‘PTEF’ 
time to Peak Tidal Expiratory Flow- ‘tPTEF’ 
2. Format of literature Original research studies published in peer 
reviewed academic journals and textbooks 
3. Location of sources Scientific Journal Databases - ZETOC, 
EMBASE,  MEDLINE, PubMed.  
Relevant academic journals (see Section 2.2.3) 
4. Selection criteria Articles were identified by the appearance of the 
search term in either the article title or the body of 
any abstract 
5. Inclusion/Exclusion criteria Described the measurement of PTEF / tPTEF 
Related to human physiology 
In English 
Full Article, not personal communication or 
conference abstract 
Available to reviewer as either paper or electronic 
copy 
6. Other Sources Journals that yielded articles identified in search 
and other Respiratory, Physiology, and Sport & 
Exercise journals were regularly appraised (see 
Section 2.4). 
Figure 2.7: TBPA Search Strategy  
 
2.3.3  Results of Search 
The search strategy yielded thirty-two articles consisting of twenty-nine original articles and 
two reviews and one methods paper. The relevant academic journals regularly appraised as 
part of the respiratory endurance review (Section 2.2.2) were also regularly checked for 
relevant articles. Each article was critically appraised for; terms and definitions used; study 
design; sample size; subject group; assessment method & protocol; and assessment results. 
The results were then tabulated (Appendix 2.3). 
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2.3.4  Range of Academic Journal and Year of Publication 
Articles appeared in a range of journals although were mainly concentrated on specialist adult 
and paediatric respiratory journals. Two journals responsible for publishing the most articles 
were the Paediatric Pulmonology (n=10) and the European Respiratory Journal (n=8).  
Despite the chronological ages of research databases used (Section 2.2.4) the earliest paper 
that fulfilled search criteria was 1994. This is perhaps driven by the computing power 
necessary to process the large amounts of data generated using this technique into the 
outcome parameters required especially over prolonged epochs. 
2.3.5  Parameter and Indices Used  
The most common parameter reported was tPTEF (in 18/23 articles) commonly expressed as a 
proportion of tE (tPTEF/tE) representing the mathematical expression of the time and volume 
needed to reach PTEF (See section 3.2)). Morris et al (1998) used Trs, the gradient of 
volume/flow which they indicated was more closely associated with airway resistance, 
although this technique would require measuring airway resistance (Section 3.4.3) and would 
require a more involved level of testing. 
2.3.6  Device Used 
Most studies used a pneumotach to measure flow profile although later studies have used 
respiratory inductance plethysmography - RIP (Stick et al 1996. Manczur et al 1999; Black et 
al 2004) which utilises belts around the chest and abdomen to indirectly assess Tidal Flow 
loops (See review by Wolf & Arnold 2005). This is not a direct measure of flow, as it uses 
changes in volume to derive flow. Manczur et al (1999) found that while both methods could 
be used to measure tPTEF/tE the results were significantly different, although RIP was better 
tolerated. 
2.3.7  Sample Rate and Sample Time/Length  
Sampling rate was only stated in 11 of the studies and was seen to range from 80hz to 256hz. 
Bates et al 2000 in an ATS/ERS standards paper states that when using resting tidal 
parameters such as tPTEF/tE, greater resolution is needed and therefore rates of ≥200hz are 
recommended.  
 
Sample length and time varied considerably between studies. The minimum used was 4 tidal 
breathing flow volume (TBFV) loops although the length of sample these were taken from 
varied from 8 (Devulapalli et al 2004;Lodrup-Carlsen et al 1999;Haland et al 2007), to 16 
breaths (Totapally et al 2002). Other studies used breath sample sizes of 10 (Greenough et al 
1998A);20 (Ranganathan et al 2003) and 25 breaths (Yuksel et al 1996). 
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Time was also used for sample length and this varied from 20 seconds (Ueda et al 1999); 30-
60 seconds (Habib et al 2003; Dezateux et al 1994); 60seconds (Dotta et al 2007); 80 seconds 
(Morris et al 2004); and 2 minutes (Williams et al 2000). 5 studies did not describe the 
sampling time or length used.  
 
Using shorter sample times relies on the operator to identify the TBFV loops that are used for 
analysis and therefore brings bias to any measurement. By sampling a longer period and 
taking the average of any parameters and filtering any outliers this can remove such bias (See 
van der Ent et al 1996 for discussion of this). Shorter periods may be poorer in terms of 
getting truly resting breathing patterns, however longer epochs may not be possible in some 
subjects. 
2.3.8  Sedation of Study Particpants 
There are issues with sedating acutely or severely ill respiratory patients (Table 2.4) and the 
sedation of healthy children in many European countries (for example Norway) for research 
purposes is not allowed for ethical reasons (Lodrup-Carlsen 2000). However collection of 
undisturbed tidal breathing is a complex undertaking as the process of measurement can 
influence the pattern of breathing (Bates et al 2000) and sedation has been used to elicit a 
rested response from infants tested.  In this synthesis 8 of the 21 studies of infants used 
sedation in their protocol, usually in children <12 months although Deeronjanawong et al 
(2005) report sedating children up to the age of 5 years. The use of sedation in a protocol 
would preclude any study in a non-clinical environment.  
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Table 2.4: Guidelines for Sedation of Infants When Measuring Tidal Breathing 
(adapted from Gaultier 1995) 
1. Contraindication for sedation - known upper airway obstruction 
 
2. High risk infant groups: a) preterm and full-term neonates (≤44 weeks post-conception 
age) even when healthy; 
b) infants presenting a history of acute life-threatening events; c) 
infants at increased risk of upper airway obstruction; 
d) infants with known respiratory embarrassment; and e) infants 
with hepatic, renal, or cardiac disorders. High risk infants must 
be monitored (oxygen saturation, heart rate) after sedation. 
Overnight hospitalisation may need to be arranged for infants 
who are clinically unstable. 
3. Sedate with caution - wheezy infant 
4. Resonation should be avoided, the total dose of chloral hydrate should not exceed 120 mg·kg-1 (and 
dose equivalents for related drugs, triclofos sodium) 
5. Always advise parents of possible unsteadiness in infants post sedation 
 
2.3.9  Research Questions to Answer 
1). In terms of tPTEF what is the best technique or protocol to use to accurately collect this 
parameter? 
Pneumotachs appear to be the simplest method to collect tidal breathing data. Shorter sample 
times involve a tester to select the ‘best’ curves for analysis which may bring in certain levels 
of error. This would appear to be removed by using longer sampling times and automatic, 
non human, selection of flow curves for analysis. To adequately define all points of tidal flow 
especially at higher fR a sample frequency of at least 200hz should be used.  
 
2). What type of participants has it been collected in and how well was this 
tolerated/undertaken?  
The use of resting tidal expiratory flow profiles have mainly been used in very young 
children who are not capable of standard lung function measurement. The only studies into 
older subjects were those conducted by Williams and colleagues. In the chronologically 
young patient groups, subjects were often sedated which would make the tests not applicable 
outside a clinical setting. The use of resting tidal breathing profile’s in older patient groups 
with respiratory disease warrants further investigation. 
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3). What differences were found between groups with different stages of lung 
disease/impaired respiratory function? 
In studies that compared healthy controls with clinical groups that had some form of changed 
airway function either from disease, obstruction or the use of bronchodilators (n=12), 8 
studies found significant differences in tPTEF/tE. Furthermore tPTEF /tE was found to vary with 
ethnicity (Stocks et al 1997), be lower in children exposed to tobacco smoke inutero (Hoo et 
al 1998; Stick et al 1996; Ueda et al 1999) and was found to be lower in children who went 
on to become wheezy or asthmatic (Yuksel et al 1996; Dezatuex et al 1994). 
 
4). How reliable a technique is it to accurately represent airway obstruction? 
The potentially most troublesome aspect of tidal breath analysis from the computational point 
of view is the identification of the beginning and end of inspiration (Bates et al 2000) 
although this can be made easier with high enough sampling rates. Establishing a truly resting 
profile is the main aim of any protocol and this should be established after a period of quiet 
tidal breathing. It is unclear whether this can be achieved within a few breaths and may take a 
longer period of time (>2min) to be achieved. The reliability and repeatability of such 
measurements in health and disease requires further investigation. 
2.3.10  Proposals for Future Research Within Measurement of TBPA 
Resting tidal flow/volume measurements may be important supplementary tools in the 
investigation of respiratory disease in both research and clinical work (Lodrup-Carlsen 2000) 
as this synthesis has identified.  More work is needed however on their use and the following 
areas for future research are proposed. 
 
1) How repeatable and reliable is any such protocol/technique? 
2) Can such protocol be used to adequately distinguish between health and disease? 
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2.4 Conclusions to Literature Review 
 
 
Reliable tests of RME have been difficult to establish (Hart et al 2002) and the reasons for 
this have been explored within this research synthesis. It has been shown that there is some 
confusion within the literature about the exact nature of respiratory endurance and what it 
exactly entails. While many studies and reviews believe endurance and fatigue to be 
synonymous terms that can be used interchangeably this has been shown to be an incorrect 
assumption. Steady state sub-maximal tests of the respiratory system would appear to be the 
most applicable way of assessing respiratory endurance. 
 
Resting tidal airflow measurements may be important supplementary tools in both research 
subjects and clinical patients who cannot cooperate with more conventional lung function 
measurements (Lodrup-Carlsen 2000). However they do not exist without some issues that 
must be addressed when using them, primarily that resting tidal airflow measurements are not 
as sensitive as spirometry. Although a simple tool to apply and as it is non-invasive and 
requires no cooperation from a participant, it cannot be used to reveal the severity or the 
presence of airflow obstruction with complete reliability (Bates 1998). However it could have 
uses in hard to test populations and situations. When used outside the laboratory, with airway 
 In Summary……. 
In this chapter I identified, located, retrieved and synthesised 142 research papers developing 
research questions for the thesis. The issues identified in the synthesis of respiratory endurance 
led to letter to the editor of the Journal of Respiratory Medicine being published.  
 
1.The Participant 
 Existing tests of respiratory endurance often require participants to continue to fatigue. 
 TBPA has been used mainly in younger children due to the difficulty in them completing 
standard lung function tests. 
2. The Test 
 Many of the studies identified have confused endurance with fatigue and no standard 
definition of endurance exists or a protocol to measure it. 
 TBPA has been used to detect change between health and disease although it is not as 
sensitive a measure as standard lung function tests. 
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obstruction already confirmed with spirometry, resting tidal airflow measurements could be 
used to monitor lung function over time in the home or at work.  
 
With both techniques the removal of significant effort on behalf of a participant means that 
they would be easier to undertake for the groups that find respiratory testing difficult and 
would also be simpler to apply. However this should be under the proviso that they may not 
be as sensitive as existing methods of assessing lung function. 
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Chapter 3 - Materials and Methods 
3.0  Introduction and Overview 
3.1  Applied Resistive Device (MicroRMA) – Development of a Protocol and 
Outcome Parameters 
3.2  Tidal Breathing Profile Analysis (TBPA) 
3.3  Development of a Paced Breathing Metronome 
3.4  Standard Lung Function Tests 
3.5  Standard Exercise Testing 
3.6  Summary and Conclusion 
 
3.0  Introduction and Overview 
This chapter details the techniques and methods used during the studies described 
within this thesis. It begins by detailing how a new technique to assess respiratory 
system endurance, using the MicroRMA, was developed. It then gives detailed 
instruction in the use of Tidal Breathing Profile Analysis (TBPA) to predict FEV1. 
The development of a Paced Breathing Metronome is then described before 
concluding with a description of standard lung function and exercise tests used later in 
this thesis. 
3.1 Constant Resistance Device: Operation, Development and 
Outcomes 
The MicroRMA1 is a commercially available device manufactured by Micro Medical 
Ltd (now Cardinal Health, USA). It is a USB driven device with proprietary software 
that can be operated by laptop or desktop computer. It is CE marked and is therefore 
safe to use for human testing. The work of this thesis details some of the early work 
with this device and its development. Currently no standard published protocol exists 
for assessing respiratory function with this device. 
 
The MicroRMA has UK and EU patent applications (2 420 077 and 1 397 994 A1 
respectively: Appendix 3.1) which describe the mechanics of the device in detail. The 
device consists of a flow sensor head and a SenSym SDX differential pressure sensor 
around the variable resistance tube (Fig 3.1). As the subject breathes through the 
MicroRMA probe, the flow and differential pressure are sampled every 100Hz. To 
                                               
1 Within this thesis the MicroRMA is also referred to as the RK device 
 50
maintain a constant resistance (RK) irrespective of flow the RMA software alters the 
internal orifice diameter of the breathing tube which transverses the flow probe (Fig 
3.1). By either increasing or decreasing size of the aperture every 100th of a second, 
RK load can be maintained at or close to the target resistance during the majority of 
each breath even at low flow rates. At a flow rate of 1 L.min-1 through the MicroRMA 
results in a resistance of 0.14 kPa.L.sec-1 (Fig 3.2). 
 
Within the UK patent application the device is described as an ‘apparatus for 
determining respiratory muscle endurance of a person’. However the concept of 
endurance assessment is suggested to be a progressive test to fatigue, which results in 
endurance time. As has been argued previously (Section 1.9) such a test does not 
represent endurance of the respiratory system. However the ability of this device to  1) 
maintain resistive load independent of air flow, therefore reducing the ability of a 
subject to modify their breathing strategy during testing; and 2) easily record and 
integrate pressure and flow data with time allowing the work to be calculated (Section 
1.12) suggests that this device warrants further investigation.  
 
 
Figure 3.1: Internal Assembly of MicroRMA Device (from EU Patent): 48 = 
mouth piece; arrows are the direction of airflow; 44 = variable orifice. 
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Figure 3.2: Inherent Resistance Developed by MicroRMA (manufacturer 
supplied) 
 
3.1.2  Operation of Device 
The appearance of the screen interface is outlined below. In simple terms an operator 
selects a RK load that they wish a subject to breathe against. The RK device is able to 
create RK loads up to 20 kPa.L.sec-1 although in practice such a level of resistance 
would be impractical for use with human testing. The software allows the RK load to 
be altered in 20 increments for an indefinite period. The period of time is expressed in 
breath cycles. For example; 
 
Subject A protocol 
 – 100 breaths@ 1.0 kPa.L.sec.-1;  
Subject B protocol  
- 100 breaths  25 breaths@ 0.25 kPa.L.sec.-1 
25 breaths@ 0.50 kPa.L.sec.-1  
25 breaths@ 0.75 kPa.L.sec.-1  
25 breaths@ 1.0 kPa.L.sec.-1. 
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As will be described later study participants were able to use this device in a variety 
of exercise modalities such as walking and cycling, and also whilst seated. 
3.1.3  Why Choose a 6-minute Endurance Trial? 
When developing techniques to assess respiratory endurance, a constant rather than 
incremental protocol would appear to be the best method to use when developing 
protocols to assess endurance (Section: 1.10; 2.4). However, the majority of existing 
techniques which aim to assess respiratory endurance use maximal and/or incremental 
protocols (Section 2.2.8). It is therefore necessary to look into another field where 
constant sub-maximal tests of endurance are widely used, for example human exercise 
testing. 
 
Many tests that have been developed to assess human exercise endurance expressed as 
maxOV 2  (ACSM 2000; Wasserman et al 1999) to assess maximal oxygen uptake 
(see Section 3.5.1 below). Alongside such tests of maximal exercise capacity, sub-
maximal tests have been developed that are used to assess physical exercise capacity 
and to predict maximal performance. These tests have been developed to use with 
specific populations such as individuals with chronic disease or for whom maximal 
testing is inappropriate. They have also been developed for situations when 
sophisticated equipment and trained staff are not available. 
 
The most obvious sub-maximal exercise test for comparison is the 6-minute walk test, 
6MWT, (ATS 2002 B). This test of functional exercise endurance is widely used in the 
clinical respiratory environment in patients with cardio-respiratory disease (see 
Section 3.5.3). Other sub-maximal exercise tests also exist such as the Astrand 
Rhyming Cycle Protocol (Section 3.52 - Astrand & Rhyming 1954). This is a single 
stage 6-minute cycle protocol that uses the relationship between HR and 2OV uptake 
to predict maxOV 2 . 
 
A 6-minute sub-maximal protocol has several benefits over maximal testing 
principally by the removal of subjective motivation to complete the test. Establishing 
a definitive end-point gives the subject a target to achieve rather than having to work 
towards an unknown designated maximal point and the subject having to judge when 
they are exhausted. Noakes (2008) argues that in relation to maximal exercise testing 
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this is important, as accurate knowledge of the exercise duration optimises exercise 
performance. The goal of this strategy is to complete an activity without homeostatic 
failure or the development of a ‘‘limiting’’ muscle fatigue. Additionally by using a 6-
minute, constant, sub-maximal protocol, subjects can achieve a steady-state level of 
ventilation and therefore steady state work rate. When given a constant stressor to 
preserve homeostasis the body adopts the most efficient manner to overcome that 
stressor. By assessing and measuring these adaptations an index of endurance 
capability should be suggested. With regards to respiratory testing this would 
represent a much better test of endurance than existing maximal techniques. 
 
The few respiratory endurance protocols identified in the review of the literature 
(Section 2.2.8) that have used constant workloads for set time periods are those which 
use; 1) Maximal Sustained Ventilatory Capacity (MVV), varying from 10-minutes 
(Fairban et al. 1991. McConnell et al. 2003), 12-minutes (Levine et al.1992), 15-
minutes (Belman & Kendregan 1982), to 150-minutes (Martin et al.1982A); 2) 
Maximum % of MIP, for 10-minutes (Chen et al.1985. Nickerson & Keens 1982); or 
3) Breathing through the smallest fixed orifice for 10-minutes (Ries et al. 1988). All 
of these studies use periods of time greater than 6-minutes.  These long-duration 
respiratory endurance studies aim to assess maximal performance over time, even 
though they did not require the participant to finish the test because of fatigue. Given 
the conceptualisation that endurance can only be represented by achieving a constant 
sub-maximal steady state, this would suggest that a shorter duration trial as has been 
outlined would be more applicable. 
3.1.3.2  The 6-minute Protocol  
All subjects gave written informed consent and completed a study relevant health 
screening questionnaire before taking part. For all trials each subject held the RK 
device (Section 3.1) while breathing through a mouthpiece and bacterial filter placed 
in series. All subjects wore nose clips and had no prior experience of breathing 
through the device. 
 
When a participant indicated they were ready to begin they were asked to breathe 
through the RK device until instructed to stop. The trial ended after six minutes or 
prematurely if the subject gave up or failed to maintain a tight seal around the 
mouthpiece to prevent air leakage. Participants had at least ten minutes rest between 
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each trial or until they felt ready to continue, during which they were given the 
opportunity to rest and drink water. Participants were given no instruction during any 
of these trials on their expected fR or tI/tTot ratio and therefore maintained a self-paced 
or volitional rate throughout. Additionally no verbal encouragement was given 
throughout the trials. 
 
All studies were approved by the Faculty of Health, Sport and Science ethics 
committee and where applicable and relevant, local NHS Trust Research departments, 
and Local Regional Ethics Committees. 
3.1.4  Development of Software 
One of the key aspects or benefits of working closely with an industrial partner, in this 
case Micro Medical Ltd, was to adapt the MicroRMA’s software to increase the 
functionality of the device.  
3.1.4.1  MicroRMA Software Version 1.01 
This was a Microsoft Windows based software allowing control over a USB driven 
device, the MicroRMA. The software consists of variety of data formats and output 
styles including tables and graphs (Fig 3.3). It is a sophisticated package that allows 
detailed input of patient parameters, gender, height & weight, date of birth, smoking 
status, ethnic origin and the capacity to assign a unique alpha-numeric patient 
identification (Fig 3.4).  
 
As described in Section 3.1.2 the RK load is set in kPa.L.sec-1 over breath cycles as 
opposed to time. The RK device allows up to twenty alterations in applied resistive 
load with indefinite breath cycles per level (Fig 3.5). The software automatically 
provides biological feedback allowing the subject to maintain a set breathing rate 
during trial (central red line; Fig 3.6), between set limits. A number of graphs and 
tables can be used to represent outcomes of particular trial (Fig 3.7). The facility also 
exists to export raw data as a comma-separated value file, consisting of time, pressure 
and flow data sampled at every 100 Hz (Figure 3.8). 
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       Figure 3.3: Main User Screen                       Figure 3.4: Adding a Patient 
 
 
Figure 3.5: Applied Resistance per Breath Cycle 
 
Figure 3.6: Bio-Feedback 
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Figure 3.7: Outcome Graphs 
 
                                                   Figure 3.8: Exporting Raw Data 
 
3.1.4.2  First Stage Software Development. 
On initial use a number of issues with the initial version of the software interface were 
identified. These included; 
 
Issue 1) Data Output.  
The software presented test results as cumulative values in both tabular and graphical 
form. However, it also allowed direct export of the raw data, although it should be 
noted that while the device samples at 100 Hz, (once every 10 milliseconds), the raw 
data recorded an average of ten such cycles and therefore represents a mean over 100 
milliseconds. Despite the operation of the device based on setting the RK load per 
breath cycle, there was no facility either in the on-screen form or raw data export to 
express the outcomes of a trial in a similar per breath fashion.  
 
 57
Resulting from this issue; 1) The exported raw data is now additionally expressed in 
per breath terms; and 2) a new graph option of Energy per Breath has been added. 
 
Issue 2) Age Limit.  
The software allowed a subjects date of birth to be entered as the day of the test i.e. 
that the subject was 1 day old.  
 
Resulting from this issue; 1) A date different from the day of test date had to be 
entered under subject details. However the range was set from 1 -150 years which 
indicates a lack of clinical relevance or experience on behalf of the software 
developer(s). 
 
Issue 3) Start of Test.  
With the software the test began as soon as the operator selected the start test option 
with no relation to the point in the respiratory cycle the subject was currently at. 
Therefore, the length of the first breath cycle was often markedly shorter than later 
breaths. This was important due to the way that applied load was set per breath rather 
than by time. 
 
Resulting from this issue; 1) a breathing cycle now begins on inspiration and ends on 
expiration; and 2) when the test is started it only begins on a subjects’ next 
inspiration.   
 
Issue 4) Sound Incentive.  
The software incorporated an audible beep on a subject’s inspiration. The pacing of 
this beep therefore matched a subject’s respiratory rate and was not an instructional 
metronomic function in any way which led to significant confusion, particularly when 
a metronome was used to pace breathing.  
 
Resulting from this issue; 1) this function was removed. 
 
Issue 5) Battery Storage.  
The MicroRMA device while host powered through a USB port also has an intrinsic 
battery that needs to maintain a level of charge for operation. With frequent use 
 58
battery charging occurs and low charge is not an issue. However with prolonged 
periods of non-use the battery can run down and needs a period of time before 
operation can commence when initially connected. An indicator of battery charge 
level would be a useful tool for an operator, either as a software option or built into 
the device.  
 
Resulting from this issue; 1) due to the capital investment and work needed to 
redesign the hardware of the device this adaptation was not undertaken. 
3.1.4.3  Second Stage Development 
Further use of the device led to the identification of further issues. These included; 
 
Issue 1) Set Zero Flow Reminder.  
Before each test the device guidelines to zero the flow reading, and there is an option 
to do this. However as with all tests, operator error can mean that this is not always 
undertaken.  
 
Resulting from this issue; 1) A prompt before each test was incorporated. However 
the manufacturer commented that some medical professionals may find this irritating 
and as a compromise, an option was created where it could be selected that an 
operator was prompted before each test to zero the device. 
 
Issue 2) Metronome Timings.  
As is discussed elsewhere a need for a metronome with the ability to pace both 
inspiration and expiration was identified (Section 2.2.12).  
 
Resulting from this issue; 1) A new metronome was incorporated within the program 
that allowed the length of inspiration and expiration within a breath to be predefined.  
Unfortunately on testing the integration of this metronome within the software 
package was found to be unreliable. This drove the separate development of a paced 
breathing metronome described below (Section 3.3). 
3.1.5  Calculation of Test Outcomes 
While it was possible to develop the controlling software it was not possible to adapt 
the software in terms of outcome measures. The MicroRMA software displays 
graphical outcomes (Fig 3.3) however these aren’t suitable for research use as they 
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give no quantifiable data and cannot be accurately controlled to end a trial precisely. 
Therefore for each trial undertaken the raw data for each test was exported as a CSV 
file, this gave continuous flow (litres per second) and pressure (cmH2O) data sampled 
at 100 Hz. Pressure data was converted to kPa in post analysis. 
  
Within a data manipulation package (Microsoft Excel), macros (a sequence of 
computing instructions as a single programe statement) were created that were used to 
calculate the following parameters from this raw data. Primarily this was so that each 
raw parameter (flow, pressure and time) could be converted from being expressed 
every 10 milliseconds to every breath. Change from negative to positive pressure was 
used to define point of inspiration/expiration. From these data all further study 
parameters were calculated. 
 3.1.5.1 Breaths 
Expressed as a respiratory rate and the cumulative number of breaths in a trial (fR).  
3.1.5.2  Time – t (seconds)  
Expressed as Total breath time (tTot), Time of inspiration (tI), Time of expiration (tE), 
and the ratio between time of inspiration and total breath time was calculated (tI/ tTot) 
(Fig 3.9). Total time to trial end (tEND) was calculated by cumulatively summing 
individual breath times in each 6-minute trial identified by the nearest whole breath to 
360 seconds which was taken as the trial end-point. 
3.1.5.3  Volume –V(Litres) 
Flow data integrated with time gives volume (Fig 3.10). The volume of air inspired 
was expressed per breath as inspired tidal volume (VTI) and per minute as minute 
ventilation ( EV ). Respiratory drive was expressed as inspired tidal volume divided by 
time of inspiration (VTI/tI). 
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Figure 3.9: Time Parameters Calculated per Breath. Time of inspiration (tI), time 
of expiration (tE) and the total breath time (tTot) in seconds. Note: representation of 
healthy breath. 
 
 
Figure 3.10: Integration of Inspiratory Flow (L) With Inspiratory Time (sec) to 
Produce Inspiratory Volume per Breath – Tidal Volume (VTI(L)) Note: 
representation of healthy breath. 
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3.1.5.4  Energy - W (Joules) 
Energy was calculated by integrating time, volume and pressure data (Fig 3.11). 
Defining the point of inspiration/expiration during each breath allowed the energy (J) 
used during the inspiratory (WI) and expiratory phases (WE) of tidal breathing to be 
calculated. 
3.1.5.5  Work of Breathing at the Mouth - Wrsmouth (J.L) 
Work of Breathing at the mouth (Section 1.10) was calculated by integrating the 
inspired volume per breath (VTI) and energy used per breath (WI or WE), and 
expressed as work of breathing at the mouth on inspiration (InWrsmouth J.L) or 
expiration (ExWrsmouth J.L). 
 
 
Figure 3.11: Energy – W (J) =Integration of flow (L), Pressure (kPa) and Time 
(sec). 
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3.1.6  Summary of Parameters From 6-minute Trial 
The regulation of respiration had been described earlier (Section 1.2), the following 
parameters are calculated during the initial use of the 6-minute trial protocol to assess 
increases in ventilation and work required by the respiratory system as a result of the 
intensity of a trial. In a steady state trial these parameters would be expected to adapt 
to the level and pattern of ventilation required and remain constant throughout. The 
level of adaptation should allow the intensity of the trial to be assessed in different 
individuals; such as in health and disease, and in different modes; such as when seated 
or exercising. Initial increases in ventilation are achieved by increases in both VTI and 
fR and represent the respiratory systems main way of adapting to increased demand. 
 
1) VTI (L). 
VTI is dependent on the size of the lungs and height. In all subjects however there is a 
physical limit to which VTI can increase to meet ventilatory demands. Although the 
respiratory system is generally described as being ‘over engineered’ and levels of VTI 
rarely meet the levels seen during maximal ventilation, even during maximal exercise 
tests. 
 
2) Increases in respiratory rate allow the respiratory system to adapt to increased 
ventilatory requirements when VTI can either be no longer increase or the increased 
demands for ventilation can be met by an increase in fR (min-1) for example that 
during exercise. Normal resting fR for example that seen in Section 5.4.3 is on average 
16±4 bpm-1, although this is elevated in disease such as COPD 20±4 bpm-1 (Colsanti 
et al 2004) and during maximal exercise can reach 51 bpm-1(Kift & Williams 2007).  
 
3) WI/tI (J.sec-1) represents the energy used by the respiratory system when 
standardised for the period of inspiration time. If energy increases but VTI and fR 
remain the same the respiratory system increases driving pressure of the system. 
As it is dependent on the volume of ventilation it is necessary to express the energy 
needed to move a volume of air as work. 
 
4) VTI/tI (L.sec-1) represents an index of the demand on the respiratory system (Millic-
Emili & Grunstein 1976) 
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5) Measuring the work of breathing described earlier (Section 1.12) is complex as 
quantifying movement and distortions of the chest wall are difficult to quantify and as 
such work of breathing measured at the mouth is not a direct measure of the work of 
breathing. However ‘measuring the work performed against an external load can 
provide sufficient information for purposes of respiratory endurance testing’ (ATS. 
2002A). InWrsmouth (J.L) can therefore be used as a measure of endurance of 
respiratory system. 
3.2  Resting Tidal Breathing Profile Analysis 
Resting tidal airflow was recorded in seated subjects breathing through a mouthpiece 
and wearing a nose-clip for 3-minutes (Section 2.3.9). The mouthpiece was connected 
in series with a low-resistance screen pneumotachograph. The principle of the 
pneumotachograph rests on Poiseuille's Law, which states that, under capillary 
conditions, in a straight rigid tube, delivery is proportional to pressure loss per unit of 
length. The continuous measurement of the pressure loss, that is the measurement of 
the pressure difference between two points on the tube, is a function of gas of the rate 
of gas flow (ARTP 2006). When airflow is integrated with time, volume can be 
calculated. 
 
A differential pressure sensor (PowerLab, ADInstruments) allowed respiratory flow to 
be logged at 100 Hz onto a computer and saved for later analysis (Fig 3.12). After 
recording resting tidal airflow, the data logging software (Chart V5, ADInstruments) 
was used to extract the final minute of the continuous flow signal for export as text 
files. This was to allow participants to achieve a rested breathing pattern. 
 
Proprietary software was used to further process the flow data into individual breaths 
and exclude unusually large or small breaths. This software was used to overcome the 
important issue when assessing resting tidal profile of the correct selection of the tidal 
flow loops or curves to assess (see Section 2.3.7). The breaths were summed to form a 
single representative breath from which a series of time and flow metrics were derived 
(Fig 3.13). Parameters are as follows: duration of inspiration, tI (a-c); duration of 
expiration, tE (c-e); duration of breath, tTot (a-e); time to reach peak flow during 
inspiration, tPTIF (a-b) and expiration, tPTEF (c-d); peak flow rate at inspiration, PIF (f) 
and expiration, PEF (g). A further flow profile indice, tPPEF80, was derived from the 
expiratory phase of this representative breath. This time point at 80% of post peak 
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expiratory flow rate (I in Fig 3.13) was used to define changes in flow rate as a 
decrease in tPPEF80 suggests airflow obstruction and hyperinflation (Colsanti et al. 
2004). 
 
3.2.1  TBPA Outcomes 
Using regression analysis Colsanti et al (2004) developed predictive formulas using 
parameters measured from resting tidal breathing profile to calculate FEV1 expressed 
as FEV1 from Tidal Airflow Profile – FEV1TAP (Table 3.1). 
 
Table 3.1: Equations Used to Calculate FEV1TAP in Healthy Controls and COPD. 
*A = age (years); H = height (metres) 
 Regression Equation 
Controls FEV1TAP = -5.41 + (H x 4.97) + (A x –0.02) +(tPTEF x 0.005) 
COPD FEV1TAP = -3.73+( tPPEF80 x 0.031)+(tPIF x 6.08)+(Age x -0.017) 
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Figure 3.12: Example of Continuous Resting Tidal Air flow 
 
 
 
 
 
                                                                     Figure 3.13 An Example of a Normal Resting Adult Tidal Flow Profile. 
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3.3  Metronomic Control of Breathing 
Initially an open source standard electronic metronome (available on-line 
http://www.bestsoftware4download.com/software/t-free-metronome-download-gmobovun.html) was used to 
set the required fR, by providing a visual cue and audible tone (Fig 3.14). The subjects 
were instructed to inspire and expire on each subsequent tone. As standard 
metronomes generate a constant (symmetrical) tempo, this meant that subjects should 
maintain a constant tI/tTot of 0.5.  
 
Existing studies (Section 2.2.12), when attempting to control the breathing pattern 
often failed to explicitly state a tI/tTot ratio. The most commonly stated ratio was 0.5, 
i.e. when the phase of expiration equals that of inspiration, however in healthy 
individuals average tI/tTot is closer to 0.4 (Williams et al 2000) where inspiration is 
approximately 40% of total breath time.  
 
An extensive search for further available metronomes was undertaken and many 
physical and electronic versions were identified. It was unusual however to find a 
metronome that was designed to operate at the slow tempo of a resting breathing rate 
8 – 20 beats per minute as most were designed for musicians who require 
substantially higher beat tempos. Only one specialised commercially available 
respiratory metronome could be located (RESPERATE - www.resperate.co.uk), but 
this is a complex device used to lower blood pressure (Schein et al 2001) and 
therefore is not suitable for use in this context. 
 
Subsequently a bespoke metronome was developed, that would specifically allow the 
proportion of time during the two phases of respiration to be set independently from 
the overall tempo of breathing. For example this device would allow participants 
breathing to be paced, both fR, and inspiratory and expiratory phase, by providing a 
computer generated visual cue and audible tone to signify the start of each inspiration 
and expiration. Separation of inspiration or expiration allowed the desired tI/tTot ratio 
to be set at the operator’s choice. Written in Microsoft Visual Basic, this Variable 
Electronic Metronome (VEM) was developed over three versions, the final version 
incorporated a colour indicated change red/green, with fR and tI/tTot fully selectable 
(Fig 3.15). 
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Figure 3.14: Standard Electronic Metronome 
 
 
Trial time 1min, fR 12 bpm, tI/tTot 0.5 
 
Trial time 6 min, fR 15bpm, tI/tTot 0.4 
Figure 3.15: Variable Electronic Metronome 
 
3.4  Standard Lung Function Measurements 
Standard techniques that are used to assess respiratory function are outlined in Section 
1.5. Forced Expiratory Volumes (Fig 3.16) were measured using a range of 
spirometers; all were routinely calibrated before use and standardised to BTPS. 
3.4.1  Measures of Dynamic Lung Function 
All subjects performed maximal expiratory manoeuvres as per British Thoracic 
Society standards (1994); specifically while seated and wearing a nose clip, all 
subjects were instructed to inhale to Total Lung Capacity (TLC) then insert mouth 
piece and expire as forcefully as possible to residual volume. Three measurements 
were made with the highest being used for subsequent analysis, with FEV1 and FVC 
being recorded. 
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3.4.2  Spirometry Reference Values 
Results obtained from spirometry are of relatively limited use unless there is a value 
for a ‘normal’ subject of similar sex, age and height that can be used for comparison. 
Large population studies have been undertaken to obtain reference values which 
enable mean or average values to be calculated (ARTP 2006) those developed by the 
European Community for Steel and Coal – ECSC (Quanjer et al 1993) were used in 
this thesis when studying adult subjects >18 years (Table 3.2). When assessing 
children’s lung function (Chapter 8) equations developed by Rosenthal et al (1993) 
were used to predict relevant reference values. 
 
Table 3.2: ECSC Spirometry Reference equations for FEV1 and FVC (L) 
h = height (cm); a = age (years) 
 Regression Equation                              ( SD) 
Male 
FVC 
FEV1 
 
= (0.0576 x H) - (0.026 x A) - 4.34          (± 0.61) 
= (0.043 x H) - (0.029 x A) - 2.49            (± 0.51) 
Female 
FVC 
FEV1 
 
= (0.0443 x H) - (0.026 x A) - 2.89          (± 0.43) 
= (0.0395 x H) - (0.025 x A) - 2.60          (± 0.38) 
 
3.4.3  Measures of Static lung function and Air way Resistance 
Participants were asked to sit in a sealed and calibrated Body Box (Master Screen 
Body, Jaeger, Germany) for 1 minute to allow temperature to equilibrate before 
testing. Whole body plethysmography was then used to measure participants Total 
Lung Capacity, Residual Volume, Functional Residual Capacity. Definitions and 
illustrations are described below (Fig 3.17). Whole body plethysmography was also 
used to assess participants air flow resistance RAW. (Goldman et al 2005). 
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Figure 3.16: Forced Expiratory Tests: Forced Expiratory Volume in one second 
(FEV1). The volume of gas expired during the first second of a forced expiration 
following a full inspiration. Forced Vital Capacity (FVC). The volume of gas expired 
when the forced expiratory manoeuvre is continued to full expiration. 
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Figure 3.17: Static Lung Function Tests (adapted from McConnell 2007) 
Total Lung Capacity (TLC). Volume of air in the lungs at full inspiration; Residual 
Volume (RV). The volume of air remaining in the lungs at the end of a full expiration; 
Functional Residual Capacity (FRC). The Volume of air remaining in the lungs after 
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resting tidal breath;  Expiratory and Inspiratory Reserve Volumes (ERV/IRV) The 
volumes of air available between the beginning or end of a tidal breath and TLC and 
RV respectively; Tidal Volume (VT). Volume of air in a single breath. 
 
3.5  Standard Exercise Tests 
A variety of methods are available for assessing the respiratory and cardiovascular 
response to exercise. These are useful as they represent a standardised stressor which 
results in an increased requirement on the respiratory system that is represented by an 
increase in the ventilation rate as the body’s demand for oxygen increases. Using 
established tests not only gives this standardised stressor but can, with maximal tests 
(measure) or with sub-maximal tests (predict) maximal oxygen uptake ( maxOV 2 ) 
which can then be used as a measure of aerobic fitness. 
 
3.5.1  Maximal Oxygen Uptake ( maxOV 2 ) Testing 
Maximum oxygen uptake is the highest value of oxygen that can be attained and 
measured during an incremental exercise test. It requires an extensive laboratory 
environment with calibrated ergnometers (cycle or treadmill), exhaled gas analysis 
devices, equipment suitable to measure large EV ’s (as opposed to the smaller EV ’s 
seen at rest) and trained staff to administer test protocols. 
 
 As attainment of maxOV 2 generally necessitates the use of large muscle groups over 
an extended period of time 5–15 min, when the body is working aerobically, hence 
maxOV 2 is also described as maximum aerobic capacity (Cooper & Storer 2005). It 
is a widely used measure and considered the ‘gold standard’ method of assessing 
human exercise performance (James et al. 2007) 
3.5.2  Astrand - Rhyming Test (Astrand & Rhyming 1954) 
The Astrand - Rhyming test is a single 6-minute stage cycle protocol developed to 
elicit a steady state exercise response by cycling at a set pedal cadence against a 
resistance to achieve a predetermined work rate. The test requires a cycle ergometer 
and means of assessing participants heart rate (fH). Using the linear relationship 
between heart rate and oxygen consumption maxOV 2  can be predicted. 
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3.5.3  6-minute Walk Test (ATS 2002B) 
The 6MWT is a practical simple test that requires a corridor with a known distance, 
ideally 30 metres but can be 10 – 25 metres. No other exercise equipment or advanced 
training is necessary making it useful for clinical use within hospitals. As walking is 
an activity performed daily by all but the most severely impaired patients it is a 
modality that most patients can undertake.  
 
This test measures the distance that a patient can quickly walk on a flat, hard surface 
in a period of 6-minutes. It evaluates the global and integrated responses of all the 
systems involved during exercise, including the pulmonary and cardiovascular 
systems, systemic circulation, peripheral circulation, blood, neuromuscular units, and 
muscle metabolism. It does not provide specific information on the function of each 
of the different organs and systems involved in exercise or the mechanism of exercise 
limitation, as is possible with maximal cardiopulmonary exercise testing.  
 
The self-paced 6MWT assesses the sub-maximal level of functional capacity. Most 
patients do not achieve maximal exercise capacity during the 6MWT; instead, they 
choose their own intensity of exercise and are allowed to stop and rest during the test.  
However, because most activities of daily living are performed at sub maximal levels 
of exertion, the 6MWT may better reflect the functional exercise level for daily 
physical activities. 
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3.6 Summary & Conclusion 
In Summary……. 
In this chapter I have outlined the testing methodologies that will be used in the rest of 
the thesis 
The Participant 
 A 6-minute trial is similar to other existing physiological tests in terms of time 
and intensity and should therefore be able to completed by the majority of 
participants. 
The Test 
 TBPA has been developed as technique to predict FEV1 from relaxed tidal 
breathing. 
 The RK device is able to measure fR, WI & InWrsmouth. 
 Work of breathing at the mouth (InWrsmouth) can be used as an indirect 
measure of respiratory endurance. 
 
 
The methods that will be used in this thesis are outlined. The two main protocols, the 
6-minute RK trial and TBPA, and the two outcome parameters InWrsmouth and 
FEV1TAP are described. Existing methods of lung function are also described which 
can be used to differentiate between health and disease. These are useful for 
comparison and to differentiate between individuals, but in themselves do not 
represent measures of endurance. FEV1 however provides a direct comparison for 
TBPA analysis. 
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Chapter 4 - Control Subjects 
 
4.0  Introduction and Overview 
4.1 Development and Analysis of 6-minute Protocol 
4.2 Applying Incremental RK During 6-minute Trials 
4.3 Hyperinflation in Healthy Adults Breathing Against a RK Load. 
4.4 Effect of Varying Respiratory Rate 
4.5 Effect of RK Load During Separate Phases of Tidal Breathing 
4.6   6-minute RK Protocol 
4.7 Summary & Conclusion 
 
4.0  Introduction and Overview 
This chapter describes the development and refinement of the 6-minute trial outlined 
earlier (Section 3.1.3.2). Initially the steady state nature of the protocol is examined 
and outcome parameters tested. Following this the level of RK needed to elicit a 
suitable response is elucidated and the effect that this level of RK has on lung 
hyperinflation is measured. The effect of standardising fR, tI/tTot and phase loading is 
then assessed so that a standard protocol can be created. This protocol is then 
examined in control subjects. 
4.1  Development and Analysis of a 6-minute Breathing Protocol 
4.1.1  Introduction 
Respiratory system endurance can only be accurately measured whilst undergoing a 
steady rate of respiratory work. Current incremental and maximal test protocols do not 
achieve this steady-state and therefore can only provide a measure of the respiratory 
system’s strength and susceptibility to fatigue, and thus not a measure endurance 
(Section 1.9). Published examples of whole body sub-maximal exercise tests that 
elicit a steady work rate were used to inform the initial time frame for the 6-minute 
protocol (Section 3.1.3).  
 
Studies that assess the time to reach peak expiratory flow, tPTEF generally have used 
much shorter sample times, although this was most likely due to the neonates and 
children studied (see Section 2.3.7). In comparable studies of adults, sample rates 
ranged from 80 seconds (Morris et al. 2004) to 2 minutes (Williams et al 2000). These 
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protocols were short as only resting tidal flow patterns were measured, and it was 
assumed that a steady-state would be already present.    
 
The aim of the following study was to assess whether participants achieved a steady 
state, assessed by measuring the breath-to-breath change in the parameters described 
in Section 3.1.6; VTI, WI/tI, VTI/tI and InWrsmouth throughout a 6-minute trial.  
 
There were two primary questions; 1) how long does it take for test participants to 
enter into a steady respiratory rate, and 2) which segment of the 6-minute trial best 
represents the participant’s response to the trial? 
4.1.2  Method  
Participants 
Forty healthy individuals (9F:31M; age range 18-64 yrs; FEV1 % pred 103 ± 13; MIP 
105 ± 34 cm H2O) undertook a 6-minute seated trial (Section 3.1.3.2). Upon gaining 
consent, body weight and height were measured and baseline spirometry performed 
(Section 3.4.1). 
 
Protocol 
A standard protocol was followed (Section 3.1.3.2) and the RK load was set at 0.75 
kPa.L.sec-1.  
 
Data Analysis 
At the end of the test the following study parameters were per breath calculated; VTI 
(ml) WI/tI (J.sec-1), VTI/tI (L.sec-1) and InWrsmouth (J.L) (Section 3.1.6). The values for 
each parameter for the last ten breaths of each trial were averaged and used to 
normalise the data, allowing a comparison of the absolute change in each breath from 
this average value to be calculated. The number of breaths when each study parameter 
was outside ± 2 SD of the average of the normalised values were summed. 
4.1.3  Results  
Participants tolerated the 6-minute protocol well and successfully completed all forty 
trials with none being stopped early and no adverse effects reported. The average 
respiratory rate per for the forty trials was 10 ± 5 breaths per minute. 
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The total numbers of breaths outside ± 2 SD for VTI, WI/ tI, VTI/tI and InWrsmouth were 
2, 4, 2 and 5 respectively, of which around half occurred within the first ten breaths 
for each parameter (Figure 4.1). 
 
Figure 4.1: Change in (A) VTI (ml), (B) WI/tI (J.sec-1), (C) VTI/tI (L.sec-1)  and (D) 
InWrsmouth (J.L), for each breath over 6 minutes. Upper solid line represents + 2 
SD, Lower solid line represents – 2 SD, grey dashed line represent zero. 
 
4.1.4  Conclusions  
This data shows that during a 6-minute protocol using a constant RK load of 0.75 
kPa.L.sec-1, participants enter into a steady state of respiration as seen by a constant 
VTI, WI/tI, VTI/tI and InWrsmouth. The majority of any deviation was seen to occur 
within the initial ten breaths, and for participants who completed these trials this 
would equate to approximately the first minute of the trial (average fR = 10 ± 5 min-1). 
 
This initial deviation most likely represents the period of adaptation to the increased 
resistive load. To ensure that the sampled data is representative of a steady state of 
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respiration it is necessary when using a 6-minute protocol to disregard the initial ten 
breaths from the analysis and use the remaining breaths to calculate study parameters. 
To ensure this represented a common factor, the first minute of data should not be 
used in the analysis of any RK trials. 
 
While all participants successfully completed the 6-minute protocol, there were 
anecdotal reports of increased salivation and some mild discomfort whilst breathing 
through the RK device. This is likely to occur as when breathing solely through the 
mouth, participants would be unable to moisten the air by breathing nasally and 
swallowing excess saliva is difficult.  
 
The aim was to develop a protocol that would be easy and comfortable to undertake, 
while ensuring the participants had entered into steady state. Previous studies of 
respiratory endurance identified in the literature review have suggested protocols of 
10-minutes or more are necessary, however this data shows that a 6-minute protocol is 
a suitable time period to elicit a steady state response. 
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4.2  Applying Incremental RK During 6-minute Trial 
4.2.1  Introduction  
To accurately quantify endurance by eliciting a steady work rate, the optimal level of 
resistance needs to be applied. This would be a resistance that is sufficient to provoke 
a quantifiable change in the respiratory parameters that can be constantly maintained 
during the 6-minute trial (Section 3.1.3.2). There is a need to optimise the RK load, as 
too small a load would not alter the respiratory parameters while too high a load 
would result in an incremental pattern of work possibly resulting in fatigue and 
preventing the attainment of a steady work rate. 
 
In Section 4.1 an RK of 0.75 kPa.L.sec-1 was shown to elicit a steady state response, 
but is this the optimum RK load? Repeated 6-minute trials with a range of RK loads 
were made to assess the minimum RK load that elicited a significant increase in study 
parameters compared with trials were no resistance was added, i.e. with an RK load of 
0, just the resistance provided by the fully open orifice and the intrinsic airway 
resistance of a participant.  
4.2.2  Method  
Participants 
Thirty two healthy individuals (4F:28M; age range 18-64 yrs; FEV1% pred 104±14) 
undertook a series of 6-minute seated breathing trials (Section 3.1.3.2). Upon gaining 
consent, body weight and height were measured and baseline spirometry performed 
(Section 3.4.1). 
 
Protocol 
The standard 6-minute protocol was followed (Section 3.1.3.2).   The first five 
subjects undertook six separate 6-minute trials at RK of; 0, 0.25, 0.5, 0.75, 1 and  
1.5 kPa.L.sec-1 administered in a varied sequence to negate any order effect. On the 
outcome of these trials the remaining subjects (n=27) undertook trials at RK’s of 0, 
0.75 and 1.5 kPa.L.sec-1 again in a varied sequence. Study parameters were calculated 
for each breath from the continuous data (Section 3.1.6.) with the first minute of data 
being discarded from the analysis (Section 4.1.4). 
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Data Analysis 
A one way ANOVA was used to assess for differences at increased RK from 0 
kPa.L.sec-1. When significance was identified a Holms-Sidak Post-hoc test was 
applied.   
4.2.3  Results  
Participants tolerated the 6-minute trials at varying RK well and successfully 
completed all trials with none being stopped early and no adverse effects reported. 
Data was lost for one trial due to a technical malfunction of the RK device. 
4.2.3.1  Initial 30 Trials (participants n=5) 
There was no difference between trials in terms of fR, VTI, and VTI/tI, while 
InWrsmouth and WI/tI were seen to significantly increase in trials with RK loads above 
0.75 and 1.0 kPa.L.sec-1 respectively (Fig 4.2). With rest phases in between the 6 
trials, cumulative testing time was in excess of 60-minutes. This data shows that only 
loads above 0.75 kPa.L.sec-1 were able to initiate differences in response therefore the 
remaining subjects completed three trials at RK loads of 0, 0.75 and 1.5 kPa.L.sec-1.  
4.2.3.2 All 89 trials (participants n = 32) 
With a greater number of participants and trials completed the findings from the initial 
trials was confirmed, with significant differences observed only in InWrsmouth and 
WI/tI with trials with RK loads of 0.75 kPa.L.sec-1  and above (Fig 4.3).  
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Figure 4.2: The mean ± SD is shown for A) fR  (min-1), B)  VTI/tI (L.sec-1), C) WI/tI (J.sec-1) , 
D) VTI (L) and E) InWrsmouth (J.L) during 6-minute trials (n=30) at six increasing RK loads 
(kPa.L.sec-1). *significantly different (p<0.05) from trial with RK load of 0 kPa.L.sec-1. 
 
 
Figure 4.3: The mean ± SD is shown for  A) fR  (min-1), B)  VTI/tI (L.sec-1), C) WI/tI 
(J.sec-1), D) VTI (L) and E) InWrsmouth (J.L)  during 6-minute trials (n=89) at three 
increasing RK loads (kPa.L.sec-1). * significantly different (p<0.05) from trial with RK load 
of 0 kPa.L.sec-1 
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4.2.4  Discussion 
The application of an RK load of 0.75 kPa.l.sec-1 significantly increased InWrsmouth and 
WI/tI from that seen when no resistance was applied (RK = 0 kPa.L.sec-1), increasing 
from -0.15 to -0.33 (J.L) and 0.06 to 0.12 (J.sec-1) respectively. These results suggest 
that this is the lowest RK load that can be applied to elicit a significant physiological 
response in the work of breathing as assessed by InWrsmouth and WI/tI. 
 
The initial 6 trials represented a cumulative testing time of over 60-minutes. This 
prolonged time could possibly provoke some form of testing fatigue although the 
maximum number and length of breathing trials that can be used remains unclear with 
some authors suggesting no more than three short trials (Wiley & Zechman 1966). 
However by varying the order in which the loads were administered confidence can 
be maintained that these differences were due to RK load and the response would be 
similar in all subjects. 
 
For the second part of this study the number of trials was reduced to make widespread 
testing more feasible and logistically possible. Increasing the number of participants 
from 5 to 32 confirms the initial results that an RK load of 0.75 kPa.L.sec-1 represents 
a suitable load to use in a 6-minute trial. However whether this is the ‘best’ load is 
still unclear as this could be somewhere between 0.5 and 0.75 kPa.L.sec-1. Further 
trials could be undertaken to further identify such a point, varying RK load by 0.5 or 
0.10 kPa.L.sec-1 rather than 0.25 kPa.L.sec-1 used in this study. It remains that all 
participants successfully completed all trials at 0.75 kPa.L.sec-1 and that this was seen 
to elicit a significant increased work of breathing in all participants. 
 
In these healthy participants the inspiratory work of breathing increased with 
increasing RK, with the InWrsmouth increasing 4 fold between 0 to 1.5 kPa.L.sec-1. As 
no concomitant increase in fR or VTI was shown, the extra work of breathing must 
have been met by an increased driving pressure generated by the respiratory muscles.  
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4.3  Pulmonary Hyperinflation in Healthy Adults Breathing Against a  
RK Load 
4.3.1  Introduction  
It has been shown that significant increases in InWrsmouth and WI/tI are provoked by 
applying an RK of 0.75 kPa.L.sec-1 or more (Section 4.2).  This RK load has to be 
higher than the inherent airways resistance (RAW) found in the healthy lung which is 
approximately 0.2 kPa.L.sec-1 (Cloutier 2007). In obstructive airway disease, such as 
COPD the intrinsic RAW is higher than this normal value. This requires greater 
pressure generation to overcome this resistance and a common strategy adopted by 
people with COPD is to develop a progressive static hyperinflation of the lungs. The 
raising of FRC helps to reduce the increased work of breathing (Cooper 2008). 
 
This study aims to address the question; Do healthy subjects respond in a similar way 
to increased RAW? (applied via the application of increased RK). The effect on lung 
volumes whilst breathing through the RK device was assessed. 
 4.3.2  Methods  
Participants & Protocol 
Eleven healthy individuals (5F:6M: FEV1 % pred 105 ± 13) underwent spirometry 
(Section 3.4.1) and whole-body plethysmography (Master Screen Body, Jaeger, 
Germany) allowing the Functional Residual Capacity (FRC), Residual Volume (RV) 
and Total Lung Capacity (TLC) and RAW to be assessed (Section 3.4.2) 
 
The RK device was then attached distally to the occlusion valve (Figure 4.4), FRC 
measurements were then repeated while the RK device applied increasing loads as 
described previously 0, 0.25, 0.5, 0.75, 1 and 1.5 kPa.L.sec-1 (Section 4.2.1).  
 
Data Analysis 
A one way ANOVA was used to assess for significant (p<0.05) differences in FRC, 
TLC, RV and RAW when an RK load was applied and when there was no added 
resistance (NAR). When significance was identified a Holms-Sidak Post-hoc test was 
applied.  
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Figure 4.4: The MicroRMA Device Attached in the Body Plethysmograph 
 
4.3.3  Results  
The 11 participants tolerated the manoeuvres well and all seventy-seven tests were 
successfully completed. With exposure to increasing RK during the seven different 
resistive loads, the participants’ TLC and RV did not change,  while the FRC 
increased significantly with an RK above 0.5 kPa.L.sec-1 (p<0.05)  (Fig 4.5).  
 
As expected, when the RK device was attached the participants’ RAW was seen to 
significantly increase when compared to the initial trial with no added resistance, 
NAR (Fig 4.6). When the NAR trial was discarded RAW was seen to increase in trials 
when the RK load was above 0.75 kPa.L.sec-1.  
 
The average RAW = 0.32 ± 0.19 kPa·L·sec-1 was slightly higher than the ‘normal 
average’ from Cloutier (2007) but was similar to the value given by Jaeger 
(Manufacturer of the body plethysmography box used), which give all healthy 
subjects a predicted RAW of 0.3 kPa·L·sec-1. 
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Figure 4.5: TLC (■), FRC(●) and RV (▲) During Trials With No Added 
Resistance (NAR) and Increasing RK. The mean ± SD is shown for 11 participants. 
*Significantly different (p<0.05) from trial with NAR. 
4.3.4  Discussion  
The significant increases observed in FRC illustrates how the lungs hyper-inflate as 
RK increases. Interestingly the significant difference in FRC begins at a lower level of 
RK (0.5 kPa.L.sec-1) than the RK level (0.75 kPa.L.sec-1) at which significant increases 
were observed in InWrsmouth (Section 4.2.3). This suggests that the change in lung 
mechanics resulting from the initial increases in FRC absorbs the higher work demand 
imparted by the raised RK. Then as the RK increases the raised FRC no longer helps 
and InWrsmouth has to increase instead. This data combined shows the healthy 
respiratory system responds to applied RK loads through an increased work of 
breathing and hyperinflation, a response similar to that found in patients with 
obstructive disease (O’Donnell & Lavaneziana. 2006). 
 84
 
Figure 4.6: Panel A) Airway Resistance, RAW (kPa.L.sec-1) & Panel B) RTOT 
(kPa.L.sec-1) During Trials With No Added Resistance (NAR) and Increasing RK. 
Mean ± SD shown for 11 participants. *Significantly different (p<0.05) from trial 
with NAR; ^ significantly different (p<0.05) for loaded trials when compared to 0 RK 
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4.4  Effect of Varying Respiratory Rate 
4.4.1  Introduction   
There is no one standardised technique for assessing non-invasive respiratory 
endurance (Section 2.2.8) and this has resulted in a range of non-invasive test 
modalities and measures (Hart 2005), plus a variety of intensities being used. So far in 
this thesis it has been shown that an RK load of 0.75 kPa.L.sec-1 is sufficient to elicit a 
significant response in InWrsmouth and WI/tI during a 6-minute trial (Section 4.2) in 
which the participants breathing was unpaced. It is still unclear if the participants 
breathing rate should be controlled or standardised while undertaking a trial.  
 
There exists diversity in the breathing pattern of awake humans at rest, alongside 
breath-to-breath fluctuations in ventilatory variables (Benchetrit 2000). Therefore the 
following questions should be asked; 1) How should a steady-state test of respiratory 
system endurance be standardised; and 2) What ventilatory variables need to be or 
should be controlled? 
 
There is little consensus on what is the optimal respiratory rate (fR) (Section 2.2.12).  
Paced breathing when measuring prolonged tests of loaded respiratory function has 
been highlighted as a means of helping to control test variability (Rohrbach et al. 
2003). Furthermore Rochester (1988) states that when testing respiratory muscle 
endurance ‘no matter what kind of load is imposed, the breathing pattern must be 
rigidly controlled’. This study aimed to assess the impact of an imposed breathing 
rate, fR on the integrity of the 6-minute test protocol. 
4.4.2  Method  
Participants 
Ten healthy individuals (4F:6M; age range 25-64 yrs; FEV1 % pred 105 ± 14) 
undertook a series of 6-minute seated trials using described methods (Section 3.1.3.2). 
Upon gaining consent, body weight and height and spirometry were measured 
(Section 3.4.1). 
 
Protocol 
Participants made two study visits at least one week apart. On their first visit they 
undertook three 6-minute trials at RK loads of 0, 0.75 and 1.5 kPa.L.sec-1 in a varied 
sequence (to negate order effect) with their fR either paced or unpaced. They 
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completed the alternate trials (paced or unpaced) in the same order on the following 
visit. Study parameters were calculated per breath from data (Section 3.1.6.) with the 
first minute of data being discarded from the analysis (Section 4.1.4). 
 
Paced Breathing Protocol 
For paced breathing trials, an open source standard electronic metronome (SEM) was 
used to set the required fR, by providing a visual cue and audible tone (Section 3.3). 
The participants faced a screen displaying the SEM and were instructed to breathe in 
and out on each subsequent tone. This paced fR at 15 bpm-1 and tI/tTot, at 0.5 .  
 
Unpaced breathing protocol 
Participants were given no instruction during any of these trials on their expected fR or 
tI/tTot ratio and therefore maintained a self-paced or volitional rate throughout.  
 
Data Analysis 
A two way ANOVA was used to assess for statistical difference between RK loads 
during paced versus unpaced breathing. When significance was identified a Holms-
Sidak Post-hoc test was applied. 
4.4.3  Results 
Participants tolerated the protocol well and successfully completed all sixty trials with 
none being stopped early and no adverse effects reported. During unpaced trials fR 
and tI/tTot were significantly lower (p < 0.05) than the target rate for the SEM paced 
trials (Table 4.1). There was no difference between paced and unpaced trials in any 
other parameter at any of the three applied RK loads. 
 
During both paced and unpaced trials only WI/tI (Table 4.4) and InWrsmouth (Figure 
4.7) were seen to significantly increase as the RK load increased. fR, tI/tTot, VTI and 
VTI/tI remained constant irrespective of the RK load. 
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Table 4.1: Parameters at End of 6-minute Trials at Increased RK, expressed as 
mean± SD† significantly different from self paced trials *significant difference from 
trial at RK 0 kPa.L.sec-1. (P<0.05). 
RK  (kPa.L.sec-1)     0   0.75       1.5 
Self-paced Breathing   
fR (min-1) 14±5 11±3 11±4 
tI/tTot  0.39±0.05 0.42±0.03 0.42±0.04 
VTI (ml) 730±203 693±217 748±252 
VTI/tI (L.sec-1) -0.35±0.07 -0.28±0.07 -0.29±0.06 
WI/tI (J.sec-1) 0.04±0.02 0.09±0.03* 0.19±0.08* 
  
Paced Breathing at 15 bpm-1  
fR (min-1) 15±0.4† 14±1.0† 15±0.4† 
tI/tTot  0.45±0.05† 0.45±0.03† 0.46±0.04† 
VTI (ml) 653±190 623±206 623±177 
VTI/tI (L.sec-1) -0.37±0.07 -0.33±0.10 -0.33±0.10 
WI/tI (J.sec-1) 0.07±0.05 0.12±0.07* 0.23±0.11* 
 
Figure 4.7: InWrsmouth (J.L) During Paced (black bars) and Unpaced (grey bars) 
Breathing at Increased Resistances. * significantly different (P<0.05) with RK trials 
at 0 kPa.L.sec-1
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4.4.4  Discussion  
During 6-minute trials an RK load of 0.75 kPa.L.sec-1 was used to increase WI/tI and 
InWrsmouth, VTI was seen to remain constant as has been observed previously (Section 
4.2). During paced trials a metronome was able to keep participants fR at 15 bpm-1, 
although fR significantly decreased in trials without the metronome when breathing 
was unpaced. Although the metronome also paced tI/tTot, average tI/tTot values were 
below 0.5 indicating that while the metronome successfully paced fR it was more 
difficult to accurately control the ratio tI/tTot. However it was found that WI/tI and 
InWrsmouth were constant irrespective if fR was paced or unpaced. InWrsmouth was seen 
to significantly increased as RK load increased above an average healthy participants 
own inherent airway resistance (average healthy participants Reff = 0.32 ± 0.19 
kPa·L·sec-1, Section 4.3.2).  
 
These data suggest that when assessing respiratory system endurance the participant 
should breathe at their own volitional rate as there is no difference in any outcome 
apart from a decreased fR. This would suggest that a more efficient breathing style is 
allowed when participants are unpaced i.e. they use less breaths to do the same 
amount of work.  
 
When using an applied RK to assess InWrsmouth  allowing participants to set their own 
fR will not only result in more efficient breathing it would make this method simple to 
apply, requiring less equipment and reducing the amount of instruction needed for 
participants. This would be important within a clinical setting, as it would remove a 
large part of the volitional element of the test, with only a time limit being imposed 
allowing a more “brain” centred response by the participant (Noakes 2008). This 
should make the application of this test in patients with obstructive lung diseases such 
as COPD easier, allowing them to match their own volitional breathing rate. While 
healthy participants breathe at 15 min-1, patients with airway obstruction tend to 
breathe faster at around 20 min-1 (Colsanti et al. 2004). 
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4.5  Effect of RK Load During Separate Phases of Tidal Breathing 
4.5.1  Introduction  
There is little consensus on what is the optimal duty cycle tI/tTot that should be used 
during any respiratory endurance test (Section 2.2.12).  Paced breathing when 
measuring prolonged tests of loaded respiratory function has been highlighted as a 
means of helping to control test variability (Rohrbach et al. 2003) although it has been 
shown that trial outcomes remain constant irrespective of fR being paced or unpaced. 
 
Previous studies have attempted to control tI/tTot even though standard metronomes 
are symmetrical i.e. if breathing is initiated on subsequent indications (clicks or ticks 
etc) it would pace the two phases of breathing equally. This would result in a tI/tTot 
ratio of 0.5, which is unnatural at rest. Furthermore many metronomes are not 
designed to operate at the lower pacing levels that are applicable to those of breathing 
at rest, approximately 8-30 breaths per minute, but are specifically designed for 
musicians’ at considerably higher tempos. This drove the development of a variable 
electronic metronome (VEM) described earlier (Section 3.3).  
 
This study aimed to establish in healthy individuals the effect varying of tI/tTot on 
ventilation and the work of breathing during the 6-minute test of endurance previously 
outlined (Section 4.4). Additionally the utility and reliability of this variable electronic 
metronome to control individual’s tI/tTot was assessed. 
4.5.2  Method  
Participants 
Fifteen healthy participants (8F;7M; age range 20-31yrs; FEV1 % pred 106 ± 8) 
undertook 6-minute seated trials (Section 3.1.3).  Upon gaining consent, body weight 
and height were measured and baseline spirometry performed (Section 3.4.1). 
 
Protocol 
Initially participants were asked to breathe, whilst seated, through a 
pneumotachograph for 3 minutes (ADInstruments, UK) allowing the self-paced fR and 
tI/tTot to be calculated.  For the variable phase loaded trials a bespoke variable 
electronic metronome (VEM) was used (Section 3.3).This metronome was designed 
to pace both fR and breathing pattern by providing a computer generated visual cue 
and audible tone to signify the start of each inspiration and expiration. The separation 
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of inspiration or expiration allowed the tI/tTot to be set at a desired ratio. For this study 
this was 0.3 and 0.5. 
 
The participants, remaining seated, followed the VEM pacing fR at 15 min-1 and a pre-
selected tI/tTot for 6 minutes. During all trials the RK device applied a constant 
resistance at 0.75 kPa.L.sec-1, a level previously shown to elicit a significant response 
(Section 4.2). In alternate order, participants undertook trials beginning with a tI/tTot of 
0.3 or 0.5.  At each tI/tTot ratio participants undertook three trials with RK applied 
during inspiration only, expiration only or throughout both phases, with the 6 trials 
delivered in random order. Study parameters were calculated per breath from data 
(Section 3.1.6.) with the first minute of data being discarded from the analysis 
(Section 4.1.4). 
 
Data analysis 
For the phase loaded trials Student t-tests were used to assess for statistical differences 
between pre-selected tI/tTot ratio, while a one way ANOVA was used to test for 
differences between phase loading. When significance was identified Holms- Sidak 
Post-hoc testing was used. Adherence to the VEM was assessed by the number of 6-
minute trials that were within ± 1 and 5 % of the target average fR and tI/tTot 
respectively. 
4.5.3  Results 
The 15 participants fR and tI/tTot at rest were 15 ± 5 min-1, and 0.43 ± 5 respectively. 
These subjects completed eighty-seven trials with data being lost for three trials due to 
technical faults. No side effects were reported, and no trials had to be halted early by 
the study investigators.  
 
In terms of fR, subjects were successfully able to follow the VEM paced rate with the 
all trials average fR during the 6-minute trials being within 1% of target rate. However 
not all subjects could accurately follow the VEM paced tI/tTot ratio with only 29/45 
(64%) and 29/42 (69%) participants being within ± 5% of the target tI/tTot, 0.3 and 0.5 
respectively (Table 4.2). These 58 successful “on-target” trials were analysed further.   
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Table 4.2: Trials Successfully Within ± 5% of the Target tI/tTot at Trial End. 
Target tI/tTot Phase Load Successful/Total 
0.3  Inspiration 6/15 
  Expiration 12/15 
   Both 11/15 
 Total 29/45 (64%) 
0.5 Inspiration 12/13 
 Expiration 7/15 
 Both 10/14 
 Total 29/42 (69%) 
 
The VTI remained constant irrespective of phase load or imposed tI/tTot (Fig 4.8).The 
Wrsmouth  during inspiratory-only loaded trials was significantly higher in the tI/tTot 
trials at 0.3 vs 0.5, at -0.59 ± 0.13 vs -0.35 ± 0.13 JL-1 respectively (Fig 4.8). During 
expiratory-only loaded and combined (inspiratory and expiratory) loaded trials 
InWrsmouth no differences were observed between different tI/tTot (Fig 4.8). During 
imposed tI/tTot of 0.5 no differences were observed in InWrsmouth, however at a tI/tTot 
0.3 InWrsmouth was found to be significantly higher in inspiratory versus expiratory 
loaded trials, -0.59 ± 0.13 vs -0.31 ± 0.10 J.L respectively (fig 4.8).
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Figure 4.8: (A) InWrsmouth (J.L) and (B) VTI (L) During Phase Loaded Trials at 
tI/tTot of 0.3 (black bars) and 0.5 (grey bars). * sig diff with expiratory loaded trial. 
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4.5.4  Discussion  
The least efficient breathing was observed when tI was shortest (tI/tTot = 0.3). 
Participants found it most difficult to adhere to a loaded inspiratory phase (unloaded 
expiratory phase), whether this lack of adherence was due to the short sharp 
inspiration or the prolonged expiration was difficult to ascertain. Overcoming airway 
resistance during expiration is a design feature of the lungs as the elastic recoil of the 
chest wall and lungs drives flow passively.   
 
Some participants found it difficult to adhere to the preselected tI/tTot ratios with only 
58 out of the 87 trials being successfully on target. In those that were successful no 
observed difference between trials at 0.3 and 0.5 when loaded in both phases.  It 
would therefore appear that controlling tI/tTot is unnecessary when applying a 6-
minute test with RK load. This precludes attempting to control tI/tTot although the 
difficulties seen in getting participants in this study to breathe at predetermined tI/tTot 
illustrates how difficult this may be. 
 
Often previous studies of respiratory endurance ask participants to follow a prescribed 
tI/tTot (Section 2.2.12) but then do not then report how well their technique was able to 
control breathing pattern. In short how well did participants adhere to any metronome 
used? This data shows that there is a fairly high failure rate/non-adherence. Were all 
trials in these previous studies analysed irrespective of how well subjects adhered to 
an intended tI/tTot rate or were they excluded from analysis? From the relevant sections 
of these studies this is unclear. 
 
When a target tI/tTot is used it is often fixed at 0.5, which is higher than ‘normal’ 
resting values (i.e. 0.43 was observed in this study). This difference is probably due 
more to the availability of standard commercial (i.e. symmetrical) metronomes, rather 
than a belief that a tI/tTot of 0.5 reflects the most appropriate breathing pattern. 
This study indicates that attempts to control breathing pattern while applying a 6 
minute sub-maximal resistive load results in an overly complex measure which 
requires the participant to concentrate on their breathing particularly when the tI/tTot is 
much lower than a subjects resting rate, a consequence of which is to increase the 
InWrsmouth. Targeting the tI/tTot ratio below 0.4 while applying an inspiratory load only 
is the most difficult breathing pattern to adopt. A 6-minute trial using a self-controlled 
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breathing pattern with a constant resistance of 0.75 kPa.L.sec-1 applied throughout the 
respiratory cycle provides in healthy subjects a suitable ‘non-volitional’ method, in 
that no prescribed breathing style or pattern is required of a participant, of measuring 
InWrsmouth. 
 
4.6  6-minute RK protocol 
When applying the 6-minute test using a RK load the following protocol should be 
adhered to: 
4.6.1  Data Analysis 
The first minute of data sampling should be discounted with only that from minutes 2 
– 6 being used for analysis. Data should be calculated and expressed per breath. 
4.6.2  Control of Breathing Pattern 
Trials should be unpaced, both fR and tI/tTot should be freely selected by participant. 
This makes the 6-minute trial protocol easy to administer in terms of instruction by an 
operator ‘breathe through this device in a relaxed manner for six minutes, I will tell 
you when to stop’ and for participants to undertake as they do not have to regulate 
their breathing pattern to a predetermined order. This reflects a more natural style of 
breathing and is closer to the overall aim of non-volitional testing of respiratory 
status. 
4.6.3  Phase Loading 
Both inspiration and expiration should be loaded as the effect on VTI and InWrsmouth  
was similar at different tI/tTot ratios. 
4.6.4  Level of Resistance 
An RK load of 0.75 kPa.L.sec-1 is a suitable load that can be applied in healthy 
individuals that can provoke a significant increase in InWrsmouth from trials with an RK 
set at 0 kPa.L.sec-1 
4.6.5  Outcome parameters and Pearson’s Correlation 
The main effect of applying a constant resistance is the increase in the pressure 
generated by the respiratory system. This increased work performed against this 
external load, InWrsmouth, is able to provide sufficient information for the purposes of 
measuring the endurance of the respiratory system (ATS 2002A).   
 
A Pearson’s correlation was undertaken (Fig 4.9) to assess for any relationships 
between the 6-minute trial parameters and standard respiratory function tests. The 
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forty trials undertaken in Section 4.1 were reanalysed (40 healthy participants 
(31M:9F; Age range 18-64; FEV1%pred 103 ±13). 
 
The lack of correlation between InWrsmouth and respiratory muscle strength confirms 
that while there may be some interaction there is no direct relationship between 
strength and endurance. This provides more evidence that suggests previous 
techniques that have used strength based methodologies are not suitable measures of 
endurance.  
 
During trials at different RK, VTI was not seen to significantly change and therefore 
remains stable during 6-minute seated tests. VTI was seen to correlate with height, 
FEV1%pred & MIP. VTI/tI correlated with height and weight.  
 
In these healthy individuals completing a 6-minute protocol to the specifications 
described above (Section 4.6.1 – 4.6.4), InWrsmouth was found to be -0.33 ± 0.08 (J.L). 
Therefore in individuals with poorer respiratory endurance such as patients with chest 
disease it would be expected that they would have an increased InWrsmouth above this 
value. Loading stresses the respiratory system in a way which is similar to those 
imposed by chest disease and may therefore afford insight into problems of clinical 
relevance (Anthonisen 1976). 
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Figure 4.9: Pearson’s Product Moment Correlation for 40 trials at RK of 
kPa.L.sec-1. [Height (M), Weight (kg), MIP (cmH20), fR (bpm-1), tI (sec), tE (sec), tTOT 
(sec), WI (J), VTI (L), WI/tI (J.sec-1), VTI/tI (L.sec-1) InWrsmouth (J.L)]. A correlation 
coefficient of 0 to 0.3 is classed as a week correlation, while between 0.3 to 0.7 
signifies a moderate correlation and above 0.7 a strong correlation. *p<0.05, #p<0.01, 
**p<0.001.
WEIGHT FEV1%pred FEV1/FVC% MIP fR tI tE tTOT tI/tTOT WI VTI WI/tI VTI /tI InspWrs
mth
HEIGHT 0.441# N N N -0.373* N N N N 0.351* -0.568** 0.396* -0.384* -0.359*
WEIGHT N N 0.347* N N N N N 0.518** N 0.498# -0.48# -0.434#
FEV1%pred 0.324* 0.333* -0.327*0.505**0.373* 0.459# N N -0.365* N N N
FEV1/FVC N N N N N N N N N N N
MIP N 0.337* N N N N -0.424# N N N
fR
tI
tE
tTOT
tI/tTOT
WI
VTI
WI/tI
VTI /tI  
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4.7  Summary & Future Directions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.7.1  Future Directions for research 
 
1. A comparison in patients with COPD would be informative as Dellwegg et al. (2008) 
report a marked increase in the work of breathing these patients. Can this 6-minute trial with 
this protocol be used to differentiate between Health and Disease? 
 
2. VTI was seen to remain constant during seated 6-minute trials, what effect does increased 
ventilation have on InWrsmouth. The most obvious way of doing this is to use the 6-minute 
trial during aerobic exercise at various intensities. 
 In Summary……. 
In this chapter I conducted 5 individual studies of 40 healthy subjects who undertook 215, 
 6-minute RK trials and of 11 subjects who completed body plethysmography manoeuvres. 
The Participant 
 All subjects tolerated all seated 6-minute trials, adapting to the RK loads within the first 
minute and entering into a steady state breathing pattern.  
The Test 
 For the 6 minute RK trial protocol, participants should be able to self select their 
respiratory pattern, the RK load should be applied throughout and the first minute of data 
should be disregarded for analysis. 
 Outcome parameters of the 6-minute trial did not correlate with standard lung function 
parameters although as these do not represent measures of endurance this was not 
surprising. 
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Chapter 5 – Repeatability and Calibration 
 
5.0  Introduction and Overview 
5.1  RK Device Calibration 
5.2  Repeatability of 6-minute Trial 
5.3  Repeatability of TBPA 
5.4  Summary & Conclusions 
5.0  Structure and Overview 
This chapter initially examines the accuracy and reliability of the RK device (Section 
3.1) before assessing the biological repeatability of the 6-minute trial (Section 4.6). It 
then goes on to assess the reliability and repeatability of TBPA analysis (Section 3.2). 
 
Realistically some amount of error is always present with physiological measurements 
and as highlighted in Section 1.6, the key to the accuracy of standard lung function 
tests such as spirometry is to try and minimise the degree of error to promote the most 
accurate result. All measurement methods employed to assess human physiology have 
some degree of test-retest error attributable to this natural biological variation 
(Atkinson & Neville 2007). Between-occasion repeatability is influenced by 
biological variation in lung function in addition to the stability of the measuring 
instrument and the technical consistency of the subject (Chan et al 2003).   
 
Therefore the reliability of a method can be considered as the amount of measurement 
error that has been deemed acceptable for the effective practical use of a measurement 
tool. Logically it is reliability that should be tested initially in any new measurement 
tool, since it will never be valid if it is not adequately consistent in whatever value it 
indicates from repeated measurements (Atkinson & Neville1998) 
 
Standard deviation (SD) can be used to describe the spread of data, 2 SD either side of 
the mean account for 95% of data points (ARTP 2006). Additionally the accuracy of 
the lung function measurement can be calculated as the typical error and is best 
expressed as the coefficient of variation (percentage of the mean) (Hopkins 2000). 
The hypothesis that this chapter seeks to test is that the two techniques described 
previously, RK and TBPA are repeatable and reliable measures. 
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5.1  RK Device Calibration 
5.1.1  Introduction 
For a new device or approach to human physiological measurement, as detailed above 
it is important to establish the repeatability of such a method. Over a period of ten 
months (March ‘08 – December ‘09) twenty separate testing sessions were conducted 
during which the repeatability of the RK device calibration was assessed. The protocol 
used was based upon the device manufacturer’s guidelines (Micro Medical 2007). 
5.1.2  Methods 
Pressure Calibration 
A custom built U-tube water manometer (Fig 5.1) was used to provide the inspiratory 
pressure required to calibrate the RK device. The calibration required a three way 
system in which the RK device was connected to the water manometer and a 
commercially available digital pressure manometer (APM130, Anton Industrial 
Services Ltd, UK). As all devices would be affected equally by ambient conditions 
(temperature and atmospheric pressure), no special considerations were made. 
Ambient room temperature, pressure and humidity were recorded on each occasion, 
the ranges were; 15-24°C; 992-1026 mmHg; 28-62% respectively. 
 
For calibration the RK device required a constant pressure of 10 mmHg to be applied 
(Micro Medical 2007) equivalent to 13.2 cmH2O. The U-tube water manometer was 
used to generate this pressure by increasing the distances between the two meniscuses 
by 13.2 cm. When this distance was observed it was cross referenced to the digital 
manometer to confirm the correct pressure had been generated. When the applied 
pressure load was seen to be 10mmHg it was applied to the RK device and the result 
recorded. (An accept button on the software ensured that the calibration was stored by 
the RK device).  
 
Flow/Volume Calibration 
A calibrated three litre syringe was used to develop inspiratory and expiratory flow as 
detailed in the RK device guidelines at flow rate between 1-2 L.sec-1. The RK device 
integrates flow and time to give inspiratory and expiratory volumes which were 
recorded. This is a common way to calibrate flow devices as it is assumed that the 
relationship between flow and volume is linear. 
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Statistical analysis 
Data was plotted for twenty separate occasions with the mean shown and ± 2 SD. 
Additionally the coefficient of variation was calculated as the mean divided by SD. 
 
 
 
 
Figure 5.1: U-tube Water manometer and pressure calibration rig 
 
5.1.3  Results 
The coefficient of variation for inspiratory and expiratory flow, and inspiratory 
pressure measurements were 0.78, 0.72 and 1.48 % respectively (Figure 5.2).  
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Figure 5.2: (A) Expiratory Volume (L),  (B) Inspiratory Volume (L) and (C) 
Inspiratory Pressure (mmHg) Over Twenty Separate Measurements. Solid black 
line = mean. Broken line ± 2 SD.  
 
5.1.4  Discussion 
The coefficients of variation were found to be less than 1.5% indicating that the RK 
device showed little deviation from the set values for pressure and flow. It can 
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therefore be confidently stated that parameters assessed by the RK device such as 
InWrsmouth can be expressed with a suitable level of reliability. This data shows that 
over a ten month period, and irrespective of season, the device is a trustworthy and 
stable measurement tool.  
 
5.2  Biological Repeatability of 6-minute Trial 
5.2.1  Introduction 
The stability of the RK device allowed the biological repeatability of the 6-minute trial 
to be assessed in healthy human participants. Two separate studies were undertaken; 
1) to assess intra-subject variability in a single subject assessed over twenty 
occasions; and 2) to assess inter-participant variability between three participants 
measured on two occasions, six months apart.   
5.2.2  Method – Intra-Participant Study  
A single healthy male participant (age 32 yrs; FEV1%pred 115) undertook twenty 
serial measurements over a period of ten months (Table 5.1). Measurements were 
conducted when the participant was in good health with no severe symptoms of any 
respiratory infections. 
 
Table 5.1: Tests Taken on Each Occasion  
Pulmonary Function Test FEV1 
FVC 
MIP 
RK 6 minute trial @ 0.75 kPa.L.sec-1 Unpaced seated  
Paced seated 
Unpaced walking on treadmill at 4 kmh-1 
 
For all 6-minute trials InWrsmouth was used as the main outcome parameter (Section 
4.6). InWrsmouth and lung function data was plotted over twenty separate occasions 
with the mean ± 2 SD shown. Additionally the coefficient of variation was calculated 
as mean/SD. 
5.2.3  Method – Inter- Participant Study 
Three healthy male participants (age range 25-46 yrs; FEV1%pred 102-123) 
undertook a series of RK trials with fR paced and unpaced on two visits 1 week apart 
(Table 5.2). These trials were repeated in a similar fashion on a second occasion 
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>8months later. For all 6-minute trials InWrsmouth was used as the main outcome 
parameter. The mean of differences in InWrsmouth and lung function data was 
calculated (Table 5.2)  
 
Table 5.2: Measures Undertaken for Each Measurement Set  (n=3) 
Pulmonary Function Test FEV1 
FVC 
MIP 
RK 6 minute trial  Unpaced 
Seated at 0 kPa.L.sec-1 
Seated at 0.75 kPa.L.sec-1 
Seated at 1.5 kPa.L.sec-1 
 
Walking on treadmill at 4 
kmh-1 at 0 kPa.L.sec-1 
Paced seated 
Seated at 0 kPa.L.sec-1 
Seated at 0.75 kPa.L.sec-1 
Seated at 1.5 kPa.L.sec-1 
 
Walking on treadmill at 4 
kmh-1 at 0 kPa.L.sec-1 
 
5.2.4  Results  – Intra- Participant Study 
The coefficient of variation for both FEV1 and FVC was 2.6%, MIP showed a 
significant increase during the twenty trials (Fig 5.3). Coefficient of variation for 
InWrsmouth during 6-minute trials whilst seated with fR paced or unpaced was 20% and 
7% respectively. The coefficient of variation for InWrsmouth the 6-minute trial whilst 
walking was 7% (Fig 5.4). 
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Figure 5.3: (A) FEV1 (L), (B) FVC (L) and (C) MIP (cmH20) Over Twenty Serial 
Measurements in a Single Participant. Panel A & B the mean (solid line) ± 2 SD 
(broken lines) is shown. Panel C,  r2 = 0.72 p<0.001. 
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 Figure 5.4: InWrsmouth (J.L) During RK Loaded Trials at 0.75 kPa.L.sec-1 with 
Breathing Unpaced (A) and Paced at 15 bpm-1 (B) and Unpaced While Walking 
on a Treadmill at 4kmh (C) Over Twenty Serial Measurements in a Single 
Subject. The mean (Solid line) ± 2 SD (broken line) is shown. 
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5.2.5  Results of Inter-Participant Study 
The mean length of time between two testing occasions was 366 ± 175 days. The 
small study size dictates that it is difficult to apply meaningful statistical testing. 
However the mean difference in the spirometric measurements show a variation of 
less than 100 ml (Table 5.3) over a period of more than six months which is below the 
maximal 150ml difference described in testing guidelines (BTS 1994) as necessary for 
reliable testing of spirometry on a single occasion. Mean differences in InWrsmouth 
during 6-minute trials appear to be higher and more variable (in terms of larger SD) 
when fR is paced rather than unpaced (Table 5.3). 
 
Table 5.3: Mean and SD of Differences in Spirometry and InWrsmouth (J.L) 
      Mean difference SD 
          
Spirometry Best FEV1 (L) 0.090 0.090 
 Best FVC (L) 0.013 0.235 
     
InWrsmouth (J.L)    
 Paced fR Trials   
RK Load 0 kPa.L.sec-1 0.12 0.20 
 0.75 kPa.L.sec-1 0.18 0.31 
 1.5 kPa.L.sec-1 0.80 1.39 
 0 kPa.L.sec-1 at 4kmh walk 0.24 0.49 
     
 Unpaced fR Trials   
RK Load 0 kPa.L.sec-1 0.05 0.05 
 0.75 kPa.L.sec-1 0.10 0.04 
 1.5 kPa.L.sec-1 -0.03 0.10 
 0 kPa.L.sec-1 at 4kmh walk 0.09 0.05 
          
 
5.2.6  Discussion 
Spirometry Variability 
In the intra-participant study the coefficient of variation of FEV1 and FVC, while 
higher than that described for the repeatability of the RK device, is still less than 2.5%, 
indicating that spirometry as expected is a reliable measure. Furthermore the mean 
difference of less than 150ml in both FEV1 and FVC when assessed over a period of 
more than eight months indicates that both are stable measurements in healthy 
individuals. 
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6-minute Trial – InWrsmouth Variability 
The coefficient of variation for RK trials in the subject study when fR was unpaced 
was lower than that observed in paced trials, additionally the mean InWrsmouth during 
seated paced RK trials was significantly higher than during unpaced trials. This 
increased average difference in InWrsmouth during fR paced 6-minute trials was 
replicated in the inter-participant study. This shows how conscious control over 
breathing increases trial outcome and confirms other data collected during the 
development of the 6-minute protocol (described in Section 4.6) which requires 
breathing to be unpaced during 6-minute trial. 
 
The coefficient of variation for unpaced seated RK trial protocol was higher than that 
seen in FEV1 and FVC. However it can still be confident in the assessment of 
InWrsmouth as a 7% variation in the mean value of InWrsmouth in healthy participants of 
0.33(J.L) (Section 4.6) would be equivalent to a range of 0.31-0.35 (J.L).  Therefore 
any changes greater than 0.02 (JL) would be measurable. MIP was found to 
significantly increase over the training period. This perhaps shows the learning or 
training effect that is influenced by repeated respiratory testing? 
5.3  RK Device – In Conclusion 
Standard spirometric testing (Section 3.4) as would be expected showed good 
repeatability and is a useful and robust measure with which to compare the RK device. 
This data shows that the RK device is both consistent and reliable, and provides a 
repeatable and stable measure of InWrsmouth in human participant. 
 
Although these small studies indicate the reliability and repeatability of the RK device 
it would be useful to expand such repeated testing in a greater number of both male 
and female participants, and in relevance to the studies described later in this thesis in 
patients with chest disease. At this point in time (November 2009) no other group has 
published repeatability data for this device.  
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5.4  Reliability of TBPA in Control Participants 
5.4.1  Introduction 
The aim of this study was to assess the tidal airflow profile analysis equations 
developed by Colsanti et al 2004 (Section 3.2.1), as an alternate measure of airway 
obstruction, as FEV1TAP, in healthy controls.  
5.4.2  Methods 
Fifty (34M:16F) healthy controls (Age range 18-48yrs; FEV1 %pred 103 ± 12) were 
asked whilst seated and relaxed to breath through a pneumotachograph for 3 minutes.  
FEV1TAP was derived using equation described previously (Section 3.2.1): FEV1TAP = 
-5.41 + (Height x 4.97) + (Age x –0.02) +(tPTEF x 0.005). Standard spirometric 
measurement (Section 3.4) provided the directly measured FEV1 with which FEV1TAP 
was compared. Linear regression was used to assess for relationship between FEV1 
and FEV1TAP, and the difference between FEV1 and FEV1TAP was also calculated. 
5.4.3  Results 
The three minutes of resting breathing was well tolerated by all participants and all 
trials were completed successfully. The average resting fR was found to be 16±4 bpm-
1. FEV1TAP was seen to correlate with FEV1 (Fig 5.5) but slightly over-predicted FEV1 
(0.123ml) (Fig 5.6). 
5.4.4  Discussion 
In healthy controls FEV1TAP can be used to provide a surrogate measure of FEV1. 
Although FEV1TAP over predicts FEV1 observed difference is still less than 150 ml in 
a similar manner to the differences in spirometry observed previously (Section  5.2.6). 
TBPA may not be as sensitive as spirometry but shows similar reliability 
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Figure 5.5. Relationship Between FEV1TAP and FEV1 in Healthy Controls. Line of 
best fit (r2 0.57 p<0.001) is shown with 95% prediction.  
 
Figure 5.6: The Difference Between FEV1TAP and FEV1 for Healthy Controls: 
The mean ± 2 SD is shown. 
 
.
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5.5  Repeatability of TBPA in Healthy Controls 
In a similar manner to the studies undertaken with the RK device (Section 5.2) further 
investigations were undertaken in control participants to assess the repeatability of TBPA. 
Three separate studies were undertaken, to assess intra- participant variability in one 
participant, and intra- participant variability over many occasions (n=6) and within occasion 
(n=11). 
5.5.1  Method – Intra-Participant Study n=1 
A healthy male participant (age 32; FEV1%pred 115) made twenty serial TBPA 
measurements. Using formula previously described (Section 3.2) FEV1TAP was calculated and 
compared with sequential measurements and directly measured FEV1 (Section 3.4). Data was 
plotted as twenty separate occasions with the mean shown and +/- 2 SD. Additionally the 
coefficient of variation was calculated as mean divided by SD. 
 5.5.2  Method – Inter Participants Study 
Six healthy participants (4M:2F age range 22-36; FEV1%pred 97-128) completed serial 
measurements over eight consecutive weeks. Using formula previously described (Section 
3.2) FEV1TAP was calculated and compared with sequential measurements and directly 
measured FEV1 (Section 3.4). A one way repeated measures ANOVA was used to assess for 
difference between measurements. 
5.5.3  Intra Participants Study n-11 
Eleven healthy male participants (Age range 18-29; FEV1%pred 99% ± 14) completed three 
spirometric and TBPA measurements over two occasions (one week apart), one on first visit 
and two on a second visit separated by approximately 20-minutes.  
 
Using formula previously described (Section 3.2) FEV1TAP was calculated and compared with 
sequential measurements and directly measured FEV1 (Section 3.4). A 2-way repeated 
measure ANOVA was used to assess for difference between measurements. 
5.5.4  Results - Single Participants 
All manoeuvres were well tolerated and were successfully completed. FEV1TAP was 
significantly lower than directly measured FEV1, 3.9 ± 0.1 and 4.7 ± 0.4 respectively. 
However FEV1TAP  had a lower coefficient of variation than directly measured FEV1, 2.6%  
and 3% respectively (Fig 5.7). 
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Figure 5.7: (A) FEV1TAP (L) and (B) directly FEV1 (L) Over Twenty Serial 
Measurements in a Single Participant. Solid line = mean, broken line = +/- 2 SD. 
5.5.5  Results - Six Participants 
TBPA manoeuvres were well tolerated by all six subjects and were successfully completed. 
Both FEV1TAP and directly measured FEV1 were not significantly different and did not 
change over time (Fig 5.8).  
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Figure 5.8: Serial (A) FEV1TAP (L) and (B) Directly Measured FEV1 (L) in Six 
Participants Over Eight Consecutive Weeks. 
5.5.6  Results -Eleven Participants 
The TBPA trials were tolerated well by all eleven participants and all were successfully 
completed. FEV1TAP was seen to correlated with FEV1 (r2 0.52 p<0.001) in a similar way to 
that reported earlier (r2 0.57 p<0.001; Section 5.4.3). There were no significant differences 
between FEV1TAP and FEV1. Both FEV1TAP and FEV1 were stable with no statistical 
difference found between the three measurement occasions (1st, 2ndA and 2ndB) (Table 5.4). 
Additionally there were no statistical differences between FEV1TAP and FEV1.  
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Table 5.4: Directly Measured FEV1 and FEV1TAP in 11 Healthy Males (mean ± SD). 
 
 
 
 
 
5.5.7  Discussion  
This study has shown that in each of the three sub studies FEV1TAP was repeatable and a good 
surrogate measure for FEV1. 
 
5.6  Summary & Conclusions 
 
 
This data shows that in healthy participants TBPA and RK trials are reliable and reproducible 
measurements using the protocols described in Chapters 3 and 4, confirming the hypothesis 
set out in section 5.0. As the subsequent work of this thesis examines the use of these 
methods in clinical groups, patients with chest disease and children it would be a valuable 
exercise to undertake similar studies of the repeatability and reliability of the techniques in 
these groups. 
 1st Visit  2nd Visit A  2nd Visit B 
FEV1TAP (L) 4.26 (0.52)  4.28 (0.55)  4.18 (0.59) 
FEV1 (L) 4.34 (0.84)  4.40 (0.82)  4.34 (L) 
 In Summary……. 
In this chapter I conducted 6 studies with 4 participants completing 108 6-minute RK trials and 68 
participants completing 143 TBPA trials. 
 
The Participant 
 Participants were able to complete all RK and TBPA trials and reported no adverse 
effects. 
The Test 
 Standard lung function was seen to be the most reliable measure with the smallest 
coefficient of variation. 
 RK trials when fR was unpaced showed lower coefficient of variation than when fR was 
paced. 
 RK and TBPA trials are both reliable and reproducible measures. 
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Chapter 6 – Work of Breathing and Exercise 
 
6.0 Introduction & Overview 
6.1 Methods 
6.2 Results 
6.3 Summary and Conclusion 
 
6.0  Introduction & Overview 
This chapter examines the effect of increased ventilation during 6-minute trials and the effect 
on InWrsmouth by asking participants to complete trials whilst exercising. Initially the intensity 
of exercise was low so the effect could be controlled, however as studies and trials were 
successfully undertaken the intensity of exercise and the level of RK applied during trials was 
increased. 
 
Physical exercise induces increases in ventilation that requires extra work to be performed by 
the respiratory system. The appropriateness of the ventilatory response to exercise depends 
not simply on the level of ventilation required for a particular work rate but also to the extent 
that it is able to maintain pulmonary gas exchange and acid base control of respiration 
(Whipp et al 2007). The lung parenchyma and airways are ‘built’ in healthy adults to handle 
these challenges of the increased gas exchange demanded during exercise (Dempsey 2006A) 
and during high intensity exercise ventilation can increase by twenty fold from resting levels 
(Guenette & Sheel 2007). In general the functional capacity of the healthy respiratory system 
exceeds the demands placed upon it, although it has been hypothesised that at high intensity 
there is a respiratory muscle fatigue metaboreflex causing reduced blood flow to locomotor 
muscles (see review by Dempsey et al 2006B). 
 
Exercise intolerance is a consequence of an individual’s inability to meet the physiological 
requirements of a particular task (Whipp et al 2007). It has become clear that the diaphragm, 
like other skeletal muscle is susceptible to fatigue with heavy whole body dynamic exercise 
(Johnson et al 1996B). At lower sub-maximal levels of exercise intensities which do not result 
in fatigue, the capacity of the respiratory system in healthy individuals should not be 
exceeded. However the work of breathing increases secondary to increases in both lung and 
chest wall elastic recoil and airway resistance during even moderate exercise (Cloutier 2007).  
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This chapter aims to define the relationship between ventilation and InsWrsmouth during sub-
maximal exercise in participants completing a 6-minute RK protocol (Section 4.6) at different 
levels of RK and exercise intensity. The hypothesis that chapter seeks to test is that increases 
in ventilation due to exercise result in increases in InWrsmouth. 
6.1  Methods 
To create a variety of ventilation rates and exercise modalities three groups of participants 
each underwent a different test protocol on single visits to the laboratory. In total forty-five 
healthy participants took part, (Table 6.1) upon gaining consent, body weight and height were 
taken and baseline spirometry measured (Section 3.4.1). These participants completed 6-
minute RK trials while undertaking steady state exercise protocols. The repeatability of the 6-
minute trial whilst exercising has already been established (Section 5.2).  
 
Table 6.1: Participant Demographics for Three Exercise Studies 
 Protocol 1 
N=10 
Protocol 2 
N=20 
Protocol 3 
N=15 
Sex (M;F) 
 
6:4   12:8   15:0  
Age (yrs) 
 
25-64 20-48 18-29 
FEV1%predicted 
 
105 ± 14 98 ± 9 108 ± 13 
MIP (cm H2O) 
 
112 ± 5 108 ± 36 124 ± 34 
 
Exercise Protocol One 
Ten participants were asked to complete two 6-minute trials with RK set at 0 kPa.L.sec-1, once 
while seated and again while walking on a treadmill at 4 km.h-1 (equivalent to 2.5 mph-1). 
This locomotion speed was selected as it was at an intensity that best reflected an average 
walking speed in healthy individuals. 
 
Exercise Protocol Two 
Twenty participants completed four trials, two seated and two exercise trials at RK loads of 
0.75 and 1.5 kPa.L.sec-1 similar to studies described previously (Chapter 4). fR was paced 
using an electronic metronome (Section 3.3) and set at 15 min-1. Ten participants completed 
exercise tests on a treadmill at 4 km.h-1 and the remaining ten completed exercise tests on a 
cycle ergonometer loaded at 50 Watts. 
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Exercise Protocol Three 
Fifteen participants completed five trials, three seated at 0, 0.75 and 1.5 kPa.L.sec-1 and two 
exercise trials at 100 and 150 Watts with an RK load of 0.75 kPa.L.sec-1.  The exercise trials 
were modified Astrand Rhyming cycle trials (Section 3.5.2) and were used to select suitable 
exercise work loads. Additionally as with the Astrand Rhyming protocol, participants only 
completed the 150 Watt trial if their fH during the 100 watt trial did not exceed a set fH, for 
this study this was set at 130 min-1. 
 
Statistical Analysis 
For each 6-minute trial InWrsmouth and EV were calculated and expressed per breath. Linear 
regression was used to assess for relationships between parameters and derived using 
statistical software (Sigmaplot V11, Systat, UK). 
6.2  Results 
Participants tolerated all seated trials during the three exercise protocols, successfully 
completing ninety-five trials with none ending early. For protocol one, all exercise trials were 
successfully completed. For protocol two, four exercise trials were not completed, three 
because participants could not maintain ventilation through the device and one due to 
technical reasons. In protocol three, all 100 Watt exercise trials were successfully completed. 
Eight participants had a fH ≤ 130 min-1 and successfully undertook all 150 Watt trials.  
 
Irrespective of breathing pattern (paced or unpaced) or exercise mode, EV was seen to 
increase with InWrsmouth in a linear fashion (Fig 6.1). The slope of this relationship was 
steeper as the load was increased, at 0.02, 0.033, and 0.064  J.L for each litre increase in EV  
at loads 0, 0.75 and 1,5 kPaLsec-1 respectively.  The combined data was used to construct 
isopleths for each five litres of ventilation (Fig 6.2).  This illustrates that at low resistive loads 
(as found in the healthy airway) InWrsmouth may triple with a four-fold increase in ventilation 
(10-40 L.min-1), (Point A, Fig 6.2), while in the presence of high loads the same increases in 
ventilation evoke an almost five-fold increase in InWrsmouth (Point B, Fig 6.2). No 
relationship (p >0.05) between MIP and InWrsmouth was observed. 
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Figure 6.1: Relationship Between EV  (L.min
-1) and InWrsmouth (J.L) at Increasing RK 
(kPa.L.sec-1). Applied load was 0 (grey fill), 0.75 (black fill) and 1.5 (no fill) kPa.L.sec-1.  
Exercise Modes; Circles, seated; squares, walking at 4 kmh-1; diamonds, cycling at 50 watts;  
triangles, at 100 watts;  stars, at 150 watts.   Fitted linear regression are shown for each 
applied load, r2 = 0.85, 0.93, 0.93, all p < 0.001, at 0, 0.75, 1.5 kPa.L.sec-1respectively.  
 
 
Figure 6.2: Exponential Relationship Between RK (kPa.L.sec-1) and InWrsmouth (J.L) at 
Increasing EV  (L.min
-1) 
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6.3 Summary & Conclusion 
 
 
 
 
 
 
 
 
 
 
When breathing pattern is self-selected all participants were able to complete 6-minute trials 
while exercising at intensities up to 150 Watts, at RK loads of 1.5 kPa.L.sec-1.  The three trials 
that were halted early in protocol two were due to the participants being unable to continue 
breathing through the device at the imposed fR of 15 min-1.  The participants reported that 
they were not able to adapt their breathing pattern required to exercise and the load applied. 
This provides evidence that this technique is easily tolerated by the participants when they 
can select their own breathing pattern. fR was fixed in protocol 2 as this was undertaken at a 
similar time that the variable electronic metronome was developed (Section 3.3) and before 
the final (unpaced) 6-minute protocol (Section 4.6) was established.  
 
When breathing against resistance, mechanisms of load compensation induce adaptations in 
the pattern of breathing proportional to the applied load (Calabrese et al. 1998) and these 
changes act to maintain ventilation at the most optimum or efficient level (Zechman et al. 
1957). The control of breathing has evolved into a highly sophisticated, negative feedback 
system which is able to accurately match the level of ventilation with the requirements of the 
body. Individuals appear to select one particular breathing pattern among the infinite number 
of possible combinations of ventilatory variables and airflow profiles (Benchetrit 2000) that 
enables the work of breathing to be minimised (Cloutier 2007). This process is an automatic 
unconscious one, in that individuals will find the most efficient breathing pattern for the 
ventilation level required. Even with additional stress such as with exercise or in disease, if 
this is not immediately fatiguing and remains constant, the respiratory control system will 
adopt the most efficient pattern of breathing.  
 
The exercise studies focused on RK loads of 0.75 kPa.L.sec-1 as it had become the established 
load for the 6-minute trial (Section 4.6). It would be a useful to see what affect the increased 
 In Summary……. 
In this chapter I conducted 3 individual studies of 45 healthy subjects who successfully 
undertook 95 seated 6-minute trials and a further 69 trials whilst exercising at various RK load 
and increasing exercising intensities. 
1. The Participant 
 When breathing pattern is self-selected participants are able to complete 6-minute trials 
while exercising at intensities up to 150 watts, and RK loads of 1.5 kPa.L.sec-1. 
2. The Test 
 Irrespective of the pattern of breathing or exercise mode, EV increases with InWrs
mouth
 in a 
linear fashion dependent on the RK load applied, confirming hypothesis set out in section 
6.0. 
 The RK device is able to maintain RK load irrespective of EV . 
  InWrsmouth increases exponentially with RK, implying that at higher RAW exercise 
becomes limited because of a reduced r spiratory enduranc  rather than lack of 
respiratory uscle strength. 
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exercise intensities had at the RK loads not studied (0 & 1.5 kPa.L.sec-1), although the 
exponential relationship identified (Fig 6.2) would suggest that participants would struggle to 
complete high intensity exercise trials at high RK loads. At higher loads the InWrsmouth soon 
becomes overpowering and few subjects feel comfortable exercising while their breathing is 
restricted. Physiologically there is an upper limit to the tolerable resistive load during 
exercise before fatigue or task failure occurs. From the data it would be expected that at 2 
kPa.L.sec-1  InWrsmouth  would become inhibitive at even moderate ventilation rates (> 30 L 
sec-1). Whether the ability to overcome a high RK load is dependent on fitness levels (and 
motivation) or dependent upon inherent respiratory function has yet to be investigated.  The 
effect of increased resistive load on exercise is important in individuals with increased 
intrinsic airway resistance (RAW) such as asthmatics, as even small increases in RAW would 
appear to result in large increases in InWrsmouth, which can affect their endurance capabilities. 
 
The efficacy of respiratory training devices that apply respiratory loads are often evaluated on 
how they increase respiratory muscle strength, but the focus should be on improvements in 
respiratory endurance, as this would provide a better measure of the ability to tolerate 
increased  InWrsmouth. These studies indicate that the RK device is able to maintain an RK load 
irrespective of the level of ventilation or breathing pattern, either imposed or self selected. 
This would suggest that the device is able to maintain an RK load irrespective of the level of 
ventilation or breathing pattern, either imposed or self selected. Suggesting that as the 
manufacturers describe, irrespective of how individuals breathe through the RK device the 
applied load remains constant. 
 
Though in healthy humans there are only a few occasions when the reserve of respiratory 
muscle function is utilised sufficiently to cause fatigue, there are certain groups of patients 
where the endurance properties of the respiratory muscles may be critical to survival or 
necessary for adequate exercise tolerance (Clanton and Diaz 1995). With the increased use of 
pulmonary rehabilitation programmes it is necessary to monitor endurance performance 
rather than strength, valid measures of endurance are thus needed to assess the outcomes of 
such interventions (Powell and Williams 2009).  Despite intense investigation the importance 
of respiratory muscle endurance in the failing patient or the obstructed patient during exercise 
is still relatively inadequate. Just as important are the development of better techniques for 
evaluating respiratory muscle endurance and work capacity in chest disease patients (Clanton 
1995). 
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In conclusion at a constant airway resistance, InWrsmouth is dependent on ventilation rate and 
independent of exercise modality. The InWrsmouth increases exponentially with resistance, 
which implies that at higher airway resistances exercise becomes limited because of a 
reduced respiratory endurance rather than lack of respiratory muscle strength. 
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Chapter 7 – Chronic Obstructive Pulmonary Disease 
 
7.0 Introduction and Overview 
7.1  Overview of Obstructive Chest Disease 
7.2  Chest Disease in the Locality 
7.3  Clinical Trial Set Up 
7.4  Work of Breathing in COPD 
7.5  TBPA in COPD 
7.6  6MWD Study 
7.7 Summary and Conclusion 
 
7.0  Introduction and Overview 
This chapter begins with the description of the pathophysiology of Chronic 
Obstructive Pulmonary Disease (COPD) and how it impacts on society nationally and 
locally in Rhonda Cynon Taf where the clinical trials described took place. It then 
goes on to describe the procedures involved in designing and securing regulatory 
approval for these clinical trials. The assessment of InWrsmouth and TBPA in COPD 
patients is then outlined, followed by the description of specific studies that took 
place. The experimental work in this chapter seeks to test the hypothesis that TBPA 
and RK trials can differentiate between COPD patients and healthy individuals. 
7.1  Overview of COPD 
It is an inevitable consequence of aging that humans will experience a gradual decline 
in lung function throughout life. On average healthy non-smoking men can expect to 
lose from their FEV1 23.7 ml/yr at age 25 to 39.0 ml/yr at age 75 (Ware et al 1990). 
Fletcher & Peto (1977) elegantly showed not only this gradual decline but also how it 
can be accelerated by tobacco smoking (Fig 7.1). It is now accepted that COPD is 
predominantly caused by prolonged tobacco smoking. Obstructive diseases are 
characterised by airflow limitation and obstruction, and include, asthma, chronic 
bronchitis and emphysema (ARTP 2006) and the recognition that COPD has both 
airway and airspace characteristics has led to the common definition of the disease 
(Shapiro & Ingentio 2005). 
 
The most recent GOLD (2008) statement defines COPD as: 
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‘a treatable and preventable disease with some significant extra pulmonary 
effects that may contribute to the severity in some individuals. Its pulmonary 
component is characterised by airflow limitation that is not fully reversible. 
The airflow limitation is usually progressive and associated with an abnormal 
inflammatory response of the lung to gases or noxious particles’. 
 
It is estimated that COPD affects 3 million people and kills over 30 000 in the UK 
each year (Chief Medical Officer 2004). Acute exacerbations of COPD are a 
significant cause of morbidity and mortality, and are acute inflammatory events 
superimposed on the chronic inflammatory characteristic of COPD (Anzueto 2009). 
As COPD severity increases, daily activities can become very difficult. Patients with 
COPD can get anxious about their breathlessness and as a result reduce their levels of 
physical activity in order to avoid becoming breathless resulting in physical de-
conditioning. This in addition to the progressive nature of COPD contributes to a 
‘Spiral of Decline’ (Jones 2009) resulting in patients suffering from increasingly 
severe attacks of breathlessness that can leave them housebound or result in repeated 
extended hospital admissions. This activity limitation acts to impair these patients’ 
quality of life by restricting their interactions with their environment (Roche 2009) 
and as such invalidism should be discouraged, with exercise programs directed at 
increasing exercise tolerance used to help treat these patients (Rankin & Dempsey 
1967). 
 
Figure 7.1: Risk of Smoking in Men – Fletcher & Peto (1977) 
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7.1.2  Tobacco Smoking as a Cause of COPD 
While there is little doubt that tobacco smoke is causal for the development of COPD 
there is a great variability in lung function among smokers and not all smokers 
develop COPD (Shapiro & Ingentio 2005). It is well known that if tobacco smoking 
was abolished, the widespread occurrence of COPD would gradually disappear and it 
would become a rare disease (Siafakas 2006). Tobacco smoke contains at least 69 
carcinogenic compounds and many other chemical compounds including nicotine the 
constituent associated with the addiction that makes tobacco smoking difficult for 
smokers to quit (Cancer UK 2009). Tobacco smoking had three major effects; 
impairment of cillary movement, mucous gland hypertrophy and altered structure and 
function of alveolar macrophages. 
7.1.3  Pathology of COPD 
Pathological changes characteristic of COPD are found in the central airways, 
peripheral airways, lung parenchyma and pulmonary vasculature (GOLD 2008). The 
heterogeneous nature of COPD is due to differing contributions of airway (chronic 
bronchitis) and parenchymal lung disease (emphysema) (ARTP 2006) and has been 
extensively reviewed elsewhere (Shapiro & Ingentio 2005: Rodriguez-Roisin & 
MacNee 2006). The primary cause of airway obstruction, regardless of aetiology is 
increased airway resistance (RAW). 
 
Chronic bronchitis is defined clinically as a persistent cough with sputum production 
for at least 3 months of the year for 2 consecutive years. As cigarette smoking affects 
both the production and clearance of mucous (Section 7.2) increased pools of mucous 
occur in the airways increasing susceptibility to infection and producing a productive 
cough. 
 
Emphysema is a destructive process that results in the destruction of the alveolar walls 
reducing the surface area for gas exchange and increasing airflow obstruction. As 
alveolar tissue is naturally elastic helping to maintain the small airways, in 
emphysema this support is lost and the airways become narrowed (Booker 2008). 
 
Increased levels of inflammatory cells and cytokines induce airway secretions, 
bronchospasm and mucosal oedema, which in turn lead to a worsening 
ventilation/perfusion mismatch and hyperinflation resulting in acute changes in a 
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patients symptoms (Anzueto 2009). As such COPD patients must generate 
increased EV to maintain respiratory homeostasis when compared to healthy subjects 
(Jolley & Moxham 2009). Currently clinical therapies for treating COPD 
exacerbations include oral corticosteroids,  antibiotics and bronchodilators however 
they appear to have only limited beneficial affects (Torres 2009).  
 
 
Figure 7.2: Effect of COPD on the Structure of the Lung (from Shapiro & 
Ingenito 2005) 
7.1.4  Diagnosis of COPD 
Demonstration of the presence of airflow obstruction is necessary when making the 
diagnosis of COPD. Spirometry is the only accurate method of measuring the airflow 
obstruction in patients with COPD (NCCC. 2004). A diagnosis of COPD should be 
considered in individuals over the age of 35 who smoke tobacco and present with 
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symptoms of exertional breathlessness, chronic cough, regular sputum production or 
wheeze. Other risk factors include environmental exposure to noxious particles such 
as air pollution associated with the burning of wood or other biomass fuels (GOLD 
2008). COPD is most probably the result of an interaction between these risk factors 
and environmental exposure. The degree of certainty of any one risk factor in COPD 
pathogenesis varies, however the deficiency of alpha1-antiitrypsin as a factor and 
tobacco smoke as an exposure has been well documented (Siafakas 2006). COPD is 
heterogeneous and as such no single measure can give an adequate assessment of the 
true severity of the disease in an individual patient (NCCC 2004). 
 
Airflow obstruction is defined as a reduced FEV1 and FEV1/FVC ratio such that FEV1 
is less than 80% predicted and FEV1/FVC is less than 0.7. GOLD (2008) have further 
classified the progressive severity of COPD (Table 7.1). 
 
Table 7.1: GOLD Classifications of COPD 
Classification Criteria 
I: Mild COPD FEV1/FVC < 0.7 
FEV1  < 80% predicted 
II: Moderate COPD FEV1/FVC < 0.7 
50% <  FEV1 < 80% predicted 
III: Severe COPD FEV1/FVC < 0.7 
30% <  FEV1 < 50% predicted 
IV: Very Severe COPD FEV1/FVC < 0.7 
FEV1 < 30% predicted or FEV1 < 50% predicted plus 
chronic respiratory failure 
 
7.1.5   Burden of Obstructive Chest Disease 
Monitoring COPD in the population is a priority as it informs both healthcare policy 
and patient treatment. The growing burden of COPD on patients, the NHS and the 
economy, both locally and nationally, is seen as important and is increasingly 
recognised, resulting in development of national disease management guidelines 
(NCCCC. 2004). In the European Union, the total direct costs of respiratory disease 
are estimated to be about 6% of the total health care budget with COPD accounting 
for €38.6 billion (GOLD 2008). This may be an underestimation of the problem as 
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under-reporting of this healthcare burden has been identified by several recent studies 
(Enright 2008; Nacul et al 2007).  
 
There are 900 000 diagnosed cases of COPD in the UK although this is widely 
recognised as an underestimate with the truer figure estimated to be around 1.5 
million (NCCC. 2004). Approximately 30 000 people die prematurely from COPD 
annually in the UK (BTS. 2006). COPD is not usually detected in smokers until more 
than half of their lung function has been irretrievably lost and frequently not until a 
severe exacerbation causes hospitalisation (Enright 2008). 
 
Estimated UK prevalence of COPD is 5.3 per cent in over 45 year olds (Nacul et al. 
2007). The General Household Survey records that self-reported diagnoses of chronic 
bronchitis and emphysema are far lower than the prevalence values from the Health 
Survey for England 1996, indicating that much of the early disease is unrecognised. 
(LAIA. 2003). Some of the highest standardised mortality ratios are seen in South 
Wales (Fig 7.3) at over 130% (LAIA. 1996). The burden of COPD on patients, the 
health service and the economy is important and increasingly recognised, resulting in 
national disease management guidelines (Booker. 2008). 
 
In addition GP consultation rates for respiratory disease are over three times as high 
as disease of the circulatory or digestive systems (Chief Medical Officer 2004). 
Around 12 % of COPD patients had visited hospital A&E departments at least once 
during the previous year because of COPD (Britton 2003). 
 
Spirometry in General Practice 
Recently there has been a lot of interest in the wider clinical literature about 
spirometric testing in General Practice. Recent studies have shown that 1) the 
prevalence and under diagnosis of COPD in adult patients in primary care make case 
finding worthwhile (Bednarek 2008), and 2) that opportunistic spirometry led to a 
higher proportion of the population at risk of developing COPD, being identified and 
treated, than just standard GP testing alone (Walters et al. 2008).  Most COPD 
patients with exacerbations can be managed at home, although some do need to be 
hospitalised, however many patients with exacerbations often delay presentation or do 
not seek therapy (Torres 2009), Early treatment of COPD may help to control 
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symptoms , reduce the impact of exacerbations and improve quality of life (Britton 
2003). 
 
  
 
Figure 7.3: Age-Standardised Mortality Rates for Respiratory Diseases by Local 
Authority, Males all Ages United Kingdom 1993-1997 (Office National Statistics 
2001) 
  
FEV1 measurements although used to define COPD progression correlate poorly with 
the presence of some symptoms and therefore new strategies for managing COPD 
patients and their disease symptoms are required (Lacoma et al 2009). The more 
severe COPD becomes the more difficult it becomes to make lung function 
measurements as, patients get older, suffer from comorbidities and from frequent 
exacerbations. Even if patients cooperate, current lung function guidelines often label 
measurements as low quality and not good enough for assessment, meaning the 
patients most at risk are the hardest to assess (Soriano & Miravitllies 2009). 
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The diagnosis and treatment of COPD in primary care needs to be improved (Britton 
2003). Maybe the holy grail of giving antibiotics only to those who benefit is not 
achieveable using simple clinical markers (Woodhead 2009) and requires a more 
sophisticated approach. Could the use of TBPA in particular be useful as a means to 
monitor respiratory function in a primary care or home setting? 
7.2 Chest Disease in Rhonda Cynon Taf: Merthyr Tydfil Breathe Easy 
Meeting 
7.2.1  Background 
Breathe Easy is part of the work of the British Lung Foundation and is a network of 
groups that aim to provide support and information to those people living with a lung 
condition and also the people that care for them (http://www.lunguk.org/supporting-
you/breathe-easy/). As such they provide a valuable opportunity to communicate with 
a group of patients and their carers within the local community. In Rhonda Cynon 
Taff this is particularly relevant as the rates of mortality due to chest diseases are 
some of the highest in the UK (Section 7.1.5). The groups are structured to provide a 
social meeting place for patients with chest disease outside a clinical setting and 
include some form of educative process involving a weekly guest speaker. 
 
By the end of the first year of my PhD studies I was beginning to prepare clinical 
studies that would involve recruiting groups of patients with chest disease. I felt that it 
was important that I communicated with such individuals to inform them of my work 
and to ask them their views about this, chest disease and clinical research in general. 
 
I had specific questions that I was keen to answer. Did they think that it was important 
for research into their lung condition to be carried out? How easy/hard did they find 
standard spirometry to complete? Would they be willing to take part in research if 
approached? What about if they had just been admitted to hospital, would that 
willingness change? What about the minimum24 hour rule of informed consent? 
 
I approached the chair of the British Lung Foundation in Wales explaining my 
situation and that I would like offer my services as a guest speaker, describing my 
own and the wider research, and to ask the group some questions that may help my 
work. She responded positively and put me in touch with the local Chronic Disease 
Nurse who invited me to a Breathe Easy meeting. 
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7.2.2  The Meeting  
I attended the weekly meeting of the Merthyr Tydfil Breath Easy group at a local 
community centre. After the announcements, information and raffle, I was given the 
opportunity to speak. I used a simple presentation to describe the ideas I wanted to 
discuss and handed out a short questionnaire (Appendix 7.1).  
7.2.3  Results of Discussion and Questionnaire 
Of the 11 people attending the meeting 8 people successfully completed the 
questionnaire. The main findings from this were: 
 
1. Those present wanted to learn about research taking place. 
2. The majority were happy about being asked to take part. 
3. They all reported that they found spirometry hard to undertake. 
7.2.4  On Reflection 
I found the meeting a really positive experience, meeting the group members was very 
interesting and enjoyable and quite a sociable experience in itself, perhaps as the 
groups were originally set out to be? As a researcher it was affirming to see that those 
attending were interested in current research, particularly that which involved aspects 
of their disease. There was also a strong altruistic sense though, many of those present 
wanted to ‘put something back’ and a common theme was the feeling that it was their 
duty to assist or take part in future research. It would be interesting to see how they 
would feel about becoming more involved in guiding research, for example from 
planning new research to actively taking on researcher type roles such as user driven? 
There is a strong focus currently by the research councils and other funding bodies to 
increase the involvement of patients not as participants or subjects of research but 
becoming actively involved in the research process (National Patient Safety Agency 
2009). In the context of chest disease and COPD, the Breathe Easy meetings provide 
an excellent opportunity for this. 
 
In conclusion I got a lot out of the experience, not only information that I thought 
would be useful (which was perhaps what drove my interest initially) but it also made 
me appreciate the need to interact with the local population I was studying.  
7.3  Clinical Trials Set Up 
Through the Breath Easy meeting, contact was made with a Respiratory 
Physiotherapist at a local hospital who co-ordinates the pulmonary rehabilitation 
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programme. Links were also developed with a consultant physician who specialised in 
respiratory medicine. Collaboratively three clinical trials were set up where I acted as 
study coordinator and was responsible for designing the study, drafting a protocol and 
study documents, and getting regulatory approval for each study. This included 
getting approval from University of Glamorgan Faculty Ethics Committee, the local 
NHS Trusts Research Department and the Local Research Ethics Committee (LREC). 
I was able to use the feedback that I collected from the Breathe Easy meeting as user 
generated involvement which was a powerful support to the applications that were 
made to the relevant ethics committees. An example of a study protocol that I created 
for one of these clinical trials can be seen in Appendix 7.2. 
 
I was responsible for conducting each study, recruiting participants and carrying out 
study measurements. As such on average during the final year of my PhD I attended 
the Royal Glamorgan and Prince Charles Hospitals for 3 clinical half day sessions per 
week which resulted in 56 patients being recruited. 
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7.4  COPD Work of Breathing Study 
7.4.1  Introduction 
The function of the respiratory muscles is impaired in COPD patients. The reasons for 
this include increased resistive and elastic loads, lung hyperinflation and less 
favourable length tension relation of the respiratory muscles and as a result, drive to 
the inspiratory muscles increases in COPD (McKenzie et al 2009). As the mechanical 
load on the respiratory muscles is increased in COPD (Jolley & Moxham 2009) the 
sensation of respiratory effort and therefore of breathlessness is also increased. This 
study aimed to assess if the 6-minute protocol described earlier (Section 3.6) could 
differentiate between COPD patients and healthy individuals. 
7.4.2  Method 
Participants 
Nineteen individuals (9F:10M; age range 44-75yrs) with clinical diagnosis of COPD 
(FEV1 % pred 44 ± 13; FEV1/FVC ratio 54 ± 14) were asked to undertake two 6-
minute seated RK trials (Section 3.1.3.2). Upon gaining consent, body weight and 
height were measured and baseline spirometry performed (Section 3.4.1). 
 
Protocol 
A standard 6-minute seated RK protocol was followed (Section 4.6) and the RK load 
was set at 0 and 0.75 kPa.L.sec-1.  
 
Data Analysis 
At the end of the test the following study parameters for each breath were calculated; 
VTI (ml), VTI\tI (L.sec-1) and InWrsmouth (J.L) (Section 3.1.6). t-test’s were used to 
assess for significance difference between RK loads and with control data described 
earlier (Section 4.2). 
7.4.3  Results 
COPD patients had a higher fR than controls in both trials, although for both groups it 
remained constant irrespective of RK load. VTI remained constant irrespective of 
participant group or applied RK load. The increase in InWrsmouth observed previously 
in control subjects when an RK load of 0.75 kPa.L.sec-1 was applied was observed in 
the COPD patients. This increase was similar in magnitude to that observed in control 
subjects approximately doubling from trials at 0 kPa.L.sec-1. 
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While the change in InWrsmouth was similar in COPD patients and controls, it was 
observed to be significantly higher in COPD as opposed to control subjects at both 
levels of RK (0 and 0.75 kPa.L.sec-1) (Fig 7.4).  
7.4.4  Discussion 
A 6-minute trial using an applied RK load is able to differentiate between COPD 
patients and healthy individuals as assessed by InWrsmouth. When completing a 6-
minute protocol as outlined in Section 4.6, COPD patients had a InWrsmouth of -0.40 ± 
0.15 (J.L), 20% greater than that reported for healthy controls (Section 4.6).  
 
Although COPD patients had a higher fR this remained constant in both trials 
alongside the constant ventilation rate would suggest that the increased inspiratory 
work (InWrsmouth) is a result of COPD. The hyperinflation of COPD reduces the flow 
and pressure generating capacity of the diaphragm (Mckenzie et al 2009). The ratio of 
tI to tTot is reduced in COPD in an effort to increase the time for available for 
expiration and minimise hyperinflation which demands an increase inspiratory flow 
rate (Jolley & Moxham 2009). 
 
 
 133
 
Figure 7.4: (A) fR (bpm-1) (B) VTI (L) and (C) InWrsmouth (J.L) in Healthy 
Controls (Black bars) COPD patients (Grey Bars) During 6-minute Trials With 
RK at 0 and 0.75 kPa.L.sec-1. * = sig diff (p<0.05) with trial at 0 kPa.L.sec-1
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7.5  COPD TBPA 
7.5.1  Introduction 
The inspiratory and expiratory airflow profile differs in the presence of airway obstruction 
and an analysis of the inspiratory and expiratory airflow profile has shown there to be 
quantifiable changes in the airflow profile in the presence of airway obstruction (Colsanti et 
al 2004). In COPD the severity of the disease is related to the degree of airway obstruction 
with the spirometric measurement of FEV1 providing the gold standard method for assessing 
the degree of airway obstruction. As discussed previously there are occasions when it is not 
always possible to accurately perform FEV1 measurement in COPD. The more severe COPD 
becomes the more difficult it can be to measure lung function as patients get older, suffer 
from comorbidities and frequent exacerbations. Even if patients fully co-operate, current lung 
function guidelines often label measurements as low quality and not good enough for 
assessment, meaning the patients most at risk are the hardest to assess (Soriano & Miravitllies 
2009).  
The aim of this study was to assess the tidal airflow profile analysis equations developed by 
Colsanti et al 2004 (Section 3.2.1), as an alternate measure of airway obstruction, as 
FEV1TAP, in COPD patients and compare this with data previously reported for healthy 
controls (Section 5.4). 
7.5.2  Method 
Thirty-one patients (Age range 44-84: 18M:13F) with a clinical definition of COPD (FEV1 % 
pred; 44 ± 15) were asked, whilst seated and relaxed, to breathe through a pneumotachograph 
for three minutes to measure TBPA (described in Section 3.2). Spirometry provided the 
measured FEV1 (Section 3.4) while FEV1TAP was derived using the equation described 
previously (Section 3.2):  COPD FEV1TAP = -3.73 + (tPPEF80 x 0.031) + (tPTIF x 6.08) + (Age x 
-0.017). Linear regression was used to assess for relationship between FEV1 and FEV1TAP, 
and the difference between FEV1 and FEV1TAP was also calculated. 
7.5.3  Results 
The three minutes of resting breathing was well tolerated by all COPD patients and all trials 
were completed successfully. The average resting fR was found to be 17±4 bpm-1. The 
relationship between FEV1TAP and measured FEV1 was r2 0.38 p <0.01, (Fig 7.5) which is less 
than that reported for healthy controls (r2 0.57 p<0.001 Section 5.4). FEV1TAP was seen to 
under-predict FEV1 in COPD by -0.154ml and over-predict in controls by 0.123ml (Figure 
7.6). 
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Figure 7.5:Relationship Between FEV1TAP and FEV1 in Controls (●) & COPD (○) 
 
Figure 7.6: The Difference Between FEV1TAP and FEV1 for Healthy Subjects (●) and 
COPD (○), the mean ± 2 SD is shown. 
7.5.4  Discussion 
Simple tidal breathing profile analysis provides a useful method for assessing airway 
obstruction in both controls and COPD patients. The appropriate TAP analysis provides a 
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quantitative measure of airway obstruction that can be used to provide a surrogate measure of 
FEV1.  The data suggests that refinement of the predictive equations of Colsanti et al 2004 
needs to be conducted to produce a more linear model. 
 
7.6 Summary & Conclusion 
 
 
COPD is a widespread and common disease affecting many individuals and providing a 
significant burden to healthcare provision in the UK and is a particular health problem in 
Rhonda Cynon Taf where the patients recruited for the studies described reside. In the 
engagement activities described these patients were keen to take part and get involved with 
relevant research taking place locally. As such the current studies and links made with local 
patients and healthcare professionals involved with respiratory disease provides a strong base 
for future research work into COPD. 
 
COPD is a treatable disease, the symptoms of which can be actively managed to improve the 
symptoms and quality of life patients. These patients should not be ‘written off’, the patients I 
met were keen, motivated and interested and represent a valuable resource to those involved 
in research into COPD. The physiological impact of daily activities that cause breathlessness 
in COPD should also be considered in terms of their impact on the load and capacity of the 
 In Summary……. 
In this chapter I set up and ran 3 clinical trials recruiting 50 COPD patients who undertook 38 RK 
trials and 31 TBPA trials. 
The Participant 
 COPD patients are keen to take part and get involved with research into their condition. 
 Many of these find completing maximal spirometry manoeuvres difficult. 
The Test 
 COPD patients were able to successfully undertake RK and TBPA trials. 
 The RK protocol described previously is able to detect differences between individuals 
with chest disease and healthy controls. 
 TBPA can be used to predict FEV1 although more work is needed to develop the accuracy 
of the equations developed by Colsanti et al. 
 The hypothesis set out in section 7.0 is confirmed 
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respiratory muscles and the neuro-mechanical disassociation that results (Jolley& Moxham 
2009). 
 
Within the wider literature there is a paucity of work on non-invasive techniques of assessing 
respiratory endurance or the work of breathing (WOB) with studies usually relying on 
established invasive methods using internal balloon catheters to assess WOB (Section 1.11) 
even in studies of non-invasive ventilation (Girault et al 2009). Using an invasive method 
Delwegg et al (2008) reports large differences in WOB between healthy controls and COPD 
patients although in their methodology they report the use of default values for chest wall 
compliance and it is unclear if this is the reason for the magnitude of the differences 
observed. Furthermore they use a range of set fR (from ~7 to 30bpm-1) however the sample 
length was not changed (40 breaths). Therefore a trial with a fR of ~30bpm-1 would be 
completed in just over a minute, while a trial at ~7bpm-1, would take almost 6 minutes which 
makes it difficult to assess whether a participant is in steady state workload or is liable to 
fatigue but prevented from doing so by the short sample length. 
 
The RK protocol was able to differentiate between healthy individuals and those with COPD, 
however the healthy controls assessed in Chapter 4 were not age matched to the patients 
described in this chapter. While it is not clear if InWrsmouth is affected by the same age related 
decline as that seen in FEV1 (Section 7.1), if suitable healthy aged matched controls could be 
recruited it would allow the impact of COPD on InWrsmouth  to be studied irrespective of age. 
While Delwegg et al (2008) found differences in the WOB they also failed to age match 
healthy controls with COPD study group which would suggest this further work would be a 
useful undertaking.  
 
Exercise was seen to affect InWrsmouth  in healthy controls and this suggests that it would also 
have an affect on COPD patients. While these younger subjects exercised at relatively higher 
exercise intensities, with 6-minute walking tests routinely used in COPD assessment there 
appear no obvious contra-indications for COPD patients to complete RK trials whilst 
completing such sub-maximal exercise. Calculating InWrsmouth could provide additionally 
useful information about a patient’s respiratory endurance capability alongside their exercise 
endurance. 
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While TBPA was able to estimate FEV1 the data suggests that further refinement of the 
predictive equations is required to improve this estimation. Furthermore the use of two 
equations complicates the practical use of TBPA, in that an existing diagnosis of respiratory 
health is required to select the correct equation. By combing all data future work should be 
focussed on developing a single predictive equation that can be applied irrespective of 
respiratory status. 
  
Both of the techniques (RK trial and TBPA) assessed in this chapter represent sub-maximal 
methods of 1) differentiating between disease and 2) estimating FEV1. While neither 
represent a finalised approach they provide a basis for future research into sub-maximal 
testing within this patients group. 
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Chapter 8 – Lung function in preterm and term children 
8.0 Introduction and Overview 
8.1  Background to Chronic Lung Disease in Prematurity 
8.2 Work of Breathing and Exercise in Preterm and Term Children 
8.3  TBPA in Preterm and Term Children 
8.4  Summary and Conclusion 
 
8.0  Introduction and Overview 
The work detailed in this chapter took place as part of a collaborative study with Prof. Sailesh 
Kotecha and Dr Suchita Yoshi of the Department of Child Health at Cardiff University. This 
Cardiac and Respiratory Outcomes of Prematurity (CROP) study was led by Prof Kotecha, 
while Dr Yoshi was responsible for recruiting the participants. However the work described 
in this chapter was undertaken by the thesis author.  
 
The primary aim of this study was to assess the differences between children born extremely 
pre term (less than 32 weeks) with and without bronco-pulmonary dysplasia, also referred to 
as Chronic Lung Disease (CLD) of prematurity and with children born at full term (≥38 
weeks). The assessment of InWrsmouth and TBPA in these children is then outlined and the 
relationship with exercise and activity levels explored. The hypothesis that chapter seeks to 
test is that RK trials can differentiate between children born preterm, preterm with CLD and at 
full term. 
8.1  Background to Chronic Lung Disease in Prematurity 
Current neonatal intensive care has greatly improved the survival of preterm infants and 
mechanical ventilation and oxygen therapy is the mainstay of pulmonary care in premature 
infants. However despite advances in neonatal intensive care, many preterm infants remain 
oxygen dependent beyond 36 weeks of corrected gestational age and they develop CLD. In 
recent years, with the widespread use of antenatal steroids, postnatal surfactant and less 
aggressive mechanical ventilation, the pathophysiology of CLD has changed. However, the 
number of children with CLD is ever increasing.  
 
Infants who die from CLD are shown to have markedly decreased numbers of alveoli and 
their medium sized airways and their pulmonary arteries have a thicker smooth muscle layer 
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(Margraf et al 1991), which can result in chronic obstructive airway disease and pulmonary 
arterial hypertension respectively (Abman et al 1985, 2002, Benatar et al 1995). Among those 
who survive, whilst the majority of the infants with CLD can be weaned off oxygen by 2 
years of age, the question arises whether these pathological changes at an early age contribute 
to diminished lung function and increased pulmonary vascular resistance later in life, 
especially, in response to hypoxia.  
 
Limited information is available about the long term cardio-respiratory function in school 
aged children born prematurely, especially, in more recent populations who have been treated 
with surfactant. Term and near term infants who had persistent pulmonary hypertension of 
the newborn during infancy when studied at 20 years of age at sea level and at high altitude, 
were noted to have significantly greater increases in their pulmonary arterial pressures, at 
high altitude, compared to normal controls (Sartori et al 1999). Follow up of lung function 
and exercise capacity in young adults born prematurely, has shown that at a mean age of 19 
years lung function parameters were within normal ranges, but compared to control subjects, 
they had evidence of airway obstruction, lower CO diffusing capacity and lower exercise 
tolerance (Vrijlandt et al 2006). However, this data pre-dates the use of surfactant and 
modern ventilation techniques. 
 
Although survival of preterm infants has improved there is limited data on longer term 
outcomes in these children. As these children may be at risk of developing COPD and 
pulmonary hypertension in later life, especially if they smoke, it is clearly important to assess 
the longer term risks of surviving CLD of prematurity. 
 
This chapter investigates if these children, on reaching 8-12 years of age still have persisting 
sub-clinical abnormalities which may have longer term implications on their health.  
8.2  Work of Breathing and Exercise in Preterm and Term Children 
8.2.1.  Method 
Seventy-five children (37M:38F: age range 8-12) who fulfilled inclusion (Fig 8.1) and 
exclusion criteria (Fig 8.2) were recruited into either study group 1, 2 or 3 (Fig 8.1). Preterm 
infants (<32 weeks of gestational age) who were born or cared for in the Special Care Baby 
Unit at the University Hospital of Wales (UHW), Cardiff from 1995 to 1999 were identified 
from the Neonatal Database maintained at UHW. A suitable cohort of healthy term children 
of similar age and gender matched control group were also recruited. 
 141
Group 1: 
 
(11M:11F) 
Preterm with CLD Children who were born prematurely at ≤ 32 weeks of 
gestational age and who had oxygen dependency 
beyond 36 weeks of corrected gestational age. 
Group 2: 
 
(13M:9F) 
Preterm without 
CLD 
Children who were born prematurely at ≤ 32 weeks of 
gestational age but did not have oxygen dependency 
beyond 36 weeks of corrected gestational age 
Group 3: 
 
(10M:13F) 
Term Control Age and gender matched healthy control children born 
at full term (38 complete weeks or more). 
Figure 8.1: Group Inclusion Criteria 
 
 Children with significant congenital structural cardiac defect 
 Children with significant congenital structural respiratory tract defect 
 Children with significant persisting cardio-respiratory abnormalities requiring 
therapy, including oxygen therapy 
 Children with any neuromuscular disease that could compromise cardiac or lung 
function 
 Children with severe neuro-developmental impairment who would not be able to 
comply with the research procedures 
Figure 8.2: Study Exclusion Criteria 
 
Protocol 
After children gave their assent and informed consent was obtained from their parents or 
guardians, each child’s height and weight was recorded. Children were initially coached 
using a spriometer with a specially designed programme incorporating graphics to explain 
how an FEV1 manoeuvre should be properly conducted. The child was given as many 
practice attempts as necessary to achieve a suitable test result. After a short period baseline 
spirometry was then performed (Section 3.4.1).  A standard 6 minute work of breathing 
protocol (Section 4.6) was undertaken with the RK load set at 0.75 kPa.L.sec.-1. A bespoke 
metronome (Section 3.3) was used to maintain fR at 18 bpm-1. At the end of each trial the 
following study parameters were calculated per breath; VTI (ml), VTI/tI (L.sec-1) and 
InWrsmouth (J.L) (Section 3.1.6). 
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To assess maxOV 2  an incremental cycle ergnometer protocol was followed (Section 3.5.1) 
with the load being increased by 30 watts every 3 minutes at a cadence of ~65 rpm until the 
child indicated they could not continue or they could not maintain pedal cadence. The 
following parameters were measured; 2OV , 2COV , EV  and fR using an online gas analysis 
system (Viasys Masterscreen: MS-CPX) allowing the respiratory exchange ratio (RER) to be 
calculated; fH-1 using a heart rate belt (Polar Ltd, UK); and rate of perceived exertion (RPE) 
using a Borg scale (Borg 1982). To attain maxOV 2  children had to exercise to at least 80% 
of their age predicted fH maximum, and/or an RER >1.0. 
  
Safety 
During this study, if any prematurely born child was noted to have abnormal test results 
compared to the control children, it was arranged for these children to be followed up by 
Paediatric Cardiology and Respiratory Consultants at UHW, who were part of the research 
team associated with the study. 
 
Data Analysis 
A one way ANOVA was used to assess for significant difference between the three groups. 
8.2.2  Results 
All children successfully completed baseline spirometry. Sixty-three children successfully 
completed the maxOV 2  protocol, three trials were lost to technical failure, two because the 
children were too short for the ergonometer and six because they did not achieve maximal 
criteria. Sixty children completed the RK trial , fifteen were excluded as they were not able to 
follow instruction. Fifity-four children were able to complete all three tests with the failure 
rate evenly distributed between the three groups (Table 8.1). Data for all subjects is shown in 
Table 8.2.  
 
In the children who completed all tests, when EV from the work of breathing trial was 
compared to the maximal EV  from the maxOV 2 trial, a ratio could be calculated that 
indicated how resting EV could be increased during maximal exercise. In those children with 
a EV  ratio of <3.5 they had a significantly lower maxOV 2  (30.3 ± 8.5 versus 35.4 ± 7.2, 
ml.kg.min-1; p<0.05) and a higher InWrsmouth (0.47 ± 0.11 versus 0.29 ± 0.05 J.L-1; p<0.001) 
but no differences in FEV1%pred. As this ratio dropped below 3.5, InWrsmouth was seen to 
rise exponentially, r2 = 0.6 (Fig 8.3). Of the seven subjects who were identified with a 
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EV ratio < 3.5 and InWrs
mouth >-0.45 there were no significant differences in any FEV1%pred 
suggesting that there may be another factor such as increased airway resistance that might be 
a causative factor. 
 
Table 8.1: Number of Children Completing Study Trials; Successful (Unsuccessful) 
 G1 G2 G3 n = Successful 
FEV1%pred 23 (0) 25(0) 27(0) 75 
maxOV 2  
(ml.kg.min-1) 
19(4) 20(5) 24(3) 63 
InWrsmouth 
(J.L) 
18(5) 20(5) 22(5) 60 
All tests 17(6) 18(07) 19(7) 54 
 
Table 8.2: Outcomes in Three Groups  
 G1 G2 G3 p 
Height (cm) 140 ± 9 143 ±  9 143 ± 11 ns 
Weight (kg) 33 ± 8 40 ±12 41 ±14 ns 
FEV1%pred 81 ± 14 92 ± 15 98 ± 12 p <0.05 
InWrsmouth (J.L) -0.33 ± 0.1 -0.37 ± 0.1 -0.30 ± 0.1 ns 
maxOV 2  (ml.kg.min
-1) 35.9 ± 6.2 36.1 ± 7.6 30.6  ± 8.4 ns 
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Figure 8.3: Relationship of EV  Ratio and InWrs
mouth 
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8.3  TBPA in Preterm and Term Children 
Due to the inherent problems involved with assessing the respiratory status of children 
discussed previously, a technique that would reduce the level of active participation required 
would be a useful alternative to standard tests. The previous work of Colsanti and colleagues 
only developed predictive equations for FEV1TAP in children with CF. This section details the 
development of predictive equations of FEV1TAP using raw airflow data gathered from the 
children tasking part in the CROP study. 
8.31   Method 
The seventy five children described previously (Section 8.2) undertook a three minute TBPA 
trial as described in Section 3.2.  The children were assessed independently of their CROP 
study group status previously described (Fig 8.1) and were classified as either having a 
FEV1%pred of <80% or ≥ 80%. Using a statistical software package (Sigma Plot version 9) 
stepwise linear regression analysis was used to develop predictive equations of FEV1TAP. Key 
factors integrated into the analysis were height and tTPEF80. 
8.32   Results 
Seventy-five children successfully completed the TBPA protocol, Data for 5 children was 
lost due to technical problems with 1 child unable to follow trial instructions. Characteristics 
of the children who successfully completed the trial can be seen in Table 8.3. For both groups 
as would be expected height was a strong predictor of FEV1.  However in both groups when 
tPTEF80 was integrated into the regression analysis the fit (r2) was better than if height was 
used alone (<80% 0.74 vs 0.69: ≥ 80% 0.75 vs 0.60). The regression equations for each group 
are plotted in Fig 8.4. 
 
Table 8.3: Characteristics of Sixty-Nine Children Who Completed TBPA 
 M:F Height (cm) Weight (kg) FEV1%pred 
FEV1%pred <80% 9M:6F 142 ± 10 37 ± 12 66 ± 11 
FEV1%pred ≥ 80% 28M:26F 143 ±  9 39 ±12 97 ± 10 
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Figure 8.4 : FEV1TAP predictive equations of children in CROP study. FEV1%p 
<80%:FEV1TAP= -5.830 + (0.0361 * Height(cm)) + (0.0143 * tPTEF80). FEV1%p ≥ 80%; 
FEV1TAP = -2.951 + (0.0372 * Height(cm)) - (0.00215 * tPTEF80). 
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8.4  Summary and Conclusions 
 
While a significant difference in FEV1 was identified between the three study groups there 
was considerable overlap in terms of other outcomes which may suggest that the arbitrary 
definition of CLD is too simplistic to be used as means of differentiation with other preterm 
children. There may be other factors such as a reduction in diffusion capacity, increased 
airway resistance or lung hyperinflation that may have resulted from their premature status 
that could be used instead as more objective measures for classification. 
 
Within the cohort maxOV 2  appear to be independent of study group status. This is most 
likely due to how the cardiovascular system develops much earlier in-utero than the 
respiratory system so a lack of difference is to be expected. Perhaps a more pertinent 
questions is how (if at all) does an impaired respiratory system (as reduced FEV1) impact on 
 
In Summary……. 
In this chapter 75 children undertook RK, TBPA and maxOV 2  trials as part of a wider study into 
the effects of prematurity on cardio-respiratory development. 
The Participant 
 Children often required substantial coaching to complete the tests required of them, 
although the amount of time spent with each individual child was not recorded. 
 Despite a relatively intensive testing protocol the majority children were able to complete 
these trials.  
The Test 
 The only outcome that was significantly different between the three study groups was in 
FEV1% pred.  
 Spirometry was successfully completed by all although this was most probably due to 
level of training provided. 
 Data indicates an exponential relationship between InWrsmouth and the ability to increase 
ventilation during maximal exercise that was independent of gestational status. 
 Using raw air flow data a predictive TBPA equation was developed for future use. 
 In the context of RK trials the hypothesis set out in section 8.0 is rejected. 
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the cardiovascular system? While the majority of children appeared symptomatically well 
and active further study of this cohort would provide useful information about how children 
born prematurely develop as they grow. For example, do the differences in FEV1 exist into 
adulthood? Could there be a link between gestational age and the impact of respiratory 
disease in later life? Should such children be specifically targeted to prevent behaviours that 
may adversely impact on their respiratory health such as tobacco smoking and environmental 
exposures?  
 
A valid goal of future assessment of respiratory function in children would be to develop 
techniques that provide less instruction while maintaining an adequate level of diagnosis. The 
development of a predictive TBPA equation would allow this to occur and provides a basis 
for future work in a similar manner to that undertaken in COPD patients (Section 7.5). 
However the relatively small group numbers prevent a robust equation from being developed 
and much larger cohort would be required but with the relatively successful testing and 
simple protocol this could be relatively easy to undertake. 
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Chapter 9 – Resistive load detection 
9.0  Introduction & Overview 
9.1  Method: Healthy Controls 
9.1.2 Method: Patients with Obstructive Disease 
9.2  Results 
9.3 Summary and Conclusion 
 
9.0  Introduction & Overview 
Breathlessness is a common reason for referral for lung function assessment (Jefferies & 
Turley 1999). Breathlessness or dyspnoea is a subjective difficulty, or distress in breathing 
and it can therefore be difficult to accurately quantify. Breathlessness can be closely linked to 
chest diseases in which airway obstruction is a common characteristic. This can be permanent 
obstruction such as with COPD or recurrent reversible airway obstruction caused by airway 
hyper-responsiveness such as with asthma. Accurate perception of changes in airway 
obstruction is a critical component in the self-management of chest disease (McQuaid et al 
1996). 
 
In healthy subjects quantification of the changes in mechanical load is a relatively simple task 
but this may be more difficult in diseases with airway obstruction. Typically 15-40% of 
adults with asthma fail to consistently recognise clinically significant breathing changes and 
better perceptual accuracy is associated with significantly less functional morbidity (Fritz et 
al 1999). Failure to perceive symptoms of an oncoming asthma ‘attack’ has been suggested as 
one of the reasons for a delay in patients seeking treatments which can then lead to life-
threatening events (Davenport & Kifle 2001). 
 
Existing methods for quantifying dyspnoea use mechanical loads that are related directly to 
airflow (Wiley & Zechman 1966; McQuaid et al 1996; Davenport & Kifle 2001). This 
chapter outlines the development and use of a new technique, using a computer driven device 
where a resistive load (RK) can be maintained irrespective of the airflow rate. The aim of this 
chapter is to quantify the ability to detect RK’s load in healthy controls and patients with 
obstructive disease. The hypothesis that chapter seeks to test is that a resistive detection 
method using RK loads can differentiate between COPD patients and healthy individuals. 
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In addition the possible protocol format for a resistive detection trial was studied. Previous 
studies apply resistive loads in a random fashion, however physiological detection tests in 
other areas of human physiology use protocols that apply loads in descending order, for 
example audiometry. The British Society of Audiology (2004) outlines a trial that uses 
descending levels for detection. This raises the question; Is there any difference between 
random and descending protocols on perceptual ability? 
9.1  Method; Healthy Control 
Participants 
Eleven healthy males (age range 18-29yrs; FEV1%pred 99±14) after completing static and 
dynamic lung function measurements (Section 3.41 and 3.42), undertook a series of resistive 
load detection trials on two separate visits. For all trials each subject breathed through the 
experimental set up (Fig 9.1) via a mouthpiece and bacterial filter. All subjects wore nose 
clips and had no prior experience of the device. Written informed consent was secured before 
testing took place. 
 
Experimental set up 
The RK device was combined in series with an analogue digital converter (ADi Powerlab 
ADinstruments) which included a pneumotachograph and push button device with a small 
rubber gasket to endure an air tight seal (Fig 9.1). 
 
Figure 9.1: Experimental Set-up 
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The RK device was used to apply an RK load during quiet tidal breathing and if a participant 
detected a resistive load they were instructed to push the button. Using commercially 
available software (Chart5, ADinstruments) this response could be recorded concurrently 
with the flow signal from the pneumotachograph and an electronic mark of the loaded phases 
to provide a record of each trial (Fig 9.2). 
 
 
Figure 9.2: Recording of resistive detection trial using Chart5 software. (A) Participant 
response to RK load; (B) Air Flow; and (C) Digital Marker of onset of applied RK load. 
 
Development of Protocol - Loaded phase cycle 
In a similar manner to Wiley & Zechman (1966), RK loads were applied in two breath cycles, 
as they describe that this can be used to avoid possible chemical influences in the detection 
resulting from blood gas changes, produced by possible reductions in alveolar ventilation that 
could occur over larger period of breathing cycles. For example an earlier study by Bennet et 
al (1962) employed a five breath loaded cycle. Subsequent studies have used a similar two 
breath loaded cycle ( Puddy et al.1992; McQuaid et al.1996; Fritz et al. 1999), however 
Davenport & Kifle (2001) used a single breath loaded cycle. 
 
Number of loads applied during how many trials? 
Wiley & Zechman (1966) used eight individual loads applied once over a maximum of three 
trials McQuaid et al (1996) and Fritz et al (1999) used five individual loads applied twenty-
five times during one trial. Davenport & Kifle (2001) used one trial of nine individual loads 
applied four times, and two trials of nine loads applied three times. For this study it was 
 
A 
B 
C 
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planned to compare two protocols (descending and random) and that each was to be repeated 
twice. Therefore each load was applied once in four trials which was similar to that described 
in these previous studies and would not be unduly taxing on study participants. 
 
Level of applied load 
As the RK device described in this thesis was to be used, the RK loads that were studied 
previously (Chapter 4) were used in this study: 0.15 – 1.5 kPa.L.sec-1 (1.5 – 15.3cmH20). 
 
Instruction to participants 
Participants were given a demonstration trial of two breaths loaded at the highest RK that they 
would experience in the subsequent trials. They were told when the load was applied and 
were instructed to simultaneously depress the push button. Previously studies used a push 
button for participants to indicate they had detected loads however not all followed the same 
instruction protocol. Davenport et al (2001) had participants listen to music to mask any 
experimental sounds, Puddy et al (1992); McQuaid et al (1996) and Fritz et al (1999) 
informed participants with a signal light that a resistance was about to be applied. Wiley et al 
(1966) describes how the operator “stood behind a curtain and manipulated the apparatus 
quietly” so to give no indication to the subject when loads were applied. 
 
An issue with the RK device is that as it continually changes its internal diameter to maintain 
a constant RK, it produces an audible noise. Therefore in the unloaded phases the device was 
set at an RK of 0.01 kPa.L.sec-1 so that the device would continue to make an operating sound 
and the lack or onset of any noise could not be used as an indication of a loaded breath. 
 
Visit 1 
Protocol A – Participants followed a protocol with RK descending loads from 1.5, 1.25, 1.0, 
0.75, 0.5, 0.3, 0.2 to 0.15 kPa.L.sec-1. This is similar to the British Audiological Society’s 
guidelines that apply hearing tests in a descending fashion. 
 
Protocol B – The same eight RK loads as in protocol A were applied in a random order which 
was selected from a prepared random list for each participants so that all followed a different 
order.  
 
Participants undertook both protocols twice completing four trials in all on their first visit.  
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Unloaded breaths between loaded phases varied from 3 – 8 breaths in a preset, non-
systematic order to prevent temporal sequence detection. This order was used for all 
participants to allow for comparison.  These periods used between loaded phases are shorter 
than that described by Wiley & Zechman (1966); (4-20 unloaded breaths), but similar to 
those reported by Davenport & Kifle (2001); (3-6 unloaded breaths) and Puddy et al (1992); 
(5 -10 unloaded breaths). Fritz et al (1999) used 3 unloaded breaths between each loaded 
phase. 
 
Protocol - Visit 2 
In a similar manner to their first visit, participants undertook four trials each with eight RK 
loaded phases. On this visit however each trial had eight identical loads at 1.0, 0.75, 0.5 and 
0.25 kPa.L.sec-1 so that the repeatability of detection of each level could be ascertained.  
 
Data Analysis 
For assessing detection a similar method was used to that described by Wiley & Zechman 
(1996), the percent detection for trials was calculated by dividing the number of successful 
detections by the maximum possible and multiplying by 100.  
9.1.1   Method: Obstructive patients 
A group of patients (n=5; median MRC Dyspnoea score 4) with clinically diagnosed asthma 
(n=2F: age range 40-51; FEV1%pred 84-102; MRC) and COPD (n=3(2M) age range 60-65; 
FEV1%pred 25-49) were invited to undertake a breathless sensitivity trial. These patients 
followed protocol A in a similar fashion to that outlined in Section 9.1.2, however due to time 
constraints these patients were only asked to complete the protocol once. 
9.2  Results 
All controls and patients were able to complete all sensitivity trials and none were halted 
early. During constant protocol trials when RK was at 1 kPa.L.sec-1 percentage detection rate 
in healthy controls was 99% falling to 8% at an RK load of 0.25kPa.L.sec-1 (Fig 9.3). A 
percentage detection rate of 50% would appear to occur at RK load of approximately 0.55 
kPa.L.sec-1. The rate of decline in percentage was similar in Protocol A and B although the 
decline was steeper in protocol B between RK loads of 0.3 and 0.75 (Figure 9.4). Chest 
disease patients displayed similar detection rates above 0.75 kPa.L.sec-1 but this dropped to 
zero detection below this RK load (Fig 9.5). 
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Figure 9.3: Percent detection in healthy controls (Mean ± SEM) of RK constant protocol 
during 2nd visit. 
 
 
Figure 9.4: Percent detection in healthy controls (Mean ± SEM) of RK during protocol A 
& B 
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Figure 9.5: Percentage detection in chest disease patients (Mean ± SEM) of RK during 
protocol A 
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9.3  Summary and Conclusion  
 
 
This chapter describes the development of a novel system to assess the ability to detect 
resistive loads. This system has benefits over existing methods (described in Section 9.1) 
such as; easily integrating an applied load and the response by a participant; allowing the 
level and duration of the resistive load to be easily adapted in a manner that avoids alerting 
the trial participant; and using a resistive load that is independent of airflow. 
 
In healthy controls both protocol A and B showed a similar decline in detection rates as RK 
load decreased. This would suggest that this method could be used to evaluate the level of 
sensitivity in these individuals. Furthermore comparison between individuals who are able to 
detect RK loads below 0.5 versus those unable could be conducted. However this would 
 
In Summary……. 
In this chapter a novel system to detect sensitivity to resistive loads was developed. Using this 11 
control subjects and 5 patients undertook 85 breathless sensitivity trials. 
1. The Participant 
 All participants were able to complete all sensitivity trials with relatively little training. 
 Substantial mental cooperation was required in terms of concentration but the trials 
themselves required comparatively little physical effort. 
 
2. The Test 
 Repeatability of detection of resistive loads was good (>90%) in healthy controls when 
the RK Load was over 0.75 kPa.L.sec-1 however it dropped when RK load was below 
0.5kPa.L.sec-1. 
 Healthy controls showed a graded decline in protocols A and B, although this decline was 
slower in protocol A where the resistances were applied in a sequential order suggesting 
that this may have caused the better detection rates.  
 Data would suggest that patients with chest disease are unable to detect RK loads below 
0.75kPa.L.sec-1. 
 Although testing only took place in a limited number of COPD patients, data suggests that 
this technique could be used to differentiate between health and disease confirming the 
experimental hypothesis set out in section 9.0. 
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require further lung function testing that was unfortunately not conducted for this study, 
specifically markers of airway obstruction such as RAW.  
 
Interestingly the decline in the mid-range of RK loads were seen to be less steep in protocol A 
than B. In short when the RK was decreased sequentially the detection rate was better than 
when the RK loads were applied in a random order, suggesting that participants were using 
the order to assist with the detection of RK loads at this point (Fig 9.4). This temporal 
patterning questions the utility of sequentially descending protocols in other physiological 
tests such as those used by the British Audiological Society. Do they overestimate these 
audiological test scores? 
 
The testing of patients was undertaken concurrently with the testing of the healthy controls in 
an ad-hoc fashion while studies for other chapters in this thesis took place. It would be useful 
to repeat the methodology undertaken by the controls to elicit what similar levels of 
repeatability exist. Although conducted in only limited trials the patient data indicates that 
there is limit to detection of RK loads below 0.75 kPa.L.sec-1 in patients with clinically 
diagnosed asthma and COPD.  It is however unclear where the exact point may be and future 
work would benefit from looking at more loads between the points identified in this chapter 
(0.5 – 1.0 kPa.l.sec-1). These patients had a high median MRC Dyspnoea score of 4 which 
could suggest that the breathlessness detection protocol described could be used to quantify 
breathlessness. 
 
The methodologies of previous studies were used to inform the development of the protocol 
that was used in this study. However where this significantly differs is in the magnitude of 
the resistive loads applied. Wiley & Zechman (1966) applied eight loads between 0.2  - 1.8 
cmH20 (0.02-0.18kPa), Fritz et al (1999) applied loads ranging from 0.25 – 8 cmH20 (0.02-
0.78 kPa), whereas McQuaid et al (1996) applied a percentage (20, 60, 100, 140, 180%) of 
subjects baseline REFF. The early work in this thesis suggested that when using the RK device 
in this way, greater loads would be needed for example between 0.25 – 1.5 kPa.L.sec-1. The 
graded responses as RK decreased seen in Figures 9.2, 9.3, and 9.4 shows this to be the case. 
It is unclear why such there is such a magnitude of difference with these previous studies, but 
is most probably due to the flow dependent loads used. 
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Chapter 10 – Thesis Summary 
Assessment of respiratory function can be difficult to accurately complete due to the complex 
interaction of different human biological systems and the reliance on the willingness and 
cooperation of the individual being assessed. Techniques have been developed that are 
accurate, reliable and repeatable, yet they frequently come with some caveat that affects their 
utility. These can include requiring maximal participant effort and in some circumstances 
involve invasive measurement techniques. Where possible the use of such approaches is the 
best method however, this is not always achievable. What should not be inferred is that 
maximal and/or invasive tests are somehow inferior to non-invasive tests. As was stated in 
the beginning of this thesis (Section 1.0) the aim of developing new methods of assessing the 
respiratory system was not to replace or supersede these established methods but to provide 
new approaches when their use was not possible. For example the gold standard measurement 
of the respiratory system that is most commonly used as a marker of respiratory health is 
spirometry (Section 1.5.1), although situations occur when it may not be possible to use such 
a technique, such as with young children, exacerbating patients or when a lack of equipment 
and/or trained staff is available (Section 1.6).  
The work in this thesis also details how meaningful these new techniques (TBPA and RK 
trials) are, as their efficacy is directly related to their ability to reliably and repeatable act as 
measures of the respiratory system. The experimental work in chapters 6 to 9 was driven by 
the expectation that these new approaches would be able to differentiate between rest and 
exercise, and health and disease. The meaningfulness of these techniques to provide useful 
measures would then be represented by this ability. This approach was taken due, in 
particular to RK trials and the difficulties identified with the definition and measurement of 
endurance (Chapter 2), and the lack of any recognised measure with which to compare them 
with (Section 2.2.13). To derive the absolute physiological mechanisms underpinning of  
each technique was not the goal of this thesis, rather their practical ability to be used safely 
and easily, and their use in differentiating between rest and exercise, health and disease. 
The focus of this thesis has been to develop sub-maximal tests that reduce the need for active 
participation allowing a passive participation, which will also simplify testing by reducing the 
need for complex equipment and trained staff. 
 
The main aims of this thesis were to investigate this sub-maximal focus using two alternative 
 159 
methods: Respiratory Muscle Endurance; and expiratory tidal profile analysis and it 
investigated these in detail. Additionally it was identified that any new methods should be 
viewed from two points to assess the validity of any outcomes:1) The Test – how well did 
these new methods represent respiratory function ; and 2) The Participant – how well did 
participants interact with these new methods. 
 
The work describes how 99 adult participants (68 Healthy controls and 31 COPD patients) 
and 75 children (48 clinical group and 27 healthy controls) were recruited and completed 467 
respiratory endurance trials whilst seated and exercising, and 249 relaxed tidal breathing 
trials. 
10.1  The Test 
From a systematic review of 111 journal articles it was identified that the terms endurance 
and fatigue are both frequently used on the (incorrect) assumption that they are 
interchangeable. This lack of clarity and confusion has resulted in no clear definition or 
protocol to assess respiratory muscle endurance. Attention should also be drawn to the use of 
‘muscle’ in these terms. Non-invasive tests cannot differentiate between different 
components of the respiratory system and as such they cannot measure the respiratory 
muscles per se. Respiratory endurance or respiratory system endurance would be a more 
suitable term. 
 
With regards to a more accurate definition of endurance it was argued that as it represents the 
property that affords resistance to fatigue, for example when endurance fails fatigue occurs, 
fatigue and endurance are not synonymous. Using such a concept of endurance, any fatiguing 
test protocols that exist cannot therefore be used to measure respiratory endurance. This 
would suggest that a sub-maximal approach, when no fatigue of a participant occurs, would 
be more appropriate. The homeostatic response of the breathing control system during a sub-
maximal non fatiguing test, would allow the most efficient breathing pattern to occur. It was 
found that measuring InWrsmouth would best represent this efficiency and as such could be 
used as an indicator of endurance. 
 
The use of expiratory tidal flow curve analysis was systematically reviewed in 31 journal 
articles with the most commonly used parameter identified as tTPEF.  The work of Colsanti 
and colleagues was shown to have developed predictive equations of FEV1 from relaxed tidal 
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breathing using TBPA.  Although the literature suggests that the use of the expiratory flow 
curve is not as sensitive a measure as standard lung function tests, it could provide useful 
information about the health of the respiratory function again in those situations when 
standard lung function testing is not applicable or practicable. 
 
A 6-minute trial similar to other sub-maximal exercise endurance tests was developed using a 
device that was able to apply a RK that was independent of respiratory air flow. This allowed 
InWrsmouth to be measured, a process that was refined through a series of studies. These 
concluded that for the 6-minute RK trial protocol, participants should be able to self select 
their respiratory pattern, the RK load should be applied throughout the breath cycle and the 
first minute of data should be disregarded for analysis. The outcome parameters of the 6-
minute trial were not seen to correlate with any standard lung function parameters, although 
as these do not themselves represent measures of endurance, this was to be expected. 
The reliability and repeatability of the RK trial and TBPA was assessed alongside standard 
lung function tests. It was found that spirometry was the most reliable measure with the 
smallest coefficient of variation. RK trials when fR was unpaced showed lower coefficient of 
variation than trials when fR was paced. While spirometry was confirmed as a gold standard 
measurement, RK and TBPA trials were found to be both reliable and reproducible measures. 
 
When the RK trial was assessed during exercise it was found that irrespective of the pattern of 
breathing or exercise mode, EV&  increases with InWrs
mouth
 in a linear fashion dependent on 
the RK load applied. The RK device therefore would appear able to maintain RK load 
irrespective of EV&  as claimed by the device’s manufacturers. During exercise InWrs
mouth
 was 
seen to increase exponentially with RK, this would imply that when resistive loads are higher, 
such as with individuals with increased RAW, exercise becomes limited because of a reduced 
respiratory endurance rather than a lack of respiratory muscle strength. 
 
In a similar fashion to healthy controls, COPD patients were able to successfully undertake 
RK and TBPA trials. By measuring InWrsmouth during a standard RK trial protocol it was 
possible to detect differences between individuals with chest disease and healthy controls. 
Additionally TBPA was seen to predict FEV1 in these patients although it tended to 
underestimate FEV1. However if the patients showed a similar pattern of repeatability as that 
shown with healthy controls TBPA could be used to monitor absolute changes over time 
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rather than be used as a diagnostic test. 
 
When comparing children born: at term; preterm; and preterm with CLD, it was found that 
only FEV1% pred was significantly different between the three study groups. Spirometry was 
successfully completed by all although this was most probably due to the level of training 
provided. An exponential relationship between InWrsmouth and the ability to increase 
ventilation during maximal exercise was identified that was independent of gestational status. 
What affect an impaired respiratory status has on this relationship remains unclear.  In 
addition no predictive equation for using TBPA existed for use in children without CF, 
therefore using the raw data gathered from these 75 participants and linear stepwise 
regression analysis a TBPA equation was developed for future use. 
 
A novel method to assess the detection of resistive loads was developed using the RK device. 
This was able to overcome the difficulties associated with the limited existing techniques 
identified such as the complexity of varying load between breaths and the need to disguise 
the onset of any load from the participant. Repeatability of detection of resistive loads was 
good (>90%) in healthy controls when the RK load was over 0.75 kPa.L.sec-1 however it 
decreased when RK load was below 0.5kPa.L.sec-1. Healthy controls showed a graded decline 
in the two protocols used when the loads were applied either 1) randomly or 2) sequentially. 
Despite the intervals between loads being randomly selected in all trials, the decline was 
slower when the resistances were applied in a sequential order. This suggests that when 
applied sequentially these healthy participants may have been able to predict or guess when a 
load may be applied than when the loads were applied in a random fashion. In a limited 
number of patients with clinically defined obstructive chest disease, data would suggest that 
these patients are unable to detect RK loads below 0.75kPa.L.sec-1 suggesting that this 
approach could be used to differentiate between health and disease.  
10.2  The Participant 
The human respiratory system will always, if allowed, adopt the most efficient breathing 
pattern for the work imposed upon it. While full cooperation from a motivated participant is 
required to successfully complete most respiratory tests, not all participants can successfully 
complete all standard lung function tests. The four main issues that affected this ability were 
identified as the equipment needed, staff required, the environment in which testing took pace 
and most importantly the participant and the cooperation of the individual being tested. 
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Minimising these effects is a key requirement when developing tests of respiratory function. 
 
From the review of respiratory endurance articles it was shown how existing tests of 
respiratory endurance often require participants to continue to fatigue, which can make it 
difficult to complete. Such tests as these require a motivated and cooperative participant. The 
review of TBPA articles indicated that it had been used mainly in younger children due to the 
difficulty in them completing standard lung function tests. It could be suggested that this is 
because standard lung function tests such as spirometry are seen as being within all 
individuals’ ability although as argued previously this cannot always be the case. 
 
The 6-minute RK trial is similar to other existing physiological tests such as the 6 minute 
walk test and the Astrand Rhyming Cycle test, for example in terms of length of time and 
intensity. As both tests are undertaken by both healthy individuals and patients with various 
forms of chronic disease it was expected that the majority should be able to complete a 
similar sub-maximal respiratory endurance test. 
 
The development of the RK trial showed that all control participants tolerated all seated 6-
minute trials, adapting to the RK loads within the first minute and entering into a steady state 
breathing pattern. In a similar fashion these participants successfully completed all TBPA 
trials. The only exception to this was in exercising RK trials when fR was controlled, as a 
limited number of subjects were unable to match their breathing pattern with the pacing 
required. This suggests that the absence of any paced breathing pattern from the final RK 
protocol is the most suited, allowing individuals to select their most efficient breathing 
pattern, resulting in the best representation of their ability to endure an RK load. When 
breathing pattern is self-selected all participants are able to complete 6-minute trials, some 
even while exercising at intensities of up to 150watts, and RK loads of 1.5 kPa.L.sec-1. 
 
COPD is a common disease nationally and is a particular health issue in Rhonda Cynon Taf 
which has one of the highest standardised mortality ratios for chest disease in the UK. During 
discussions with COPD patients as part of clinical studies and outreach work it was found 
that these patients were keen to take part and get involved with research into their condition. 
When asked many of these patients stated how they found completing maximal spirometry 
manoeuvres difficult, further confirming the need for alternative sub-maximal methods of 
assessing respiratory function.  
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It was identified in the literature that children often required substantial coaching to complete 
the tests required of them. During the study of children in this thesis a large period of time 
was devoted to training to complete FEV1 manoeuvres which resulted in a 100% success rate. 
The level of instruction for both RK and TBPA trails was substantially less which perhaps 
explains the lower rate of successful outcomes. However such approaches to RK and TBPA 
trials reflects how such trials may be used without strict instruction away from specialist 
clinical environments.  
 
Using a novel approach to assess restive loads detection, all participants were able to 
complete all trials with relatively little training. Substantial mental cooperation was required 
in terms of concentration but the trials themselves required comparatively little physical 
effort. A graded decline was observed in healthy controls, but patients with obstructive 
disease showed a rapid decline, with none able to detect RK loads below 0.75 kPa.L.sec-1. 
10.3  Summary 
 This thesis describes how I developed and used  new and existing technologies to provide 
new methods for sub-maximally assessing respiratory function. These methods were 
successfully applied in healthy controls at rest and while exercising, in children and patients 
with COPD. 
 
In Chapter 5 it was hypothesised that RK trials and TBPA would be both repeatable and 
reliable measures. In a series of small scale studies it was shown that Spirometry showed the 
greatest level of repeatability which confirms its status as a gold standard measure. While not 
as repeatable as spirometry, both RK trials and TBPA showed a sufficient level of 
repeatability to make them a practical alternative in the situations identified when existing 
techniques like spirometry would not have been practicable, confirming the experimental 
hypothesis. At rest in healthy participants InWrsmouth was observed as 0.33 (±0.08) J.L. 
 
In Chapter 6 it was hypothesised that increases in ventilation due to exercise results in 
increases in InWrsmouth. During RK trials at rest and during exercise irrespective of the pattern 
of breathing or exercise mode, ventilation increased with InWrsmouth in a linear fashion 
dependent on the RK load applied. This confirmed the experimental hypothesis. When 
ventilation was constant, InWrsmouth was shown to increase exponentially with RK indicating 
how an increased resistive load, similar to that in patients with obstructive chest disease, 
would have a greater limiting effect. 
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In Chapter 7 it was hypothesised that RK trials and TBPA would be able to differentiate 
between healthy individuals and patients with COPD. When completing an RK trial, COPD 
patients had an InWrsmouth of-0.40 ± 0.15 (J.L) 20% greater than that reported for healthy 
controls confirming the experimental hypothesis in terms of RK trials. TBPA was dependent 
on knowing the respiratory status of an individual to apply the correct predictive equation. 
However when the appropriate TBPA equation was applied it provided quantitative measure 
of airway obstruction that could be used to provide a surrogate measure of FEV1 confirming 
the experimental hypothesis.  This suggests that in its present form that TBPA in not capable 
of differentiating between health and disease without knowledge of an individuals respiratory 
status diagnosed by spirometry for example. However TBPA may provide a suitable 
alternative to existing measures in environments such as home monitoring when its ease of 
use and analysis could provide an advantage. 
 
 In Chapter 8 it was hypothesised that RK trials would be able to differentiate between 
children born preterm, preterm with CLD and at full term. As has been shown in previous 
studies FEV1 was significantly lower in preterm children. In a similar manner to measures of 
height, weight and physical fitness, there were no differences in InWrsmouth between the three 
experimental groups, rejecting the experimental hypothesis in terms of InWrsmouth. Although 
significant differences were found between the groups in terms of FEV1, suggesting some 
form of greater airway obstruction in children born preterm, the severity of this obstruction 
was not as great as that seen in COPD patients. The children in the preterm CLD group had a 
FEV1%pred 81% ±14 which in terms of GOLD classification of COPD (Table 7.1) would put 
them on the cusp of mild COPD (FEV1%pred<80%). This would suggest that InWrsmouth is 
much less sensitive a measure than spirometry and is only able to detect greater differences 
between health and disease. 
 
In Chapter 9 it was hypothesised that a resistive detection method using RK loads could 
differentiate between healthy individuals and COPD Patients. Healthy individuals showed a 
graded decline in their ability to detect RK loads. In contrast in the limited number of COPD 
patients who undertook trials were unable to detect loads below 0.75 kPa.L.sec-1. This 
suggests that this method could be used to differentiate between health and disease 
confirming the experimental hypothesis. 
 
 165 
Chapter 11 – Thesis Conclusion 
11.1  Accuracy of Respiratory Measurement 
Spirometric Assessment of FEV1 was shown to be the most reliable and accurate measure of 
lung function in all the participants groups assessed, as was expected and discussed earlier 
(Section 1.0). As has been argued throughout this thesis there are occasions when this method 
of testing is neither practical nor applicable, such as when assessing children, when patients 
are exacerbating or when these tests are used outside of a controlled clinical environment. A 
need for new approaches to assessing respiratory function to overcome these and other issues 
was identified. This raises the question; Can such new methods, particularly those that use a 
sub-maximal approach to assessing respiratory function, be as good as existing techniques? 
 
There exists a trade-off when using any method that assesses respiratory function between the 
level of accuracy required and the level of test sophistication involved (Figure 11.1) which is 
dependent on the required outcome of the test, whether for diagnosis, screening or 
monitoring. Test sophistication encapsulates the four factors identified earlier (Section 1.6) as 
being key to overcoming the potential for error in tests of respiratory function. The level of 
these factors (either individually or concurrently) has a direct effect on the accuracy of a test.  
 
Figure 11.1: Effect of Test Sophistication on Test Accuracy. 
 
When a test has a high level of sophistication the factors that can contribute towards error are 
rigorously controlled or negated. Using an invasively taken measurement of oesophageal 
pressure to assess respiratory muscle function for an example requires:1) a high level of 
participant cooperation; 2) to be conducted in a highly developed clinical environment; and 
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3) with well trained staff could be expected to achieve a highly accurate result, such as Point 
A on the continuum (Fig 11.1). Note that even in this situation it would not be expected to be 
100% accurate or precise, due to the inherent variability when testing a biological system. 
 
Conversely for a test with a low level of sophistication the chance of these negative factors 
occurring are magnified. Using a peak flow test being conducted in a home environment with 
a simple peak flow meter for an example would mean: 1) No trained staff to check technique 
or the status of the machine; 2) and would still require maximum effort on behalf of subject, 
providing a result of questionable accuracy. While if correctly conducted such a test may 
provide valid, clinically reliable results it could also result in a test where one or more 
sources of error invalidate any test outcome. This would be represented at a point anywhere 
between A and B on the continuum (Fig 11.1) making any accurate interpretation difficult to 
achieve. There exists then a point where the level of test sophistication is such that it is 
questionable whether there exists any benefit from conducting tests as the level of accuracy is 
unreliable and not clinically usable, represented to the right of Point B on the continuum (Fig 
11.1).  
 
The work of this thesis has been to investigate and develop new methods of assessing 
respiratory function that fall between Points A and B. In that they may not have the accurate 
diagnostic ability of existing tests that are highly sophisticated but that they are able to 
reliably and repeatedly provide important clinical information about an individual’s 
respiratory system in a test that has a lower level of sophistication requiring less effort on 
behalf of a participant and reduced clinical oversight. 
 
The aim of this thesis was to investigate and develop such new methods of assessing 
respiratory function focussing on two techniques 1) Measurement of respiratory endurance 
and 2) Predicting FEV1 from relaxed tidal breathing. From this work a third technique was 
developed by combining the two devices so that the ability to detect resistive loads could be 
assessed. 
11.2   Key Findings 
Using a sub-maximal 6-minute trial which applied an RK load, InWrsmouth was measured 
which was used as an index of respiratory endurance. This was found to be higher in patients 
with COPD (described in Chapter 7) indicating that it could be used to differentiate between 
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health and disease. However in 8-12 year old children (Chapter 8) despite significant 
differences in FEV1%pred between children born at term and preterm with CLD, no 
differences was seen in InWrsmouth. While some children did show a decreased FEV1 this was 
not of a similar magnitude to that seen in COPD and it may indicate that such techniques may 
only be useful in screening individuals with pronounced airway obstruction.  
 
TBPA was seen to predict FEV1 in controls and COPD patients although this was not as 
sensitive as spirometric measurement of FEV1 (Chapter 7). The use of two predictive 
equations meant that it was necessary to know the respiratory status of an individual before 
assessment which would prevent its use as a simple screening device. There is a need to 
further develop this predictive TBPA work into one single equation which is explored below. 
 
By adapting the RK device and using it conjunction with the pneumotachograph used for 
TBPA a protocol was developed that was able to assess a participant’s ability to detect 
resistive loads (Chapter 9 ). The ability to detect such loads may be able to act as an objective 
measure of breathlessness. While healthy controls showed a graded decline in detected RK 
loads as they were reduced from 1.5 to 0.15 kPa.L.sec-1, COPD patients were unable to detect 
any RK loads below 0.75 kPa. L.sec-1.  
11.3  The meaning of the tests in terms of physiological variation between 
individuals. 
It was expected as detailed in section 10.0 to find differences in RK trials in individuals on the 
basis of their lung health, in this context on the basis of FEV1 as a marker or airway 
obstruction As discussed previously TBPA required the existing respiratory status to apply 
the correct analysis equation, which controlled for physiological variation due to age and 
height (Section 3.2.1). 
 
In a similar way when performing RK trials, the outcome measure,  InWrsmouth was scaled for 
physiological variation between individuals by expressing the energy used per litre of 
inspired breath. This took into account the variability in tidal volume and breathing rates seen 
between individuals  For example an individuals with a high fR and low VE  (such as a child) 
compared to an individual with low
 
fR  and high VE  (such as an adult) may have the same  
InWrsmouth .. This meant for example that InWrsmouth at rest seen in healthy adults (Chapter 4) 
was similar to that seen in healthy children (Chapter 8) despite substantial differences in 
height and age.  
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When testing human participants some form of variation is unavoidable and participants in 
particular sub-groups, eg COPD patients in Chapter 7 and the term/pre-term children in 
Chapter 8 were carefully selected. Furthermore as only patients with clear common pathology 
(COPD) were recruited the work within this thesis is unable to provide any inference on the 
techniques described ability to differentiate with other lung diseases. 
 
While the TBPA equations were designed to take age and height into account InWrsmouth 
currently does not. This was in part due to the limited number of participants, 174, who 
displayed a wide range of age and respiratory health status assessed during this thesis. This in 
turn would preclude investigation into any effect physiological differences; age, gender, 
height etc, may have on InWrsmouth. Further work would allow the opportunity to develop 
predictive equations for this parameter from which the variation of diseased values could be 
gauged. 
11.4:  Validity of new methods when there are no new obvious means of 
comparison 
Within a research paradigm scientific exploration progresses by the comparison of new 
techniques and methods with those that already exist and have been shown to be valid and 
reliable. New techniques have to show some advantage over existing techniques whilst 
maintaining a similar level of validity and reliability. TBPA was developed as a method to 
predict FEV1 (as measured by spirometry), which provided a gold standard for it to be 
compared with. It was shown that spirometry was the more reliable and sensitive measure 
and the use of TBPA was also confined by the need to be aware of an individuals respiratory 
status to apply the correct predictive equation.   
 
 It is the inherent difficulty with the work of this thesis that the RK trial developed cannot by 
its very nature be compared to existing techniques, specifically because of the difficulties 
identified in the definition of endurance and existing methods to measure it. What this thesis 
sets out in terms of respiratory endurance is a different paradigm as to what is endurance is 
and how it should be measured.  
 
Therefore the work of thesis initially focussed on developing a reliable and repeatable 
measure (Chapter 4-5) and then testing this against a series of experimental hypothesis 
(Chapter 6-9). In essence the gold standard was this repeatable measure that the work 
undertaken was compared to in the experimental chapters in the latter half of the thesis.  
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This research paradigm was to assess whether a difference could be detected where it would 
be reasonable to hypothesise that one existed, for example between healthy individuals and 
those with obstructive chest disease, and at rest and during exercise. By testing these 
hypotheses and detecting a difference would show that the RK trials are valid, even if it were 
not immediately clear what these differences mean or why they occur. The experimental 
hypothesis in terms of health and disease assume these differences on the basis of existing 
respiratory status although this may not be the case, and could be due to lack of  physical 
fitness or de-conditioning for example. However without a gold standard measure of 
endurance what they do not show is that they are able to measure respiratory endurance per 
se. 
 
This difficulty could be overcoming by undertaking  6 minute RK trials whilst internally 
assessing oesophageal pressures to calculate work of breathing, a technique described 
previously (ATS 2002A)which would allow the effect of RK loads to be assessed. This could 
allow a means of direct comparison between the work of breathing measured by internal 
pressure change against InWrsmouth and whether the differences observed in the experimental 
chapters could be replicated. Due to practical constraints primarily the lack of sophisticated 
equipment and technical and medical support required, this type of investigation was beyond 
the scope of the work undertaken within this thesis. 
11.5  Advantages / Disadvantages of the Techniques Described 
Both the RK and TBPA trials were undertaken by individuals of a wide range of ages and 
respiratory status, in a variety of modalities including whilst seated, and exercising at 
intensities with work rates up to 150 Watts. As a result of these trials there were no adverse 
events and participant safety was not compromised. On the limited occasions when RK trials 
were halted early this was during protocols when fR was paced and participants could not 
maintain required rate. During Breathlessness Sensitivity trials none were halted early and 
healthy participants and COPD patients were able to successfully complete them all. 
Therefore all three methodologies would appear simple and safe to undertake. 
 
The length of RK trial was used as it was a similar length to existing sub-maximal exercise 
tests although anecdotally this was felt by some subjects to be a long time. When compared 
with some methodologies identified in the synthesis of existing methods however 6-minutes 
was a relatively short trial length. This raises questions of a participant’s comfort and 
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willingness to complete longer protocols such as MSVC trials when maximal effort is 
required that while usually 15-minutes in length, could be as long 150-minute (Section 3.1.3). 
In this context a shorter test could be better in maintaining participant motivation and 
willingness to complete. The early development work of the RK trial showed that a steady 
state breathing pattern was achieved within the first minute (Section 4.1), so that the 6-minute 
trial could be reduced in length such as the 3-minutes used in TBPA. The length of 
Breathlessness Sensitivity trials was governed by an individuals fR as all participants had to 
complete the same number of breaths, allowing participants to self select fR which may have 
had a positive effect on cooperation during the trial. With the concentration needed during the 
trial however it would be difficult to introduce a system of controlling fR without it affecting 
the trial. 
 
The use of bespoke software analysis of the data output of TBPA removes the potential for 
human error when selecting tidal breathing curves for analysis. As was identified, previous 
techniques relied upon study investigators selecting the best flow curves which may be 
suitable for use in small scale research studies but would preclude its clinical use. 
Furthermore another significant advantage of the bespoke software is its potential to speed up 
the analysis process allowing the simple data files generated to be quickly processed. 
Currently the output of this analysis is rudimentary although it would require only a small 
amount of development work to produce a polished TBPA outcome report.  
 
The Breathlessness Sensitivity device that was developed has many advantages over the older 
techniques that were described in Chapter 9, principally the ability to electronically control a 
trial, varying the resistive loads between breaths without halting a trial or giving any 
indication to a participant when this may be about to happen. The equipment while 
cumbersome was able to be used with relatively little training by both healthy controls and 
COPD patients although how sensitive the device is between smaller changes in RK load 
needs to be explored. By using RK as the resistive load it represents a more natural flow 
independent resistance that could be better than using fixed resistances that are flow 
dependent. 
11.6  Sophistication of RK trial, TBPA and Breathlessness Sensitivity 
Of the three techniques breathlessness sensitivity would have the highest level of 
sophistication as it requires a trained operator to complete the trial and as such can only be 
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used within a clinical setting. In addition the high level of concentration necessary would 
preclude its use in all but the most cooperative of participants, this would be possible for 
example in children. However the low levels of physical effort required would mean that it 
could be used in those situations when maximal testing is not possible and it may provide a 
useful and simple way of objectively measuring breathlessness. When placed on the 
continuum described previously (Fig 11.1) it would be placed towards Point A at T1 (Fig 
11.2). 
Both the RK trial and TBPA would have a lower level of test sophistication, and it would be 
possible for participants to conduct these tests without any assistance or requirement for a test 
operator. The removal of the requirement for maximal effort from these methods reduces the 
effect on the accuracy of these tests and as such would be represented at Point T2 on the 
sophistication continuum (Fig 11.2). 
 
Figure 11.2: Sophistication of RK trial, TBPA and Breathlessness Sensitivity 
 
11.7   Future Work Building on That in This Thesis 
The work in this thesis could be used as the start point for future work in the following ways: 
11.7.1  Technical Development 
TBPA 
As more adult data is collected this can be used to develop a single predictive equation, 
which removes the need to know the respiratory status of an individual before they are 
assessed. Such an equation could then be used to provide a simple technique to screen 
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individuals to identify those who may require further specialist respiratory testing, 
streamlining and improving the delivery of respiratory function assessment services. 
Using the raw flow data from the children cohort (Chapter 8) a new predictive equation using 
TBPA was developed as part of the work of thesis which would require a prospective study 
using this to estimate its predictive ability. The accuracy of spirometry was clearly shown in 
this thesis and this was again shown in these children, although this was undoubtedly due to 
the high level of instruction and support given to individual children to ensure a valid result 
was achieved. Such intense support is not always practical for example home monitoring of 
children with asthma or those with cystic fibrosis. Could TBPA analysis be able to provide a 
simple method of monitoring lung function for these patients? Early detection of a decline in 
lung function could be a useful way of preventing the onset of disease exacerbations which 
have both a considerable impact on quality of life and financial impact on the health service. 
Repeatability 
Currently the repeatability work described (Chapter 5) was conducted only in healthy adults 
who do not represent the groups most at need of new sub-maximal test, patients with chest 
disease, children etc. Therefore there needs to be further work looking at the repeatability in 
specific groups and environment within in which they would be used. 
Combining the techniques into one device? 
Currently the devices used for all three methods are too big and cumbersome to be used in 
any practical way, performing more as proof of concept devices. The technology used though 
is relatively simple and could be scaled down into more appropriate devices although this 
would come with inherent work and cost involved. If this could be undertaken it would be 
beneficial to combine the technologies into one device that would be able to complete all 
three methodologies. Alternatively a family of devices could be developed with increasing 
complexity and cost for a range of uses i.e. from home testing, primary care assessment in GP 
surgeries and pharmacies through to tertiary care on inpatient wards and in specialised 
respiratory function centres. This would be in a similar way to the development of standard 
spirometers that are found in all these environments. 
11.7.2   Clinical Use 
Home monitoring, Tele monitoring, Emergency Monitoring 
TBPA and RK trials could be particularly useful in clinical groups where large changes in 
respiratory function occur rapidly with the onset of disease such as in exacerbations of CF or 
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COPD. Either of these techniques could be used as an early indicator of decreased function 
particularly when assessed in a home environment away from specialist testers or equipment. 
Previously the thesis author has worked with telemedicine in COPD (Lund et al. 2009) where 
it was found that while patients could easily master the electronic diary element of the study 
the biggest issue was the correct measurement of respiratory function. A simple test that 
could replace FEV1 measurement and still provide useful information either as FEV1TAP or 
InWrsMouth would be useful. 
Preterm Children 
Further study of this cohort could provide useful information about how children born 
prematurely develop as they grow. For example do the differences in FEV1 shown continue 
into adulthood? Could there be a link between prematurity and respiratory disease in later 
life? Should such children be specifically targeted to prevent behaviours that may adversely 
impact their respiratory health such as tobacco smoking and environmental exposures?  
Breathlessness Sensitivity 
It would be interesting to assess the ability to detect resistive loads in terms of breathlessness 
status as this could provide an objective measure of breathlessness. While this thesis has 
shown the concept for using RK load to assess resistive detection more work is needed to 
quantify the exact load increments and protocol design. Furthermore bronchodilators could be 
used in a similar way to a standard salbutamol challenge test with the Breathlessness 
Sensitivity method described. In a standard salbutamol challenge test with a 15 minute gap 
between drug administration and spirometric assessment there would be time to conduct a 
sensitivity trial. 
11.7.3  Exercise 
Whether the ability to overcome a high RK load is dependent either on fitness levels (and 
motivation) or upon inherent respiratory function has yet to be investigated. With the 
increased use of pulmonary rehabilitation programmes it is necessary to monitor endurance 
performance rather than strength. Valid measures of endurance are thus needed to assess the 
outcomes of such interventions (Powell and Williams 2009).  Despite intense investigation 
the importance of respiratory muscle endurance in the failing patient or the obstructed patient 
during exercise is still relatively inadequate. The RK protocol was able to differentiate 
between healthy individuals and those with COPD although the effect of exercise on 
InWrsmouth in COPD patients would be a valuable finding. For example how does InWrsmouth 
change during a 6-minute walk test? In healthy subjects there appear no obvious contra-
indications for COPD patients to complete RK trials whilst completing sub-maximal exercise. 
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Furthermore calculating InWrsmouth could provide additional useful information about a 
patient’s respiratory endurance capability alongside their exercise endurance.  
11.8  The Thesis in Summary 
The difficulties with lung function assessment are well established and have been described 
in this thesis. Much recent emphasis has been put on developing existing devices and 
protocols rather than developing new techniques and approaching these difficulties from 
alternative viewpoints. This thesis has described the development of three innovative 
methods to assess the function of the respiratory systems that aim to overcome the issues 
associated with maximal testing. It has been shown that they are easy to undertake for a range 
of participants, simple to analyse and are able to reliably differentiate between health and 
disease, suggesting that they could become a useful adjunct to existing methods of respiratory 
assessment. 
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 II 
‘Respiratory Muscle Endurance’ 
 Author Term Stated Definition  N= Subject Method 
A25 Scherer et al 2000 1. Respiratory muscle endurance (RET) 
 
2. Inspiratory muscle endurance 
RET = sustained 
ventilation 
 
RMT 
30 (19M) COPD patients 1. based on 12 sec MVV, x 3 highest recorded. RME = time of sustained ventilation at 
66% of highest MVV. No coaching or paced breathing although VE feed back given. 
Normocapnia maintained. If >15mins repeated at 75% of MVV. 
2. IME inspiratory threshold loading, (Nickerson & Keens) start at 20% of PImax increased 
every 2min by 50% of intial weight until subject unable to continue. greatest weight 
sustained for 1 min = IME. Test repeated 3 times. 
A42 Stuessi et al 2001 Respiratory Muscle Endurance 
 
Breathing Endurance 
RMT 28 (16M) Healthy sedentary 
 
 
Breath at VE corresponding to 70% MVV (fb paced by metronome)for more than 2 mins. If 
< 2mins V E  reduced to 65% and trial repeated. Performed a breathing endurance test to 
exhaustion(determined by V E  having dropped by >10% below target or by subject 
stopping) at the V E  previously established. 
A56 
Mueller et al 2006 
Respiratory Muscle Endurance RET=exhaustive 
normocapnic 
hyperpnoea 
RMT 
14 (11M) 8 = paraplegia 
 
6 = tetraplegia 
RET assessed using SpiroTiger. Device set at 20, 40 or 60% of individual MVV in 
random order over 3 sessions at least 72 hrs apart. Familiarised with normocapnic 
hyperpnoea technique. Encouraged to maintain target Ve, test halted on exhaustion or if 
Ve = >5L/min lower than target for 30 sec or test lasted >60min. 
A131 Fiz et al 1998 Respiratory Muscle Endurance 
 
 
1. IME = maximum 
tolerated load for a 
2min incremental 
Martyn test (Cmax) 
 
2.time of sustained 
breathing against an 
inspiratory pressure 
load equivalent to 
80% of Cmax 
99 (50M) Healthy sedentary 
 
Age groups: 
1 = 20–29 years;  
2 = 30–39 years;  
3 = 40–49 years; 
4 = 50–59 years; 
5 = 60–70 years 
modified  Martyn and Nickerson & Keems  was applied. Before test, subjects trained with 
100-gram insp load for 60 s. Subject synchronized fb with pacing. fb were monitored . 
Subjects breathed at 0 load for 2 min. 100-gram weight added every 2-min. At end of 
each 2-min, subject breathed without loads for 2 min. Heaviest load tolerated for 2 min 
was recorded as Cmax load expressed in grams.  
 
Subject breathed with load of 80% of Cmax until threshold pressure for 3 consec breaths 
ceased to be generated (exhaustion)=  Time that elapsed from start of test to exhaustion 
(Tlim).  
Cmax and Tlim protocols were repeated 2 times by each subject on the same day, with a 
20-min rest between each test. The inspiratory time ratio (TI/TTOT) was kept constant. 
The respiratory rate was approximately 20 breaths per minute.   
 III 
A132 Larson et al 1999 Respiratory Muscle endurance  48 (35M) COPD prior to 3 week 
pulmonary rehab  
Discontinuous incremental threshold loading (DC-ITL) test modification of Nickerson & 
Keens, = 3-min stages, 2-min work followed by  1-min rest. During 1st stage, breathed 
against ITL=30% of Pimax, load increased 50g for each subsequent stage. 
RME expressed as relative maximal load, defined as peak mouth pressure during last 
completed stage divided by the PImax,  measured at beginning of each visit (Rel mouth 
pre) and as Absolute maximal load defined as inspiratory pressure at mouth during last 
completed stage of the test (Ab mouth pres)  and weight added (ITL wei)  
During rest interval, patients released mouthpiece to clear saliva, cough, drink water 
Patients replaced mouthpiece approx 10 s before restart.  In addition, patients were 
vigorously coached to continue breathing against ITL until fatigue 
A138 
 
McElvaney et al 
1989 
Respiratory Muscle Endurance RME = time(tlim) that 
the maximum load 
(ascertainted in an 
incremental test) could 
be tolerated 
10 (5M) Normal healthy RME measured  using a 1) 2-min incremental threshold loading protocol (Martyn)  
weighted , subjects started at 100 g and 100 g weights added at 2 min intervals. Subjects 
continued until no longer inspire after 2-3 unsucc attempts before end test. Tests 
repeated x3 with >24 hrs between. Heaviest load tolerated 2 min= max load. 
2) Maximal loading protocol on 3 occasions. 1-min inspired against half highest max load 
= ITL test as warm-up, then against max ITL load until exhaustion. Length of time subjects 
could inspire against their max load was endurance time (tlim).  
A152 
Koppers et al 
2006A 
Respiratory Muscle Endurance Capacity 
 
Inspiratory muscle endurance test 
 
Hypernea endurance test 
RMT 36 (18M) COPD awaiting 
pulmonary rehab prog 
1) IME measured by incremental threshold loading (Nickerson & Keens)  Patients inspired 
against a weighted inspiratory valve,  increased at regular intervals. Pressure achieved 
during  heaviest load tolerated for at least 45 s was defined as maximal sustainable 
inspiratory pressure (Pismax) 
2) HET assessed endurance performance of respiratory muscles. Subjects breathed in a 
closed spirometer circuit to maintain an isocapnic situation during the test. Oxygen was 
supplemented. Patients breathed with a fixed fB= 30 duty cycle =0.33 using an electronic 
metronome and TV 45% of VC. Given visual feedback of TV and were not encouraged. 
Test terminated when patient not sustain the fB or TV during 3 consec breaths or after a 
max of 20 min, and  time was recorded (seconds). 
A153 Mador et al 2005  Respiratory Muscle Endurance RMT 29  
no 
gender 
COPD starting 
pulmonary rehab 
RME tested using same device used during hyperpnea training.  
V˙ e, end-tidal CO2 (Petco2), and O2 sats continuously monitored. Subjects maintained a 
target V˙ e of 70% of the 12-MVV. (MVV measured x3 best result chosen). When target V˙ 
e no longer maintained test halted and endurance time calculated. RME measured x3 and 
longest endurance time was chosen.  
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A154 Wirnsberger et al 
1997 
Respiratory Muscle Endurance RME time = max time 
(sec) subject sustain 
breathing against 
inspiratory pressure 
load=70% of individual 
PI,max 
36 
(18 M) 
18 = sarcoidosis 
18 = control matched age 
and gender 
RME assessed by measuring the endurance time using a modified threshold loading 
device as designed by NICKERSON & KEENS. Expiration can be performed without any 
resistance. First warmed up against an inspiratory pressure load = to 15% of  PI,max 
during 2 min. Then breathe at 70% Pimax until test fatigue/exhaustion. Test  terminated if 
RME time > 15 min.  
A156 Rassler et al 2007  Respiratory Muscle Endurance RMT 10 (4M) Myasthenia Gravis RME assessed x2-3,Using RMT device connected to a metabolic cart. Instructed to 
breathe 25–40 per min with a VT between 50% and 75% of VC to induce test termination 
due to task failure after max of 10–12 min, encouraged them to breathe faster or slower if 
necessary. Criteria to terminate test = patients’ perception of exhaustion or a reduction in 
ventilation by >10% of  target for 1 min. Measured endurance time (TLim: time until test 
termination) and endurance volume (VLim: total ventilation during test, calculated as TLim 
multiplied by average V_ E).  
A157 Matecki et al 2001 Respiratory muscle endurance  20(M) 10 = Duchenne muscular 
dystrophy 
10 = control age & sex 
matched 
RME measured by max time against load = 35% Pimax at FRC, so time would approx 
range from 3-10min. Period of loaded breathing defined as endurance time (Tlim) 
A159 Koechlin et al 2005 Respiratory Muscle Endurance RME = max time Tlim 
a subject is able to 
sustain a specific 
submaximal muscle 
task 
29(14M) 15 = pre- peri pubertal 
14 = near the end of the 
pubertal process 
(defined by Tanner 
stages) 
Standardized method of RME in healthy and DMD children (Mateki 2001) Pressure 
threshold test to assess time limit (Tlim),  Nickerson & Keens at 50% Pimax., Ti/Ttot equal 
to 0.5. Measurements of Pimax and breathing pattern used to calculate tension-time index 
of respiratory muscle, TTI,  product of mean pressure developed by respiratory muscles in 
relation to maximal capacity (Pm/Pimax) and duration muscle contraction in relation to 
duty cycle. Children had to produce 50% Pimax, with Ti/Ttot =0.5, their tension-time 
index, TTI (Pm/Pimax _Ti/Ttot) estimated = 0.25. 
A161 
 
 
 
 
 
Laghi et al 2005 
Endurance of the respiratory muscles  21(M) COPD 
11= Hypogonadal 
10= Eugonadal 
No detailed methodology refers to A182. Similar device to Nickerson & Keens, 
inspiratory threshold test. Weights added so that initial Pth (negative threshold pressure) 
subjects had to generate was 40% MIP Every 2 min weight increased by 10% of MIP,  
end of test = failure of the subject to sustain the breathing task. No instructions given to 
subjects regarding breathing pattern. Max Pth was defined as inspiratory pressure 
developed with each breath at  highest load at which ventilation could be sustained for 
230 s.  
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A163 
Chang et al 2005 
Inspiratory Muscle Endurance 
Respiratory Muscle Endurance 
Fatigue Resistance 
Index = FRI 
20(11M Patients who had 
received mechanical 
ventilation for≥ 48hrs 
Patients breathed through an inspiratory resistance that was equivilant to 30%* intial 
measurement of Pimax for 2 min, Pimax was recorded every 30 seconds. FRI = final 
Pimax/intial Pimax 
* not all subjects able to complete this for 2 mins n=3 
A164 Koessler et al 2001 Respiratory Muscle Endurance RMT 27 
no 
gender 
stated  
18 = Duchenne Muscular 
dystrophy 
9 = spinal muscular 
atrophy 
12s MVV used as parameter for RME. Repeated x3 best trial used. 
A = VC 27 – 50% pred 
B = VC 51 – 70% pred 
C = VC 71 – 96% pred 
A165 Weiner et al 1992 Respiratory Muscle Endurance RMT 30 (12M) Moderate to severe 
asthma (ATS guidelines) 
 To determine IME, a device = Nickerson & Keens used. Inspiratory work was increased 
by addition of 25- to 100- g weights at 2-mm intervals, (Martyn) until subjects were 
exhausted and no longer inspire. Pressure achieved with heaviest load (tolerated > 60s 
defined as peak pressure (P.,peak). RME = P.peak/Pimax % 
A166 Nava et al 1992 Respiratory Muscle Endurance 
Endurance time 
 15 
no 
gender 
COPD >20% reduction of 
pred values 
Used a tube with adjustable orifice so inspiratory resistance = 70% baseline MIP, fB 20 
bpm, ti/tot 0.4. fatigue time = point when target pressure could not be maintained 4 
breaths 
A167 Lake et al 1990  Respiratory Muscle Endurance  28 (24M) Severe Chronic Airflow 
obstruction 
 
FEV1 = 32% pred 
Randomized to either control or 4 intervention groups. 
RME = inspiratory loaded breathing modified Nickerson & Keens and Martyn.  
1) inspired against a load which was increased by 2.5 – 10 cm H2O every 2 mins for as 
long as tolerate. 
10 min rest 
2) Inspire against load = 60% MIP until fatigue ~ sec. Halted if reached 10min. 
A168 Morrison et al 
1989A 
Respiratory Muscle Endurance 
 
Inspiratory Muscle Endurance 
 10 (5M) Healthy normals RME measured using 2 min incremental threshold loading test modified Nickerson & 
Keens. Ppk with each breath and Pmean during the whole respiratory cycle were 
recorded. Subjects began 2 mine incremental test, at a low load (100 g) and 100 g added 
every 2 mins until could not continue. Only weights which could be tolerated for full two 
minutes were used to calculate max. Average Ppk (generated over six breaths), Pmean, 
VT, VE, Ti and Pr for each breath were recorded for each weight.  Max values of Ppk, 
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Ppk/MIP, Pmean and max load were used as measures of RM endurance. Subjects  
tested at fB of self chosen, 6, 12, and 20 breaths per minute. subjects were free to choose 
Ti and VT.  
A169 Morrison et al 
1989B 
Respiratory Muscle Endurance RME= MSVC = 
Maximal Sustainable 
ventilatory capacity = 
is the highest 
ventilation that can be 
sustained for 15 min. 
16 (11M) 8 = COPD 
8 = healthy age matched 
RME measured using 2 min incremental threshold loading test (Nickerson & Keens). Ppk 
with each breath and Pmean during the whole respiratory cycle were recorded. Subjects 
began at 100g and 100g added every 2 mins until not continue. Last weight tolerated for 
full two minutes were used to calculate max. Average Ppk (generated over 6 breaths), 
Pmean, VT, VE, Ti and Pr for each breath were recorded for each weight.  Max values of 
Ppk, Ppk/MIP, Pmean and max load were used as measures of RME. Tested at fB of self 
chosen, 6, 12, and 20 bpm,  Ti and VT uncontrolled 
A171 Sonne et al 1982  Respiratory Muscle Endurance RMT 6(7) no 
gender  
COPD  
FEV1 <35%Pred 
Not listed in methods 
 
In results: RME was measured by the amount of inspiratory resistance that could be 
tolerated for 10 min, indicated by diameter of inspiratory orifice tolerated. 
A172 Orenstein et al 
1981  
Respiratory Muscle Endurance  31 no 
gender 
after drop 
out 
CF RME measured in nine exercise and eight control  by  modified of Leith & Bradley and 
Keens, assessed by MSVC. Patient breathed at 90% Maximum breathing capacity. End-
tidal gas monitored. Not all patients were able to maintain ventilation at 90% MBC, were 
allowed to continue at highest sustainable level above 65% and up to 90% MBC for as 
long as possible or 15 min, whichever came first. Scores were assigned in “sustained 
hyperpnea” (SH) units, by multiplying % of MBC achieved by the time in min for which it 
was sustained. Thus a patient who performed at 70% of his MBC for ten minutes earned 
an SH score of 700 SH units. 
A173 Holm et al 2004 Respiratory Muscle Endurance RMT 20 (16M) Triathletes or 
experienced cyclists 
RME assessed using SVC test similar to Leith & Bradly. 3 min warm up period (at approx 
80% MVV) preceded all tests. for a test to be included in the final analysis, VE during the 
first 30 breaths of the test had to be greater than or equal to the subjects MVV to ensure 
that the effort was maximal.  average VE during the plateau phase (over the last 2–3 
minutes of the test) was taken as the SVC.  SVC from two tests had to be within 10% of 
each other and this was considered a baseline measurement to which all subsequent 
SVC tests were compared 
A174 Boussana et al 
2001 
Respiratory Muscle Endurance RME = is the property 
of respiratory muscle 
that affords resistance 
12 (M) Competitive triathletes RME assessed by Tlim = the maximal time a subject can breathe against a predetermined 
inspiratory submaximal load. Set at 75% PImax at FRC at each inspiration. Subjects fB 
controlled by electronic metronome rate at 30·min_1, in order to reproduce the respiratory 
cycle at rest (Ttotrest _ 4 s) with Ti/Ttot _ 0.5. Loaded breathing continued until subject 
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to fatigue reached task failure; corresponding to time when no longer maintain the target tidal 
volume for 3 consec breaths or no longer tolerate procedure. At test end, assumed all 
inspiratory muscles were fatigued. Period of loaded breathing was defined as endurance 
time (Tlim).  
A175 Weiner et al 1998A Respiratory Muscle Endurance 
 
Inspiratory Muscle Endurance 
 21 
no 
gender 
Obese mean BMI 
41.5kg/m2 
To assess IME used a similar device to Nickerson & keens, inspiratory elastic work 
increased by 25-100g weights at 2 min intervals = Martyns, halted on exhaustion no 
longer able to continue. Pressure achieved with the heaviest load tolerated for at least 60 
sec defined as peak pressure PmPeak. RME defined as ratio PmPeak/Pimax % 
A176 Uijl et al 1999  Inspiratory endurance capacity of the 
respiratory muscles Pendu 
Respiratory Muscle Endurance 
RMT 9 (8M) Tetraplegia at C3 –C7 Endurance capacity or fatigability of RM assessed by Incremental threshold loading test 
(Martyns), 10 – 40g weights added every min aimed at achieving max protocol within 
20min. Highest pressure achieved and maintained for 1 min defined as Pendu. 
A177 Chatham et al1996 Respiratory Muscle Endurance RMT 10(5M) normal Test of RME ‘TIRE’ at 80% of sustained maximal inspiratory effort ‘SMIP’. Followed 
pressure template, failure to achieve at least 90% = end of test. RME was assessed using 
point of TIRE failure expressed in total pressure time units 
A178 Mancini et al 1995 Respiratory Muscle Endurance RMT 14 
no gender 
Congestive heart failure RME assessed by incremental MSVC test where target flow increased every 3 min until 
failure to maintain target. Iscopania maintained throughout. Begin at 20% MVV, 10% 
increase every 3 min to a maximal tolerated level, MSVC defined as highest workload 
completed for a full 3 min.  
A179 Supinski et al 1985 Respiratory Muscle Endurance Suggested that RME 
is determined in part 
by the balance 
between energy 
consumption and 
energy availability 
12(8M)  Normal  
University students 
RME assessed modified Nickerson & Keens from the time to exhaustion while subjects 
inspired against massive inspiratory threshold loads (54-140 cmH2O), by adding weights 
of 350-1000g 
No time increments given 
A180 
 
 
DiMarco et al 1985  
Respiratory Muscle Endurance RMT 11 
no 
gender 
Muscular Dystrophy RME assessed as max duration that ventilation levels of 30, 50, 70, and 90% of 15sMVV 
could be sustained. Test terminated after 15 min or bag no longer inflated. 
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A183 
Fairban et al 1991 
Respiratory Muscle Endurance  10 M Elite cyclists RME assessed by MSVC test = max ventilation sustainable for 10 min.. Isocapnic 
hyperpnea. 2 minwarm up at 50% max exercise ventilation, 1 rest, during first 2min of test 
air flow increased from warm up level to max ventilation that could be sustained for 8 min. 
repeated until 2 test 48 hrs apart were within 5%. Mean ventilation in last 8 minutes of 
highest test was baseline measurement. 
A185 Cimen et al 2002 Respiratory Muscle Endurance 
 
 33 (13M) 25 = Rheumatoid Arthritis  
21 = Control age and 
BMI matched 
Not clear how RME was assessed either by MIP, MEP and MVV or just MVV by itself. 
No details on how MVV was measured, MIP and MEP only 
A187 McConnell et al 
2003 
Respiratory Muscle Endurance  24 (18M) Class III Heart Failure RME determined by MSVC.. Isocapnia maintained throughout. MSVC defined as highest 
breathing volume (L/min) that could be maintained for the entire 3 min. 
A188 Sharma et al 2007  Respiratory Muscle Endurance  7 M Experienced Climbers 
assessed between 3450 
– 5350m 
RME assessed by  1) 12sec MVV 
2) Maintenance of inspiratory load until fatigue develops modified Grassino 1991. given a 
target of 50% MIP each subject inspired to target from RV and sustained this pressure for 
as long as possible. Time taken to task failure = Tlim sec 
A190 Koppers et al 
2006B 
RME Training 
 
IME 
RMT 20 (7M) Healthy IME assessed by Inspiratory threshold loading. Subjects inspired against a load = 10% 
Pimax and 25g added every 1.5min, pressure continually assessed. Breathing continued 
until inspiration could no longer be sustained. Pressure achieved during the heaviest load 
tolerated for at least 45s was defined as maximal sustainable inspiratory pressure 
(SIPmax) Subjects divided into normocapnic and hypercapnic 
A191 Enright et al 2006  Respiratory Muscle Endurance 
 
Inspiratory Work Capacity 
 40 (20M) CF 20(10M) 
Controls (10M) 
Subjects habituated to Sustained maximum inspiratory pressure (SMIP).  3 SMIPs, 
inspiratory target set at 80% of max pressure profile, subject matched target x6 over six 
consecutive levels with rest between each effort decreasing per level 1min, 45 sec, 30 
sec, 15 sec, 10 sec, 5 sec. Test halted when subject unable to match at least 90% of 
computer curve template/target.  
A192 
 
 
 
Boussana et al 
2002  
Respiratory Muscle Endurance  11 (M) Triathletes 
5 = elite 
6 = competition 
RME assessed by controlled breathing Matecki 2001. Tlim = max time subject can 
breathe against a predetermined inspiratory submax load = 75% of PImax = Pm. fB = 
15min-1 and target of 700ml VT at each inspiration. Test halted when subject could not 
maintain target volume for 3 breaths or when mouthpiece was rejected. Length of loaded 
breathing was defined as Tlim. 
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A193 
Boussana et al 
2003 
Respiratory Muscle Endurance RME= corresponds to 
length of time resp 
load can be sustained 
before fatigue 
develops sufficiently to 
cause task failure 
10 (M) Triathletes RME assessed by controlled breathing Matecki 2001. Tlim = max time subject can 
breathe against a predetermined inspiratory submax load = 75% of PImax = Pm. fB = 
15min-1 and target of 700ml VT at each inspiration. Test halted when subject could not 
maintain target volume for 3 breaths or when mouthpiece was rejected. Length of loaded 
breathing was defined as Tlim. 
A194 Eastwood et al 
2001 
Respiratory Muscle Endurance 
 
Ventilatory muscle endurance 
 12 no 
gender 
6 = endurance trained 
athletes 
 
6 = sedentary controls 
RME measured by ITL test (Martyn) Subjects breathed through a modified inspiratory 
threshold valve which required negative threshold pressure (Pth).No instructions given 
regarding fB. Pth was increased by adding weights and was monitored at the mouthpiece.  
Subjects sat quietly and breathed for 5 min through unloaded threshold valve while 
baseline metabolic and chest wall motion measurements were collected. Inspiratory load 
was then increased by 10% PImax measured at baseline  every 2min until the subject 
was no longer able to sustain the breathing task (task failure) Pth associated with each 
increase in load was recorded and expressed as a percentage of the subjects’ PImax 
(%PImax).. RME expressed as max threshold pressure Pthmax. 4 tests > 24 hrs apart 
A195 Sturdy et al 2004  Respiratory Muscle Endurance  10 (8M) COPD RME measured by ITL test (Martyn) Subjects breathed through a modified inspiratory 
threshold valve which required negative threshold pressure (Pth).No instructions given 
regarding fB. Pth was increased by adding weights and was monitored at the mouthpiece.  
Subjects sat quietly and breathed for 5 min through unloaded threshold valve while 
baseline metabolic and chest wall motion measurements were collected. Inspiratory load 
was then increased by 10% PImax measured at baseline  every 2min until the subject 
was no longer able to sustain the breathing task (task failure) Pth associated with each 
increase in load was recorded and expressed as a percentage of the subjects’ PImax 
(%PImax).. RME expressed as max threshold pressure Pthmax. 4 tests > 24 hrs apart 
A196 Tobin et al 2002 Respiratory Muscle Endurance 
 
Inspiratory Muscle Endurance 
RMT 16 M Duchenne Muscular 
Dystrophy 
 
IME assessed by time limit (Tlim) = maximal time a subject able to sustain breathing  
against a inspiratory load without inspiratory muscle fatigue [Roussos 1979]. Duration 
patient could inhale against a resistance used as index of endurance. Children requested 
to breathe at constant inspiratory load =35% Pimax. Instruction given on fB . TV constant 
throughout and corresponded to the patient’s resting Vt. Loaded breathing continued until 
subject could no longer maintain target volume for 3 consecutive breaths or no longer 
tolerate the procedure. Period of loaded breathing was defined as the endurance time 
(Tlim). .  
A198 
van der Esch et al 
Inspiratory Muscle Endurance 
 
 12 M Ankylosing Spondylitis IME assessed by 2 min incremental inspiratory threshold loading protocol (Martyns). End 
tidal CO2 monitored. 5 min unloaded breathing, then 25% Pimax applied, increased by 
5% until subjects gave up. Subjects had to maintain VE at resting levels. Used loads 
 X 
2004  Respiratory Muscle Performance tolerated only for complete 2 mins for analysis. Piend expressed as the max tolerable load 
cmH2O and a percentage of reference  
A199 Weiner et al 1998B  Respiratory Muscle Endurance 
 
Inspiratory Muscle Endurance 
RMT 18 (8M) Myasthenia Gravis 
 
Group A Moderate n = 10 
(3m) 
Group B Severe n = 10 
(5M) 
IME assessed by similar device to Nickerson & Keens. Inspiratory elastic work increased 
by 25 – 100g weights every 2 min = Martyns, until exhaustion and subject no longer 
continue. Pressure achieved with heaviest load tolerated for at least 60 sec, defined as 
PmPeak. 
A200 Sairikaya et al 
2003 
Respiratory Muscle Endurance  51 (10M) 
44 no 
gender 
Obese >BMI 25 
 
BMI < 25 
No detail in method of Respiratory Muscle endurance assessment technique 
In Results = MVV measurement reflecting the respiratory muscle endurance (no detail in 
method of MVV) 
A202 Cimen et al 2003 Respiratory Muscle Endurance  142 F 88 Osteoporosis 
54 Controls 
No description of RME in either method or results 
In discussion = MVV values which reflect respiratory muscle endurance 
A203 Covey et al 2001 Respiratory Muscle Endurance 
 
Respiratory Muscle Performance 
RMT 27 (18M) COPD/Severe airflow 
obstruction FEV1<50% 
pred or FEV1/FVC <45% 
pred 
RME assessed by discontinuous-incremental threshold loading protocol (DC-ITL). 
Adapted design of Nickerson & Keens.  Patinets began at 30% of Pimax, increased every 
2 min in 50g increments until symptom limited end point. Allowed 1 min rest between each 
2 min stage. Peak load Pm defined as work load g of highest stage completed. 
A205 Heimer et al 1990 Respiratory Muscle Endurance  62 No 
gender 
31 Type 1 diabetes 
31 age, sex matched 
controls 
MVV was measured using 12 second maximum voluntary ventilation test, and used as an 
index of RME 
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A226 Morgan et al 1987 RMET 
Ventilatory endurance 
RMT  
Endurance breathing 
time 
9 M Moderately trained 
cyclists  
Exp group = 4 
Control group = 5 
Endurance breathing test = time subjects could ventilate at 100% of 15 sec MVV., re-
breathed proportion of their expired CO2. 
A227 
O'Kroy et al 1993  
Respiratory Muscle Endurance 
Respiratory Muscle Performance 
RMT 35 (16 M) Untrained students Threshold loaded inspiratory fatigue bout (IF) assess ‘RME in resistive strength mode’ by 
threshold loaded valve similar to Nickerson & Keens. At 80% MIP at freely chosen fB and 
TV, duty cycle maintained at 0.5 to prevent reduced inspiratory work. after each min, MIP 
reassessed  and subject returned immediately to breathing through loaded valve, 
repeated until MIP fell to 80% of pre test MIP on 2 or more consecutive measurements, 
length time = time to fatigue. 
A234 Walsh et al 1996 Respiratory Muscle Endurance 
Inspiratory Muscle Endurance 
 30 (27) M 20 = stable chronic heart 
disease 
10 (M) healthy age 
matched control 
RME assessed by pressure threshold valve using a 2min incremental loading protocol 
(Martyn et al). Using a weighted plunger 100g, 100g added every 2 min until fatigue, not 
able to lift plunger over 2 consecutive breaths. Maximum tolerated threshold load that 
could he sustained for2 mins = Pmax. Pmax also expressed as proportion of MIP provide 
measure of inspiriatory load 
‘Inspiratory Muscle Endurance’ 
A124 Watsford et al 2007 Inspiratory Muscle Endurance 
RM Function 
 72 (36M) Healthy older adults A = 
50-59yrs 
B = 60-69 
C = 70-79 
IME assessed  with POWERLUNG device. 2min incremental threshold loading 
test (Fiz et al). After inspiring against a resistance for 2min, 2min rest @ normal 
breathing, then threshold pressure increased, repeated until participant not 
overcome threshold pressure. Max pressure sustained for 2 min stage = Pend. 
A136 Eastwood et al 
1998 
Inspiratory Muscle Endurance  18 (M) Healthy control Progressive Inspiratory threshold loading (Martyn et al). Pth required to be developed with 
each inspiration could be increased by addition of weights to the valve. O2 uptake,  CO2 
output , Ve  and  component TV, fB, Ti, Te, Ttot and end-tidal CO2tension were collected 
continuously. Protocol required subjects to sit quietly and breathe for 5 min through 
unloaded threshold valve for baseline, load increased by 100 g every 2 min until the 
subject was no longer able to sustain the breathing task. No instructions given regarding  
breathing Not stated but in results Pth Max = IME 
A137 Clanton et al 1985 Inspiratory Muscle Endurance  6 (3M) Healthy Normal’s Subjects breathed against threshold load (Nickerson & Keens) with constant fB until not 
match 2/3rds of control target flow rate for at least 1/2 of control inspiratory phase for 3 
consec breaths. Time from beginning to 1st breath subject could no longer match 2/3rds 
target flow used as measurement of endurance (Tlim).  
A207 
Johnson et al 
Inspiratory Muscle Endurance IMT 10 no 
gender 
Stable chronic heart 
failure 
Use THRESHOLD Trainer and pressure threshold valve (Eastwood & Hillman).  Subjects 
Inspired 4 min, total work calculated as pressure-time product (PTP)  
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A208 Wanke et al 1994 Inspiratory Muscle Endurance IMT 42 (22M) COPD IME assessed NICKERSON& KEENS subjects inspired through 2-way valve,  with 
weighted plunger weights added. Duration patient could inhale against a weight=  index of 
endurance. Weight= Pdi 70% max sniff-assessed Pdi. fB constant = resting fR,  using an 
audible cue; inspiratory and expiratory times were adapted according to the patient's duty 
cycle. Resistive breathing maneuvers stopped when patients not generate target Pdi for 
3consec breaths. Not stated but expressed as Tlim 
A210 
Foglio et al 1994 
Inspiratory Muscle Endurance Time 
Respiratory Muscle Endurance 
 24 (7M) Multiple Sclerosis IME  measure, using modified procedure(GROSS). Patients taught to breathe with a 
Pflex device set to elicit a mouth pressure of 70%  MIP (target pressure) that had to be 
maintained. Expiration was unloaded and  respiratory rate uncontrolled Endurance time 
was determined when patient was not able to sustain the target pressure for longer than 
three consec breaths,   
A211 Mannix et al 1993 Inspiratory Muscle Endurance 
Inspiratory muscle fatigue 
 5 M Healthy normal IME assessed by threshold resistive device (Clanton et al) set at 75% MIP. Target values 
for breathing pattern parameters were inspiratory flow, 0.5 l/s; tidal volume, 0.85 liter; 
respiratory rate, Wmin; and ratio of inspiratory time to total breath time, 2:4.3 s. 
Inspiratory muscle endurance was determined be length of time inspiratory maneuver 
could be maintained. 
A212 Chen et al 1989A Inspiratory Muscle Endurance 
Respiratory muscle function 
 160 (80M) Healthy Sedentary 
Chinese 
IME assessed by inspiratory pressure load (modified Nickerson-Keens) at duty cycle of 
0.4 and br Fq of resting rate. Target pressure set at 60% MIP. If test>15min target rate up 
10%. Test stopped when subject unable to reach target pressure 3 consec breaths. 
Product of target pressure and endurance time (pressure time index) as index of IME, 
End tidal CO2 and O2 sats monitored 
A214 Dodd et al 1988 Inspiratory Muscle Endurance 
Respiratory Muscle Endurance 
 5 (4M) Normal Subjects given target pressure 65-70% MIP.VT selected to ensure adequate Ve to 
prevent significant CO2 retention achieved by maintaining Ti/tot. Performed test at Fb at 
15 22 and 30 min. resistance applied via valve with 3 way port. Subjects instructed to 
reach target pressure quickly and maintain throughout inspiration and relax throughout 
expiration. Tlim was computed at onset of 1st of 3 consec breaths where target pressure 
not be maintained and fell by >20% during each inspiration 
A217 Weiner et al 1995  Inspiratory Muscle Endurance 
Inspiratory Muscle Function 
IMT 12 (5M) Patients receiving 
corticosteroids for 
diseases other than 
respiratory conditions 
6=Group A control 
6=Group B IMT 
IME assessed by weighted plunger device (Nickerson & Keens). 25-100g weights added 
every 2min (Martyns protocol) until no longer continue. Pressure achieved with the 
heaviest load that was tolerated for at least 60sec was defined as peak pressure 
PmPeak. 
In results : Inspiratory muscle endurance as expressed by the relationship between 
PmPeak and the PIMax… 
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A218 
Preusser et al 1994 
Inspiratory Muscle Endurance 
Inspiratory Endurance 
IMT 22 (8M) Ambulatory COPD 
patients  
12=Group 1 High loading 
8=Group 2 low loading 
1). Symptom-limited pulmonary ITL test, subjects matched fB of 1 breath every 3 s, a duty 
cycle 0.33 and flow rate of 0.6 (L/s) for M subjects and 0.53L/s for F subjects. After 
breathing unloaded for 2 mm, threshold load began at -4 cm H2O and increased by -2 cm 
after every fifth breath (every15 s) until subject either signalled to stop test or unable to 
match fB , duty cycle, and flow rate during 3 of 5 breaths for that pressure load. Max 
threshold load successfully completed recorded as Pitl 
2) Inspiratory Endurance steady-state test = threshold load at 75% Pitl. Tlim determine 
point subject unable to match fB, duty cycle, and flow rate for 3 consec breaths. Load 
based on % of Pitl as this load more reproducible than load based on % of Pimax. 
Because improvement in IME a function of both increased endurance time and pressure, 
results reported in terms of the total external work performed during the IE test. Work 
(volume X average pressure XTlim)/3-s total breath period), where volume = average tidal 
volume pen breath, expressed in liters. Pressure = average threshold pressure for each 
breath expressed in cm H2O, Tlim = total time of  test in secs. Work is expressed in liters 
X cm H2O. 
A220 Weiner et al 1993 Inspiratory Muscle performance 
Inspiratory Muscle Endurance 
 8 (4M) Patients receiving 
corticosteroids for 
disease other than 
respiratory 
IME assessed by weighted plunger device (Nickerson & Keens). 25-100g weights added 
every 2min (Martyns protocol) until no longer continue. Pressure achieved with the 
heaviest load that was tolerated for at least 60sec was defined as peak pressure 
PmPeak. No explanation that  PmPeak/PIMax is used to represent IME 
A221 Goldstein et al 
1991 
Inspiratory Muscle Endurance  6 (1M) Patients with Respiratory 
Failure as a 
consequence of 
restrictive Ventilatory 
disease  
IME measured by pressure threshold loading (Nickerson&Keens) = endurance time (Tlim) 
during which subject could maintain inspiration at 45% MIP. Subjects inspired against a 
weighted plunger sustaining throughout inspiration.: (1) duty cycle (TfF,,ı) at 0.5; (2) fB 
resting level (3) VT at 125% of previously measured resting value, When subjects failed 
either to match preset ventilatory controls or to generate required pressure, they came off 
mouthpiece, effectively terminating test.  
A222 Goldstein et al 
1989 
Inspiratory Muscle Endurance IMT 5 no 
gender 
Severe but stable COPD IME measured by pressure threshold loading (Nickerson &Keens) sustained through 
inspiration.: (1) duty cycle (TfF,,ı) at 0.5; (2) fB  resting level (3) VT 125% previously 
measured resting value. Practice attempts to establish load subjects could breathe at for 
time ranging from 5-10min.  When subjects failed either to match preset ventilatory 
controls or to generate required pressure, they came off mouthpiece, effectively 
terminating test. Doesn’t define threshold pressures 
A223 O'Donnell et al 
1998 
Inspiratory Muscle Endurance  20 (12M) Chronic airflow limitation IME assessed at load = approx 50% of  max achieved in pre-control visit using threshold 
breathing device (Nickerson &Keens) load remained constant for all tests. to a symptom-
limited endpoint (Vlim). 
 XIV 
A225 Inbar et al 2000 Inspiratory Muscle Endurance IMT 20 no 
gender 
Well trained endurance 
athletes 
10=IMT 
10-Control 
IME assessed with ITL device (Nickerson & Keens), Inspiratory elastic work increased by 
progressive addition of 25-100-g weights at 2-min intervals (Martyn) until subjects were 
exhausted and could no longer inspire. Pressure achieved with heaviest load (tolerated 
for at least 60 s) defined as peak pressure (PmPeak). 
A231 De Jong et al 2001 Inspiratory Muscle Endurance IMT 16 (8M) Cystic Fibrosis 
8=IMT 
8=SHAM IMT 
IME assessed with threshold-loading device during an incremental loading procedure. 
Patients started inspiring at  30% Pimax for 2 min. Threshold load was increased every 2 
min in increments 10% Pimax. Max load defined as highest load reached and maintained 
for at least 1 min as a % of Pimax. fB not regulated. 
A232 Sette et al 1997 Inspiratory Muscle Endurance 
 
Respiratory Muscle Endurance 
 20 (17M) Bronchial Asthma 
 
2 attempts 
RME assessed using technique (Nava)Children started breathed through inspiratory 
resistance 70% PI,max as long as they could. fB  20 bpm, using metronome. TI/Ttot and 
tidal volume measurements were obtained during unobstructed breathing. IME expressed 
as time from start of resistive run to moment when the patient could not maintain the 
target pressure for at least 5 consec breaths  = ‘‘limiting time’’ (Tlim) 
A236 Reiter et al 2006 Inspiratory Muscle Endurance 
 
 68 (29M) Healthy Normal’s IME expressed as Tlim, defined as max time sustained breathing against a resistance 
and flow dependent load. Inspiratory resistance was variably adjusted. Subjects had to 
achieve 80% PImax with each inspiratory maneuver, expiration unloaded. Visual 
feedback of inspiratory and expiratory pressures. fB at 15bpm paced by audio cassette. 
Time elapsed from start of test until exhaustion, when subject did not achieve 80% PImax 
on 4 consec breaths was recorded (sec). 
A237 Inzelberg et al 
2005 
Inspiratory Muscle Endurance 
 
Respiratory Muscle Endurance 
IMT 
Training used 
POWERBREATHE 
20 (12M) Parkinson’s Disease 
10=IMT 
10 =placebo (low load) 
IME assessed by inspiring through Nickerson & Keens device. Inspiratory elastic work 
was increased by progressive addition of 25-100-g weights at 2-min intervals (Martyn) 
until subjects were exhausted and could no longer inspire. The pressure achieved with 
heaviest load (tolerated for at least 60 s) was defined as the peak pressure (PmPeak) 
A238 Brancelone et al 
2004 
Inspiratory Muscle Endurance  53 (33M) 34 = Sarcoidosis 
19 = Healthy Controls 
IME assessed by ITL test, subjects started at 20% PImax, increased at 2 min intervals by 
10% PImax. Mouth pressure, O2 sats and end tidal CO2 continuously measured. IME 
defined as max insp pressure tolerated for 2min (Plim2) and as % PImax (Plim2/PImax) 
A239 Klefbeck et al 2000 Inspiratory Muscle Endurance IMT 10 (7M) Polio 
7=IMT 
3=control 
IME assessed with THRESHOLD inspiratory trainer, produces inspiratory pressure loads 
independent of flow. Patients breathed through device for 5 min and pointed end every 
min at RPE scale. Resistance (Pressure) was chosen through 2 to 3 sets with rest 
intervals between so that patients at end of the 5 min period rated 15 “Hard”. After 10-15 
min rest resistance increased so that at end of the 5 min period patients rated 17 “Very 
hard”. The resistance (pressure) at 15 and 17 RPE was used as endurance value. 
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A240 Scardella et al 
1993 
Inspiratory Muscle Endurance  5 M Normal IME assed by repeatins a sequence of 3 sec contractions followed by 4 sec relaxation 
(duty cycle 0.43) at 80% MIP until fatigue. Point subject failed to attain at least  90% 
previous generated inspiratory forced defined mechanical fatigue of inspiratory muscles. 
Expressed as Tlim in results  
A242 Wanke et al 1991 Inspiratory Muscle Endurance  76 (61M) 36 (31M) = insulin 
dependent diabetics 
40 (33M) = healthy 
normal’s 
Parameter for endurance was 12sec MVV test (L/min) completed over 2 days, best  two 
values recorded 
A264 Ker et al 1996 Inspiratory Muscle Endurance  27 (15M) COPD pFEV1 <80% RME defined as max load that subjects could maintain for 2 min interval against 
increasing ITL, expressed in gram weight = g, peak mouth pressure = Pmpk and relative 
load Pmpk/PImax. Modified Nickerson & Keens device used, breathing patterns, mouth 
pressure, insp airflow and TV monitored continuously. 
IPM Integrated Mouth Pressure 
A245 Collet et al 2007 Inspiratory Muscle Endurance  55 (12M) Severe Obesity BMI >35 
kg/m2 
IME assessed by ITL Test (Martyn). subjects started at 20% PImax, increased at 2 min 
intervals by 10% PImax. Mouth pressure, O2 sats and end tidal CO2 continously 
measured. IME defined as max insp pressure tolerated for 2min (Plim2) and as % PImax 
(Plim2/PImax). Low IME defined as Plim2/PImax <60% 
A246 Chen et al 1989B Inspiratory Muscle Endurance  30 M Healthy (sleep loss) IME assessed by time against inspiratory pressure load (Nickerson & Keen) at 60% 
PImaxFRC, if sustained >15 min, then load >10% and repeated. Visual feedback of target 
and mouth pressure to guide each inspiration. Duty cycle (0.4) and fB (at rest level) were 
maintained through test. Test halted when target pressure missed 3 consec breaths. 
Pressure time index PTI (target pressure x endurance time) index of IME. CO2 and O2 
continuously monitored . 
A247 Chen H-I et al 1985 Inspiratory Muscle Endurance IMT 13 (7M) Stable COPD (pulmonary 
rehab) 
7 (3M) = IMT 
6 (4M) = sham 
1) IME assessed pressure threshold test (Nickerson & Keens) set at 60% Pimax at FRC. 
Subjects inspired until exhaustion time taken recorded. 
2) SIP, highest % of Pimax generate for 10min determined by 10% decrement or 
increments in Pimax until subject could tolerate load for 10min, 15 min rest in between 
trials. FB and duty cycle unconstrained. 
A248 Chen et al 1989C Inspiratory Muscle Endurance  20 F Healthy Sedentary  IME assessed by time against inspiratory pressure load (Nickerson & Keen) at 60% 
PImaxFRC, iff sustained >15 min, then load >10% and repeated. Visual feedback of 
target and mouth pressure to guide each inspiration. Duty cycle (0.4) and fB (at rest level) 
were maintained through test. Test halted when target pressure missed 3 consec breaths. 
Pressure time index PTI (target pressure x endurance time) index of IME. CO2 and O2 
continuously monitored . 
A250 Newell et al 1989 Inspiratory Muscle Endurance  22 M 11 = Chronic airflow 
obstruction 
11 = Control 
Subjects performed 18 maximal static contractions lasting 10 sec (5 sec rest between), at 
FRC in body plethysmography. Average pressure sustained, initial peak pressure and 
initial lung volume recorded. IME calculated as ratio between force in best of last two 
contractions and force in best of first 3 contractions. Expressed as %. Supplemental O2 at 
6 L/min. 
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A261 McKeon et al 1986 Inspiratory Muscle Endurance IMT 18 No 
gender 
Chronic Airflow 
Limitation, during 
pulmonary rehab. 
No definition of IME or method used to assess in methods. No IME data in results. 
During IMT aperture on device decreased 5mm-2.5mm in six increments. In 
discussion states that ability to tolerate smaller apertures …an indication of improved 
muscle endurance. 
A262 Innes et al 1982 Inspiratory Muscle Endurance IMT 11 (7M) CF IME assessed during Inspiratory Resistive (IR) breathing (Pardy’81), for 10 min with 
intervening rest periods (How long?) against sequentially greater IR’s, at flow rates 25 
l/min = 64, 124, 140, 166, 272, 316, 680, 1000 and 1500 cmH2O/L/sec. Patinets self 
selected fB, encouraged breathe slowly and deeply. End tidal CO2, mouth pressure, TV 
and fB continuously recorded. Greatest IR tolerated for 10min = Rmax 
A264 Ker et al 1996 Inspiratory Muscle Endurance Endurance def’ by 
length time load can 
be endured before 
process of fatigue 
develops sufficiently  
to cause task failure 
10 (8M) Ultra-Marathon Runners 
(Above average) 
IME sustained inspiratory pressure,  device (Black & Hyatt), target pressure of 75% MIP, 
inspire against for 5 sec with 5 sec rest (Duty cycle 0.5). Task failure = unable to sustain 
or reach target pressure 3 breaths. IME = time from beginning to task failure = Tlim sec 
 
‘Ventilatory Muscle Endurance’ 
A114 Nickerson et al 
1982 
Ventilatory Muscle Endurance Endurance is the 
property that 
affords resistance 
to fatigue 
15 (4M) Healthy Normal Inspiratory pressure threshold (Pth) load via weighted plunger, at sustained inspiratory 
pressure.  Begin inspiring at Pth near MIP until fatigue, rest at least 10x duration of that 
run. Repeated after decreasing weight by 5% until subject can inspire against Pth for 
10min. This pressure = SIP = average mouth pressure of last 20 breaths as SIP. fB and 
duty cycle unconstrained. 
 
A252 Levine et al 1992 Ventilatory Muscle Endurance  5 M COPD receiving 4hr/day 
NPV 
VME assessed as MSVC for 12 min. Incremental target flow rate (resting ventilation) 
increased incrementally to determine max ventilation subject could maintain for 12 min. 
Insp minute ventilation during highest target flow rate termed MSVC. Continually 
measured end tidal CO2 and o2 sats. 
A254 Keenan et al 1995 Ventilatory Muscle Endurance  27 (14M) 13 = Generalised 
Myasthenia gravis 
13 = Ocular Myasthenia 
gravis 
10 = normal’s 
VME assessed by 2min incremental threshold loading test, weighted plunger. Subjects 
began with 50g load increased every 2 min until not continue. Last load completed for 2 
min = max load (g) and mean mouth pressure over 6 breaths at max load = P(average) 
were taken as measures of RME 
 XVII 
A255 Belman et al 1988  Ventilatory Muscle Endurance VMT 25 (11M) Elderly (65-75yr) Healthy 
VMT = 12 (7M) 
Control = 13 (4M) 
VME assessed by MSVC. 1st “practice” MSVC measured at flow rate 70%  previously 
measured MVV and adjusting flow rate during first 2 min. Subsequent MSVC tests flow 
rate initially set at slightly above previously recorded MSVC. Adjustments in flow were 
made to encourage maximal effort. Average MSVC value was calculated using the last 8 
min of the 10-min test. 
A256 Martin et al 1982A  Ventilatory Muscle Endurance  9 (4M) Active healthy No direct measurement of VME Work designed to reduce VME consisted of 150min of 
sustained max ventilation performed isocapnically ~ Long term hypernea regimen ~ 
subjects asked to maintain max possible ventilation  150 min period. FB at or <60bpm by 
metronome. Every 15 min subjects had 4 min rest. Ve and Vo measured continually,  
Decrease in VME indicated by decrease in Ve and Vo as hypernea test progressed 
A257 Ries et al 1986 Ventilatory Muscle Endurance  12 (3M) COPD pulmonary rehab No defined measurement of VME MVV, MSVC used to assess ventilatory muscle 
performance 
A258 Belman et al 1982A Ventilatory Muscle Endurance Physical Training 15  No 
Gender 
COPD 
 
 
VME assessed by MSVC defined as max minute ventilation sustained for 15 min under 
isocapnic conditions.. Test repeated x2, test with highest MSVC was used for later 
comparison. 
A259 
Silva et al 1998 
Ventilatory Muscle Endurance Aerobic Trainig 24 M 12 = Spinal Cord Injury 
12 = matched controls 
VME assessed sustained time at 70% MVV-12sec value (70%-MVV time). Hypocapnia 
avoided by partial rebreathing. Expired FECO2 maintained range (5+1%). fB and B 
pattern uncontrolled. Test ended when subject unable to sustain target ventilation, with 
reduction higher than 10%. 
A260 Bradley et al 1976 Ventilatory Muscle Endurance    Sustainable Ventilatory Capacity used as index of VME. 
A266 Inselman et al 
1993 
Ventilatory Muscle Endurance  13 (8M) Obese children 147 –
300% Ideal body weight 
VME not referred to in methods or results, in discussion measurement of MVV 
indicates ventilatory capacity and ventilatory muscle endurance. No detail of MVV 
assessment. 
A267 Loveridge et al 
1989 
Ventilatory Muscle Endurance VMT 12 No 
Gender 
Quadraplegics 
6 = VMT 
6 = control 
Sustainable Inspiratory Pressure used as index of VME, assessed by modified Nickerson 
& Keens threshold load device at 75% MIP until exhaustion. If >10 min, 2nd test at 85% 
MIP, if <10min 2nd test at 65% MIP.Pressure time plot made between 2 points, 
extrapolated pressure at 10 min = SIP 
A268 Warren et al 1989 Ventilatory Muscle Endurance  10 (9M) Ultra-marathon runners VME assessed by 12-MVV (stated in intro and results not method) to ATS standards 
except only made x2 not x3 due to time. 
A269 Ries et al 1988 Ventilatory Muscle Endurance Upper extremity 
training 
28 No 
gender 
COPD pulmonary rehab VME assessed by tidal breathing through inspiratory resistive device PFLEX to determine 
smallest orifice patients could sustain for 10min, 10 min rest between trials. Smallest 
orifice sustained for 10 min and time next smallest orifice recorded. 
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A270 Levine et al 1986 Ventilatory Muscle Endurance VMET 
 
32 M COPD Patients matched 
pairs   15 = VMET 
17 = IPPB(placebo) 
No mention of VME in method or results, in introduction describes other papers 
using MSVC. 
A271 Martin et al 1986 Respiratory Muscle Endurance 
Ventilatory Muscle Endurance in Discussion 
RMT 18 M Duchenne Muscular 
Dystrophy 
 
No definition of RME or VME in method or results. In discussion states that 
RME/VME =time Pimax and Pemax could be held for. 
Max time each max static insp and exp pressure could be held was recorded until reading 
fell below 90 Pi and Pe max. 
A272 Keens et al 1977 Ventilatory Muscle Endurance VMET 
‘muscle endurance 
is correlated with 
resistance to 
fatigue’ 
85 (44M) 55 (28M) = CF 
30 (16M) = Normal 
VME assessed by MSVC under normocapnia. 
   
A273 
Belman et al 1980 Ventilatory Muscle Performance 
Ventilatory Muscle Endurance 
VMT 10 COPD No description of VMP/VME assessment in methods or results. Probably used 
MSVC as index? 
A274 
Forte et al 1997 
Ventilatory Muscle Endurance Endurance of the 
Inspiratory muscles 
can be measured 
as the capacity to 
sustain intense 
breathing tasks 
18 M Healthy VME = no definition in methods or results. In Discussion defined as MSV 
 
‘Breathing Endurance’ 
A46 Peret et al 2000 Breathing Endurance  20 M Healthy 
10 = Exp 
10 = Con 
BE assessed by: 1)incremental breathing test, against Inspiratory resistive load at 60% 
PImax for at least 3min. Expiration unloaded, fB 18bpm-1 paced by metronome. Every 3 
min load increased by 5% PImax, until subjects no longer able to continue. Last step 
sustained for 3 min = target pressure for constant load test. 
2) Constant load breathing test a target pressure (above) until task failure. fB 18bpm. Max 
breathing endurance time = start to task failure 
A59 Kohl et al 1997 Breathing Endurance RMT 8 (6M) Healthy BE assessed by time at 70% MVV until exhaustion 
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A26 Markov et al 1996 Breathing Endurance RMT 16 (8M) Healthy Active 
8 = RMT 
8 = Control 
BE assessed by training device, instructed to breathe at individually determined 
frequency and tidal volume until exhaustion, TV targeted at 60% VC and fB calculated to 
obtain VE approx 70% MVV. Time to exhaustion = BE 
A52 Boutellier et al 
1992 
Breathing Endurance RMT 8 Normal endurance 
trained 
BE assessed by voluntarily breathing with individually adjusted fB and TV, both chosen so 
that exhaustion occurred <10min. Time recorded when subject no longer maintain fB or 
TV. 
A60 Boutellier et al 
1992 
Breathing Endurance  4 (3M) Healthy Sedentary BE assessed by subjects breathing at fB 45bpm and a TV of 2.5-3.0 L (60-66% VC), 
when subjects could maintain targets time recorded. 
A275 Williams et al 2002 Breathing Endurance 
Breathing Endurance Time (BET) 
Respiratory Muscle Endurance 
RMT 7 (5M) Healthy Runners Breathing endurance capacity assessed with inspiratory resistive device set at 60% MIP. 
Duty cycle 0.5, fB 22bpm. After each minute MIP taken, subject returning to loaded 
breathing. Procedure continued until two conec MIPs ≤80% of pre-fatigue MIP, time = 
BET 
A276 Martin et al 1982B  Ventilatory Endurance  16 (8 M) Healthy 
8 = athletes 
8 = siblings 
VE assessed by 1) 12 sec MVV 2) 80% MVV until exhaustion 
Journal Search 
A278 Hill et al 2007 Inspiratory Muscle Endurance IMT 33 (22M) COPD 
16 IMT 
17 placebo 
1) Incremental test – modified threshold loading valve, subject chose breathing pattern. 
Insp loads increased by 10% of baseline MIP until task failure. IME defined as Pthmax 
(max pressure) sustained for a minimum of 30 sec. 
2)Constant load test – breath against load determined during familiarization stage to elicit 
Tlim 5-10min ~80 baseline Pth.max. IME defined as Tlim. 
A279 Jardim et al 2007  Endurance of Respiratory Muscle Function  13 M Healthy post grad 
students 
RME measured with aneroid manovacuometer, subject inspiring generating pressure 
corresponding to 80% MIP in each respiratory Cycle. Max time (sec) tolerated at 20fB 
considered endurance measurement. 
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Appendix 2.1 Continued 
‘Respiratory Muscle Endurance’ 
 Author Result Study Design Technique References; Nickerson & Keens, Martyn, 
Leith and Bradley 
A25 Scherer et al 2000 1. RMT 320.3±48.6            Control 400.2±68.0        (seconds) 
2. RMT 106±26.6              Control 117.8±22.7            (grams) 
cohort Threshold Loading 
MVV 
A & B 
NK 
A42 Stuessi et al 2001 Breathing Endurance (mins) RMT group 5.2 (sd 2.9) Control 6.5 (sd 5.7) cohort MVV  
A 
 
A56 Mueller et al 2006 RET min       Paraplegia       Tetraplegia 
                 20% = 51.8        20% = 46.0 
                 40% = 38.8        40% = 18.9 
                 60% = 12.2        50% = 4.2     
Cohort MVV 
A 
 
LB 
A131 
Fiz et al 1998 
                      Cmax, g  
     male       female     
1.  640.0±195.5  580.0±204.4  
2   570.0±170.3  327.3±110.4 
3   440.0±117.3  333.3±70.7  
4   310.0±73.8  288.9±105.4 
5   220.0±91.9  310.0±152.4 
Tlim, s 
       male         female 
1. 701.2±228.8  650.0±267.3 
2. 565.8±185.9  412.2±196.2 
3. 470.6±104.5  386.2±146.5 
4. 344.0± 71.5  374.3±121.6 
5. 316.6±79.2  297.3±56.5 
cohort Threshold Loading 
 
B C1 
NK, M 
 XXI 
A132 Larson et al 1999 *calculated mean of 3 tests 
Men     duration          18.3 min 
            Rel mouth pr   59.7 % of PImax 
            Ab mouth pr    43.7 cm H2O 
             ITL weight      337.3 g 
Women duration            20.1min 
            Rel mouth pr   64.7 % of PImax 
              Ab mouth pr    42.0 cm H2O 
               ITL weight      323 g 
 
cohort Threshold loading 
B 
NK, M 
A138 McElvaney et al 1989 *calculated average of 3 tests 
1)Max load =  636.7 g 
2) Tlim = 6.36 min 
Cohort Threshold loading 
B 
NK, M 
A152 Koppers et al 2006A 1) PIsmax 
RMET = 25 (sd 09) cmH20 
Control = 29 (sd12) cmH20 
2) HET 
RMET = 534 ( sd 349) s 
Control = 389 (sd 265) s 
*’randomly assigned to groups’ no 
explanation of differences of baseline 
scores 
Cohort Threshold loading 
B+C1 
NK, M 
A153 Mador et al 2005      1)RM Time, min RMT 13.2±1.7             Control 10.6±1.6 
 2) VE, %MVV RMT 69.1±1.8          Control 69.9±2.6 
Cohort MVV 
A 
LB 
A154 Wirnsberger et al 1997 Patient 756 sec (sd 246)     Control 869 sec (sd 130)  Matched healthy 
control 
Threshold loading 
C1 
NK 
A156 Rassler et al 2007  Tlim = 8.4±0.9 min           at  55.0±2.8% MVV   Vlim = 555±87 L Cohort MVV 
A 
LB 
A157 Matecki et al 2001 Tlim   DMD = 4.47 min   Control >30min (stopped testing) Matched healthy 
control 
Threshold loading 
C1 
NK 
 XXII 
A159 Koechlin et al 2005 Tlim      Pre Puberty 138.5 sec (s.d) 20.9 
Near end puberty = except 1 subject all able to continue for than 1,200 sec (20min) tests 
halted. 
Cohort Threshold loading 
C2 
NK 
A161 Laghi et al 2005 Time of total loaded breathing  Hypo = 302 sec ±29  Euo = 313 sec±48 Cohort Threshold loading 
B 
NK, M 
A163 Chang et al 2005 FRI = 0.88% (sd 0.13) cohort Threshold loading 
C2 
 
A164 
Koessler et al 2001 
Baseline 12sMVV (L/min) 
A = 52.23 ±27.8     B = 56.9 ±24.75    C = 61.2 ±14.2 
cohort MVV 
A 
LB 
A165 
Weiner et al 1992 
RME         RMT group = 67.5 ±3.1     Control group = 66.7±2.0 cohort Threshold loading 
B 
NK, M 
A166 
Nava et al 1992 
Endurance time  
Group A = 234.8± 48.9     Group B = 187.2 ±31.06 
cohort Fixed Resistance tube 
C1 
 
A167 Lake et al 1990  1) Progressive 
Control 782 sec ±258 
A  695 sec±328 
B  538 sec±236 
C  542 sec±208 
2) Endurance 
control 224sec ±163 
A  189±194 
B  140±72 
C  135±78 
Cohort Threshold loading 
B + C1 
NK, M 
A168 
Morrison et al 1989A 
There was no significant difference between tests with unfixed or fixed breathing frequency 
for any of the measures of RM endurance (max load, Ppk, Ppk/MIP, Pmean). 
Data in figs only not tabulated or given in result section 
Cohort Threshold loading 
B 
NK, M 
A169 
Morrison et al 1989B 
Data in figs only not tabulated or given in result section Matched healthy 
control 
Threshold Loading 
B 
NK, M 
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A171 
Sonne et al 1982  
Not given in body of results.0.48 cm ±0.03  cohort Fixed Orifice 
C2 
 
A172 Orenstein et al 1981  SH score Exercise group = 713.6 units (sd 390.5) 
Control group = 943.2 units (sd 254.2) 
Unmatched healthy 
control 
MSVC 
C1 
LB 
A173 
Holm et al 2004 
Not given in data or body of text fig only Endurance capacity of the respiratory 
muscles (estimated as sustainable ventilatory capacity) no data 
cohort MSVC 
C2 
LB 
A174 
Boussana et al 2001 
Tlim basleine (not given in body of text fig and abstract only) Trial 1 = 4.19 min ±0.3  
Trial 2 = 4.02 min  ±0.3 
cohort Threshold loading 
B 
NK 
A175 
Weiner et al 1998A 
IME ratio  PmPeak/Pimax = 56 (SE1.4) % Cohort Threshold loading 
B 
NK, M 
A176 
Uijl et al 1999  
Baseline  Pendu = 3.98 Kpa Cohort Threshold loading 
B 
M, LB 
A177 
Chatham et al1996 
No data in body or abstract, fig only. Pilot cohort Fixed Orifice 
C1 
NK 
A178 
Mancini et al 1995 
MSCV L/min    RMT 70 ±21        Control 49 ±11 cohort MSVC 
B 
LB 
A179 
Supinski et al 1985 
Placebo 
79% MIP         397±107 
89% MIP         110±21 
Caffeine 
79% MIP         856±142 
90% MIP         272±47 
cohort Threshold loading 
B 
NK 
A180 DiMarco et al 1985  Given as 100% from which intervention was measured. 
No individual data except In a fig. 
cohort MVV 
A 
LB 
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A183 
Fairban et al 1991 
MSVC    RMT group = 155.4±11.2 L/min   Control group = 155.1±26 L/min cohort MSVC 
C2 
LB 
A185 Cimen et al 2002 MVV(%)        Patients = 85.80±17.80     Control = 96.19±15.67 Matched healthy 
control 
MVV 
A 
 
A187 
McConnell et al 2003 
MSVC = 45.0 (sd 11.0) cohort MSVC 
C2 
 
A188 
Sharma et al 2007  
MVV @ 3450 m = 166±24.71    MVV @ 5350 m = 120.14±24.48 
Tlim @ 3450 m = 14.27±4.43      Tlim @ 5350 m = 12.96±3.39 
cohort MVV 
A 
NK, M 
A190 
Koppers et al 2006B 
SIPmax(kPa)      Normocapnic = 3.6 (sd 1.6)     Hypercapnic = 4.5 (sd 1.9) cohort Threshold loading 
B 
NK, M 
A191 
Enright et al 2006  
IWC (j breath-1)   CF = 9.7 (SD 2.8) Controls = 11.8 (SD 2.8) Matched healthy 
control 
Threshold loading  
B 
 
A192 
Boussana et al 2002  
No pre intervention Tlim data in abstract or body of text, fig only. cohort Threshold loading 
C1 
NK, M 
A193 
Boussana et al 2003 
TLim min    5.22±0.28 cohort Threshold loading 
C1 
NK,  
A194 
Eastwood et al 2001 
Pthmaxas a proportion of their PImax ( 3rd test) 
Sedentary = 78 ±10%           Athletes = 90 ±8% 
Unmatched healthy 
controls 
Threshold loading 
B 
NK, M, LB 
A195 
Sturdy et al 2004  
Baseline test 1  
Pthmax = 35 ±17 not clear whether Pthmax is expressed as % or cmH2O 
Could this be PmPeak/PImax therefore % 
cohort Threshold loading 
B 
NK, M 
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A196 Tobin et al 2002 Tlim @ baseline       Trained 307.6 ±126.6 sec       Control 271±40.4 sec Double blind RCT 
(training study) 
Threshold loading 
C1 
NK, M 
A198 
van der Esch et al 2004  
PIend  not reduced on average (mean = 103±36% pred) Cohort  Threshold loading 
B 
M 
A199 
Weiner et al 1998B  
RME  - as expressed by relationship between PmPeak and Pimax (not defined in methods 
appears to be %). 
Group A 47.9%  ±4.0      Group B 26.0% ±2.9 
cohort Threshold loading 
B 
NK, M, LB 
A200 
Sairikaya et al 2003 
MVV % (of predicted values?)    Obese 97.92 ±20.00   Control 98.75 ±15.56 Unmatched healthy 
controls 
MVV 
A 
 
A202 Cimen et al 2003 MVV %     Patient = 83.35 ±19.14     Control = 74.74 ±21.77 Matched healthy 
controls 
MVV 
A 
 
A203 Covey et al 2001 Pm cmH2O    IMT group = 37 (SD 12)    Control group = 44 (SD15) Single blind RCT (Training study) 
Threshold loading 
DC-ITL 
B 
NK 
A205 
Heimer et al 1990 
MVV% pred     Diabetes = 88.9 ±20.    Control = 103.9 ±15.8 Matched healthy 
controls 
MVV 
A 
 
A226 Morgan et al 1987 EBT sec                                 MVV (l/min) 
Exp 48 ±10                        213 ±8 
Control 48 ±10                   205 ±3 
Unmatched control MVV 
A 
LB 
A227 
O'Kroy et al 1993  
No data only figs . cohort Threshold Loading 
C1 
NK, LB 
A234 
Walsh et al 1996 
Pmax (cmH20)  Patients 18.5 (6.4)  Control 30.7 (6.6)Pmax/Mip (%) not tabulated or in 
results 
Matched Healthy 
Controls 
Threshold loading 
B 
NK, M 
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‘Inspiratory Muscle Endurance’ 
A124 
Watsford et al 2007 
Pend (cmH20)      Male                 Female 
A                     88.0 ± 14.5           77.5 ±20.5 
B                     80.5 ±19.5            52.0 ±18.1 
C                    67.0 ±24.4            39.3 ±13.4 
cohort Threshold loading 
B 
 
A136 Eastwood et al 1998 Pth Max (cmH20)    69 ±17 cohort Threshold loading 
B 
NK, M 
A137 
Clanton et al 1985 
Tlim (min)  All subjects  153 ±52 cohort Threshold loading 
C1 
NK 
A207 Johnson et al 1996 No data not clear work load patients inspired at. deals with comparison of devices 
rather than measure of IME. 
cohort Threshold loading 
C2 
NK 
A208 
Wanke et al 1994 
Tlim (min)   Controls    12.0 ±6.7   IMT            12.2 ±6.2 RCT (training study) Threshold Loading 
C1 
NK, LB 
A210 
Foglio et al 1994 
Endurance time (sec) 
Group I (able to complete exercise test n=16)          397 ±1545 (SD error?) 
Group II (not able to complete exercise test n=8)            247 ±148 
cohort Resistive Threshold 
C1 
 
A211 
Mannix et al 1993 
IME Time (min) 
@21% O2  3.3 ±0.4   @13% O2  1.6 ±0.4    @30% O2  4.0 ±0.6 
cohort Threshold loading 
C1 
 
A212 
Chen et al 1989A 
Endurance time (sec)      M = 396 ±29              F = 404 ±30 
PT index      M = 25,477 ±2,011   F = 25,698 ±2,035  
cohort Threshold loading 
C1 
NK 
A214 Dodd et al 1988 Tlim (sec)  @15bpm   504 ±76   @22bpm   297 ±31   @30bpm   164 ±12 cohort Threshold loading  
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C1 
A217 
Weiner et al 1995  
PmPeak/PImax   Group A   82.7 ±2.6%   Group B   79.5 ±3.0% Single blind group 
comparative trial 
(Training study) 
Threshold loading 
B 
NK, M, LB 
A218 
Preusser et al 1994 
                  Pitl cm H20 
Group 1     14± 6 
Group 2      20 ±6 
             IE  L x cm H20 
Group 1     487 ±524 
Group 2     1,059 ±549 
Double blind two 
group repeated 
measure design 
Threshold loading 
B + C1 
NK, M 
A220 
Weiner et al 1993 
PmPeak/PImax        84.4   ±2.4% cohort Threshold loading 
B 
NK, M 
A221 Goldstein et al 1991 Tlim min   7.1 ±3.4 cohort Threshold loading B NK 
A222 Goldstein et al 1989 Tlim min 4.90 ±1.31 cohort Threshold loading B NK, LB 
A223 O'Donnell et al 1998 Vlim Reports the increase but not actual values in text, results in bar chart cohort Threshold loading C1 NK 
A225 Inbar et al 2000 PmPeak cmH20    IMT          121.6 ±13.7    Control    128.2 ±8.7 Single blind 
randomised control 
trial (training study) 
Threshold loading B NK, M, LB 
A231 De Jong et al 2001 IME (%PImax)       IMT = 50 (SD 5)    SHAM = 49 (SD 12) cohort Threshold loading B  
A232 Sette et al 1997 Tlim (sec)        1st.   154 ±65    2nd.  164 ±66 cohort Threshold loading C1 NK 
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A236 Reiter et al 2006                      Tlim (sec)   mean(sd) 
 Age               Women                   Men 
17-29     902.4 (416.91)    842.33 (166.14) 
30-39     791.08 (315.48)  847.34 (384.34) 
40-49     834.79 (384.45)  878.61 (344.22) 
50-59     942.09 (221.00)  991.75 (193.87) 
60-69     648.44 (179.48)  854.76 (253.66) 
cohort Threshold loading 
C1 
NK, M 
A237 
Inzelberg et al 2005 
PmPeak (cmH2O)     IMT          20.0 ±2.8    Placebo   18.2 ±2.3 Placebo Controlled 
(training study) 
Threshold loading B NK, M 
A238 Brancelone et al 2004         Plim2 (cmH20)  Plim2/PImax (cmH2O) 
Sarcoid     89 ±4                53 ±3 
Control     103 ±5               75 ±2 
Unmatched healthy 
controls 
Threshold loading B NK 
A239 
Klefbeck et al 2000 
Res @ 15 RPE       Res @ 17 RPE     10.7 (5.0-16.5)        11.9 (6.0-18.0)  cmH2O 
Unclear whether baseline is n=10 or n=7 
Cohort Threshold loading C1 NK, LB 
A240 Scardella et al 1993 No data in tables or results Fig only Cohort Inspiratory Load C1  
A242 
Wanke et al 1991 
MVV (L/min)  Diabetic  153.2 ±35.1   Control    167.2 ±50.6 Unmatched healthy 
controls 
MVV A LB 
A244 Ker et al 1996 1st week test results used 
Max Load(g)        235 (sd  97.9) 
Pmpk (cm H2O)    34  (sd 11.4)  
Pmpk/PImax (%)   62 (sd 23.3) 
cohort Threshold loading B NK, M 
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IPM (cm H2O)       63 (sd 40.8) 
A245 Collet et al 2007 Plim2 (cmH2O)        52.2 ± 16.8       Plim2/PImax (%)      57.1 ±19.0 cohort Threshold loading B M 
A246 Chen et al 1989B Endurance time 11.2 ±0.8 min PTI                    871 ±61 cmH2O.min cohort Threshold loading C1 NK 
A247 
Chen H-I et al 1985 
1)Endurance time (sec) 
IMT = 160 ±78    Sham = 259 ±78 
2) SIP (%Pimax at FRC) 
IMT = 42 ±10      Sham =  29 ±11 
Placebo controlled Threshold loading 
Sustained Inspiratory 
Pressure B+C1 
NK, LB, M 
A248 
Chen et al 1989C 
IME (cmH2O.min)  Midluteal (high progesterone)  815 ±43  
Mid follicular (low progesterone)  649m±62 
Cohort Threshold loading 
C1 
NK 
A250 
Newell et al 1989 
No tabulated or text data, figs only Unmatched healthy 
controls 
Max Static pressure 
C2 
 
A261 
McKeon et al 1986 
After IMT all subjects able to tolerate smallest (2.5mm) aperture therefore ‘could be 
considered to have improved their IME’  
cohort Fixed orifice 
C1 
LB 
A262 Innes et al 1982 Rmax      No data in results fig only cohort Sustained pressure 
C1 
 
A264 Ker et al 1996 Tlim sec     62.3 ±42  C1  
 
‘Ventilatory Muscle Endurance’ 
A114 Nickerson et al 1982 SIP cmH2O                             82 ±6 cohort Threshold loading C2 Nickerson & Keens 
A252 Levine et al 1992 MSVC L/min 25.0 ±3.6   cohort MSVC C2 LB 
A254 Keenan et al 1995             Max Load (g)                  P(average)                       Mean (SD)                      
G MG     246(166)                       19.4 (14.9) 
O MG     400 (87)                        29.3 (2.9) 
Normal    580 (155)                     31.1 (8.0) 
Matched Healthy 
Control 
Threshold loading 
B 
NK, M 
 XXX
A255 
Belman et al 1988  
MSVC (L/min)   VMT        73.2 ±6.8  Control    63.9 ±5.4  Matched Healthy 
Control 
MSVC C2 LB 
A256 Martin et al 1982A   Cohort MVV A LB 
A257 Ries et al 1986  cohort MVV A LB 
A258 Belman et al 1982 MSVC L/min Arm   46 ±5 Leg    36 ±2 cohort MVV A LB 
A259 
Silva et al 1998 
70%-MVV time (min) SCI    1.15 Control 14.60 Expressed as median Matched healthy 
controls 
MVV A  
A260 
Bradley et al 1976 
NO data in text or table fig only Matched healthy 
controls 
SVC C2 LB 
A266 Inselman et al 1993 MVV (L/min) 62 ±5 cohort MVV A  
A267 Loveridge et al 1989 SIP (cmH2O)   VMT =    56.2 ±15.4  Control =  50.2 ±12.1 RCT (training study) Threshold loadingC1 NK, LB 
A268 Warren et al 1989 No data in text or tables fig only cohort MVV A  
A269 
Ries et al 1988 
Orifice Number  Control    2.9 ±1.5   GR          2.9 ±1.7   PNF        3.1 ±2.0 Unmatched healthy 
controls 
Fixed resistance C2  
A270 
Levine et al 1986 
MSVC  L/min   VMET 56 ±5   IPPB  45 ±4 Placebo matched 
control 
MSVC C2 LB 
A271 Martin et al 1986 Pi time (sec)  11.9 (sd 3.8) cohort MSVC C2 LB 
A272 
Keens et al 1977 
MSVC (L/min) 
                   CF                Normal 
Male        83 ±5             125 ±7 
Female    54 ±4               81 ±5 
Unmatched healthy 
control 
MSVC C2 
 
LB 
   A273 Belman et al 1980 MSVC (L/min) 32 ±11 Cohort MSVC C2 LB 
A274 Forte et al 1997 MSV (L/min) 141 ±7 cohort MSV C2 LB 
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‘Breathing Endurance’ 
A46 Peret et al 2000 1) Fig only no data in results 
2) Constant endurance test (min) 
 Exp =       6.9 ±2.5 
 Control =   6.2 ±2.2 
Unmatched healthy 
controls 
Threshold loading 
B+C1 
NK 
A59 Kohl et al 1997 70% MVV (min) 5.8 (SD 2.9) Cohort MVV A  
A26 Markov et al 1996 BE (sec) RMT 455 ±193 Control 293 ±143 RCT (training studies) MVV A  
A52 Boutellier et al 1992 Breathing Endurance (min) 6.1 (SD 1.8) cohort MVV A LB 
A60 Boutellier et al 1992 BE (min) 4.2 (SD 1.9) cohort MVV A LB 
A275 Williams et al 2002 No data in results or table, fig only. cohort Threshold loading B LB 
A276 Martin et al 1982B   MVV (l/min) Test 2(min) Athletes   172 ±11            7 Siblings    107 ±9             3 Sibling controlled MVV A LB 
Journal Search 
A278 
Hill et al 2007 
1) Pth.max (cmH20) IMT = 38.5 ±9.7 Sham = 40.5 ±18.3 2) Tlim Not stated fig only and 
percentage change after IMT 
Double blind RCT 
(training study) 
Threshold loading 
B+C1 
NK, M 
A279 
Jardim et al 2007  
RME (sec) Placebo 1205±957.2 Intervention 1161.2±1034.7 Significant increases in 
RME in both placebo and intervention. 
cohort Fixed Orifice C1  
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Appendix 2.2 
ID Author Type Subjects Parameter Resting data Sample 
rate 
Study Outcome 
BFA
01 
Lodrup - 
Carlsen 
(2000) 
Review      
BFA
02 
Morris et al 
(2004) 
Article 15 COPD 
16 Healthy 
tPTEF/tE 
trsTidal 
Seated 
80seconds 
100hz 
100hz Sig diff in tPTEF/tE between groups 
BFA
03 
Dotta et al 
(2007) 
Article Infants 
13 Congenital 
Diaphragmatic Hernia 
28 healthy 
tPTEF/tE Spontaneous quite sleep without sedation 
60seconds 
Not stated Sig diff in tPTEF/tE between groups 
BFA
04 
Lum et al 
(2004) 
Article Infants 
29 healthy 
 Behaviourally determined quite sleep after 
sedation 
Uses a restrictive ‘jacket’ 
Not stated n/a 
BFA
05 
Lodrup - 
Carlsen et al 
(1997) 
Article Infants 
24 healthy neonates 
26 asymptomatic children 
24 healthy controls 
tPTEF Awake – semi-recumbent 
Time not given 
250hz  Asthmatics had lower tPTEF than 
controls 
 XXXIII
BFA
06 
Emralino et al 
(1997) 
Article Infants 
79 healthy neonates 
tPTEF Sleeping non sedated 
Recordings made until 4 repeatable TBFVL 
were gathered 
256hz Reproducibility of tPTEF affected by 
timing of recordings 
BFA
07 
Deerojanawon
g et al (2005) 
Article Infants 
47 wheezing children 
tPTEF/tE Sleeping sedated 
Four stable TBFV loops were selected 
Not stated Significant difference in tPTEF/tE 
after bronchodilator 
BFA
08 
Devulaplli et 
al (2004) 
Article Young children 
54 treated with inhaled 
steroids 
15 healthy controls 
tPTEF/tE Awake – quiet breathing 
Four loops used- each loop chosen from 8 
stored loops (max 32 breaths??) 
256hz Sig diff in tPTEF/tE between groups 
BFA
09 
Ranganathan 
et al (2003) 
Article Infants 
47 Cystic Fibrosis 
95 Healthy controls 
tPTEF/tE Sleeping sedated – minimum 20 breaths during 
at least 2 periods of quite breathing 
Not stated No difference in tPTEF/tE between 
groups – although they found high 
fR? 
BFA
10 
Morris et al 
(1998) 
Article Adults 
118 patients attending lung 
function lab with a diagnosis 
of airflow obstruction 
Trs 
EV 
Awake – ‘the first ten breaths’ 80hz Sig diff between groups 
BFA
12 
Bates et al 
(2000) 
Review Infants  The potential most troublesome aspect of tidal 
breathing from the computational point of view 
is the beginning and end of 
inspiration/expiration  
50-100hz 
timing and 
volume 
200hz for 
tPTEF/tE 
 
Need to standardise methods and 
equipment when assessing infants. 
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BFA
13 
Williams et al 
(2000) 
Article 64 children and young 
adults with CF 
tPTEF/tE 
Trs 
S 
Seated, 2 minutes 
 
S = the slope of the whole post peak expiratory 
flow pattern) 
 tPTEF/tE poor correlation with 
airflow obstruction 
Trs strong relationship “” 
Using S (angle) the post expiratory 
profile could be categorised in to 
three shapes and provided a good 
indicator of airflow obstruction. 
BFA
14 
Totapally et al 
(2001) 
Article Twenty Infants <1 year tPTEF/tE 
TEF10 
TEF25 
TEF50 
Sedated 
Four loops used- each loop chosen from a 
minimum 16 
Not stated No change in tPTEF/tE after 
bronchodilator, sig change in TEF10 
and TEF25/PTEF 
 
BFA
15 
Lodrup-
Carlsen et al 
(1999) 
Article 802 neonates 
77 bronchiol obstruction 
88 controls 
tPTEF/tE 
 
Awake  
Four loops used- each loop chosen from 8 
stored loops (max 32 breaths??) 
Not stated No difference in tPTEF/tE 
BFA
16 
Haland et al 
(2007) 
Article 135 children at 2years 
90 studied 
tPTEF/tE 
 
Awake 
Four loops used- each loop chosen from 8 
stored loops 
With fR as low as possible 
256hz  
 
BFA
17 
Greengough et 
al (1998) 
Article 85 infants 
61 studied at =>1 year 
23/61 symptomatic wheezers 
 Non sedated sleeping 
First two consecutive periods of regular 
breathing each of at least 10 breaths 
- No difference in tPTEF/tE 
 XXXV
BFA
18 
Greengough et 
al (1998) 
Article 120 premature children 
assessed at mean 11months 
tPTEF/tE 
 
Sedated  
Pneumotach 
First 10 regular breaths were used for analysis 
- Sig dif in tPTEF/tE who in neonatal 
period had not required mechanical 
ventilation, had not required 
increased inspired O2, and who were 
not symptomatic at follow-up. 
Suggest low tPTEF/tE independently 
associated with symptom status 
BFA
19 
Hoo et al 
(1998) 
Article 108 preterm infants 
40 whose mothers had 
smoked in pregnancy 
tPTEF/tE 
 
Asleep 
60 consecutive regular breaths collected over 2 
03 epochs 
- tPTEF/tE significantly lower in 
preterm  infants exposed to tobacco 
inutero 
 
BFA
20 
Stocks et al 
(1997) 
Article 56 preterm infants at 
discharge (mean 19 d) 
28 white/28 black 
tPTEF/tE 
 
Naturally asleep (no sedation) 
Inflatable jacket and Pneumotach 
- tPTEF/tE longer in black infants 
 
BFA
21 
Stick et al 
(1996) 
Article 500 healthy infants tPTEF/tE 
 
Naturally asleep 
Respiratory Inductance Plethysmography 
Not stated Lower values of tPTEF/tE 
Associated with respiratory rate, age, 
maternal smoking during pregnancy, 
maternal hypertension during 
pregnancy and a family history of 
asthma 
BFA
22 
Yuksel et al 
(1996) 
Article 60 term infants (mean 2 
weeks) 
tPTEF/tE 
 
Non –sedated sleeping 
25 Flow loops from a pool of 60 
Not stated 13 infants who became wheezy had a 
sig lower tPTEF/tE, however 
predictive value of tPTEF/tE is 41% 
limited use? 
BFA
23 
Haland et al 
(2006) 
Article 616 children at birth and at 
10 years of age 
tPTEF/tE 
 
Awake  
Four representative loops used 
Not stated Children whose tPTEF/tE at birth 
was at or below median were more 
likely at 10 year to have a history of 
 XXXVI 
asthma 
BFA
24 
Habib et al 
(2003) 
Article 16 very low birth weight 
preterm infants (mean day 5) 
 Not clear awake/sleeping 
Pneumotach and chest wall sensor (+invasive 
balloon catheters) 
Collected in stretches 30-60sec 
100hz tPTEF/tE higer than that reported in 
older infants. 
BFA
25 
Dezatuex et al 
(1994) 
Article 168 infants tPTEF/tE 
 
Sedated sleep supine position 
Data collected in 30-60 sec epochs 
Data calculated from minimum of 20 breaths 
collected in 2 epochs 
100hz In older infants (50 weeks) tPTEF/tE 
sig lower in those infants with lower 
respiratory illness with wheezing. Not 
seem in children at <3months 
BFA
26 
Ueda et al 
(1999) 
Article 64 healthy infants 19 had 
mothers who smoked during 
pregnancy 
tPTEF/tE Sedated sleep 
1x 20sec recording (approx 11 breaths) 
Not stated Dose response relationship between 
cigarettes smoked and lower 
tPTEF/tE 
BFA
27 
Van der Ent et 
al (1996) 
Technic
al note 
     
BFA
28 
Djupesland et 
al (1998) 
Article 17 healthy newborn tPTEF/tE 
tPTEF 
Awake-pneumotachograph 
Four loops used- chosen from 8 stored loops 
256Hz No difference between flow profiles 
from either right or left nostril 
BFA
29 
Harrison et al 
(2009) 
Article 41 CF infants tPTEF/tE 
 
sedated 
Pneumotachograph 
Time period not stated 
Not stated No correlation with tPTEF/tE and 
FEV1 
 
BFA
30 
Haland et al 
(2009) 
article 607 birth cohort tPTEF/tE 
 
Awake 
Pneumotachograph 
256Hz Changes in tPTEF/tE from birth to 
10years of age not sig. associated 
with lower respiratory tract 
 XXXVII 
Time period not stated infections. 
BFA
31 
Manczur et al 
1999 
Article 47 children 1month-1year tPTEF/tE 
 
Used Respiratory Inductance Plethysmography 
and pneumotachograph  
Sampled first 10 ‘analysable’ breaths 
Not stated Both techniques can be used although 
result were significantly different. 
RIP is better tolerated 
BFA
32 
Black et al 
(2004) 
Article 29 children 4-8years with 
diagnosis of asthma. 
tPTEF/tE 
 
Used Respiratory Inductance Plethysmography -  tPTEF/tE does not detect mild airway 
obstruction or response to 
bronchodilator provocation. 
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Appendix 7.1 
Respiratory Research – Feedback Form 
 
Please circle 1 answer per question 
Regards current studies into respiratory diseases: 
1. It is important for me to know what research is being carried out. 
Agree 1 2 3 4 5 6 7 Disagree 
 
2. I would like to be consulted on what research should be undertaken 
Agree 1 2 3 4 5 6 7 Disagree 
 
3. It is important for the research to take place 
Agree 1 2 3 4 5 6 7 Disagree 
 
4. I would be happy to be asked to consider taking part in a research study 
Agree 1 2 3 4 5 6 7 Disagree 
 
Measurement of respiratory function 
5. I have undertaken tests that measure how my lungs work  Yes  No 
6. I found these:   
Easy 1 2 3 4 5 6 7 Hard 
7. If you have any other comments please make below: 
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1.0 Research Team 
Principal Investigator  Dr Paul Neill   Royal Glamorgan Hospital 
Investigators   Dr Mark Williams   University of Glamorgan 
Mr Tom Powell    University of Glamorgan 
2.0 Rationale for proposed study 
A variety of ways have been developed to quantify endurance properties of respiratory muscles. 
These generally involve asking individuals to breathe maximally or progressively against a load until 
the point of fatigue, with this point depending heavily on subject motivation and compliance. It has 
long been recognised that there is a need for better techniques for evaluating respiratory muscle 
endurance and work capacity in patients with obstructive chest disease (Clanton. 1995). 
 We propose a new 6-minute non-volitional test, during which study participants will breath against a 
constant resistive load. We utilise a device that can apply a resistive load throughout tidal breathing, 
both on inspiration and expiration. By incorporating a flow measurement head and differential 
pressure sensor, the device samples pressure and flow at 100Hz and uses this to continually adjust 
its internal diameter to ensure that irrespective of flow generated, the applied resistance remains 
constant. Sampling pressure and flow allows us to calculate energy needed to move the volume of air 
whilst breathing through this device.  
We define this outcome as breathing energy expenditure (BEE) and express it in terms of joules of 
energy per litre of inspired air (J.L-1). Put simply, it is the amount of work performed by the respiratory 
system and we believe it can provide a measure of functional respiratory endurance in a non-volitional 
way.  
This seated 6-minute test offers an improvement on existing techniques as it is non-invasive, non-
volitional and does not require maximal effort on behalf of the subjects and is of a shorter duration 
than most maximal tests of respiratory endurance function. In mild to severe COPD, resting lung 
function is often compromised and patients alter their breathing pattern to minimise their work of 
breathing. This new approach could therefore be of particular benefit in patients with respiratory 
diseases such as COPD. We plan to control the pattern of breathing of study subjects using a 
bespoke metronome that allows the ratio of inspiratory and expiratory time to be set independently of 
the breath per minute rate.   
We have already performed this test in healthy control subjects, completing over 200 separate trials, 
during which no adverse events or other difficulties were reported. In addition our research team has 
recently received approval to use this technique to measure BEE as part of a wider ranging study with 
COPD patients.  
This study will allow us to gain a better insight into the mechanics of endurance breathing in patients 
with chest disease, possibly leading to a non-volitional, effort independent test of functional 
respiratory status. This may ultimately lead to a better understanding of functional respiratory status, 
and inform clinical treatment and management of the patient with respiratory disease. 
 3.0 Objectives and Aims 
The primary aim of this study is to investigate whether responses to constant loaded breathing in 
patients with chest disease are similar to that in healthy subjects already studied. The study will test 
the hypothesis that patients with chest disease will have a greater BEE than healthy subjects at rest, 
and that BEE assessment with this technique may provide a useful tool in assessing patients with 
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chest disease. The secondary aim of this study will be to assess the utility of a new method to control 
the pattern of breathing in patients with chest disease. 
4.0 Participants 
Prospective participants will be patients attending out-patients clinics for assessment of their 
pulmonary lung function within the Department of Respiratory Medicine at the Royal Glamorgan 
Hospital. All these patients, who will be under the care of Dr Paul Neill and colleagues will, after 
informed consent has be obtained (Section 4.2), be assessed and screened using study inclusion and 
exclusion criteria (Section 4.3 & 4.4) that will be recorded using the study screening form (Appendix I). 
4.1 Recruitment of Participants 
Prospective participants will be as normal, contacted by letter prior to their appointment at the 
pulmonary lung function clinic.  This letter will also contain a copy of the study information sheet for 
their attention that will outline the study (appendix II). On arrival prospective participants will be asked 
whether they would be interested in taking part. Patients who express an interest in the proposed 
study will have it explained to them in detail during which they will have the opportunity to ask 
questions, what they can expect and what is expected of them. If they are happy to take part informed 
consent will be taken.  
4.2 Informed Consent 
Informed Consent will be secured from all participants before any study investigations take place. If 
they are happy to take part participants will be asked to sign a Study Informed Consent Form 
(appendix III) a copy will be given to the participant, one to be kept with the clinical record form and 
the original being retained in the patients Medical Notes. As a matter of course every patients GP will 
be informed by letter of their participation (appendix IV). Once informed consent is given participants 
will be screened using study inclusion and exclusion criteria (4.3 & 4.4). 
4.3 Inclusion Criteria 
Clinically defined obstructive or restrictive respiratory disease 
Clinically stable  – not currently receiving prescribed medication for an exacerbation of their 
disease symptoms 
- free from exacerbation of their respiratory disease for a period of at least 2 
weeks 
No significant unstable disease co-morbidity’s 
Capable of providing informed consent. 
Willing for GP to be informed of participation in study 
Willing to take part in all study measurements. 
4.4 Exclusion Criteria 
Any history of severe unstable disease co-morbidity’s. 
Any other serious medical condition 
Any prescribed medical condition (unless associated with respiratory disease status) 
Pregnancy 
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Inability to complete study measurements 
Significant visual or audiological impairment 
5.0 Study Parameters to be Assessed 
  
1. Breathing Profile (Colasanti et al. 2004) 
 -Total breath duration    - seconds 
 -Duration of inspiration and expiration  - seconds 
 -Peak inspiratory and expiratory flow  -litres per second 
 -Timing of peak inspiratory and expiratory flow -seconds 
 -Expiratory flow profile    -angle 
 -Tidal volume     -litres 
- Resting Respiratory Breathing Rate  - respirations per minute 
 
2. Questionnaires of Dyspnoea Measurement (Appendix V) 
 - Medical Research Council Breathlessness Score (Bestall et al. 1999) 
 - St Georges Respiratory Questionnaire 
  
3. Specific Respiratory Muscle Function (Powell et al. 2007) 
 - Respiratory Muscle Endurance   - BEE (Joules/Litre) 
5.1 Clinical History 
 In addition to study measurements after the screening, informed consent and study measurement 
processes but whilst still in possession of a participants medical notes, the following information will 
be recorded. 
 - Height      - metres 
 - Weight     - kilograms 
 
 - Forced Expiratory Volume in 1 second (FEV1)  - litres sec-1 
 - Forced Vital Capacity (FVC)   - litres 
- Maximal Inspiratory Mouth Pressure (MIP) - centimetres of water (cmH20) 
 - Medication History  
  - current medications 
  - number of IV/oral antibiotic courses in the previous year 
 - Clinical Visit history 
  - number of out-patient attendances in previous year 
 LXVIII
  - number of in-patient attendances in previous year 
 - Pulmonary Function Test history  
  - best lung function in previous year (if undertaken) 
  - result of previous six minute walk test (if undertaken) 
- Blood Gas History 
- haemoglobin concentrations 
 
5.2 Calibration and Hygiene 
All equipment used in study measurements will be calibrated and maintained to ensure accuracy of 
results. All protocols to ensure hygiene of equipment will be strictly adhered to, for example single use 
mouth pieces and filters for spirometry. 
6.0 Location of Study Investigations 
It is intended that all study investigations will be undertaken within the Department of Respiratory 
Medicine at the Royal Glamorgan Hospital.  
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7.0 Flow chart of patient participation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screening of Patient 
Fulfil  
Inclusion 
Criteria ? 
No Excluded from study 
Yes 
1. Breathing patterns 
2. Dyspnoea questionnaires 
3. Functional Respiratory Endurance 
Measurements  
Informed Consent Taken 5-10 min 
1-2 min 
2 - 4 min 
24 min 
4. End of Session 
Total Time 40 min 
Study Information sheet included with 
Lung Function clinic letter 
Willing 
to take 
part? 
Yes 
No No further action 
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8.0 Primary Outcomes 
 The primary outcome of this study will be the level of BEE at constant applied resistances to 
breathing, and any relationship to existing methods of pulmonary function assessment. Secondary 
outcomes will be utility of a bespoke metronome to control breathing pattern. 
9.0 Number of Participants and Power Calculations 
This study will be used to help provide a better estimate of the number of participants needed to gain 
statistical accuracy for possible future studies. Typically other recent studies in this area have used 
study samples of 20 – 50 patients (Cardoso et al. 2007; Su et al. 2007; Rosa et al. 2006), often based 
around pulmonary rehabilitation programmes, retrospective studies normally have much larger 
sample sizes [n  >100] . As such we plan to recruit only a limited number of subjects (minimum of 30) 
and use the results to inform further study.  
10.0 Statistical Analyses 
 Simple descriptive statistics will be used to describe the participant population. Using computer 
statistical software package (SigmaStat V3), parametric statistical testing will be used to assess for 
statistical differences.  Regression analysis will be used to define trends and correlation within the 
data.   
11.0 Anonymisation and Data Management 
All participants will be anonymised and assigned a study number that will be used to identify them in 
all forms of data storage. Tom Powell and/or Dr Paul Neill will be responsible for allocating each 
successfully screened participant a study number. This will be used to identify the participant and 
associated data at all times. Dr Neill will securely hold the master list of patient names and 
corresponding numbers in a locked filing cabinet in his office at the Department of Respiratory 
Medicine.  
Data analysis will be conducted at the University of Glamorgan, by members of the study team. All 
collected data will be kept securely stored both in paper form and electronically on password 
protected computers.  A hard copy of all data will also be securely kept in case of electronic de-
integrity in locked filing cabinets.  Only members of the research team (Section 1.0) will have 
password access to study computers and all paper copies will be kept in filing cabinets in locked 
offices to which only members of the study team will have access. 
12.0 Ethical Considerations 
 All participants will have their breathing profile patterns and functional respiratory endurance 
measured. These are simple, non-invasive tests that have already been ethically approved and 
undertaken in healthy individuals and in patients with COPD. There have been no reported adverse 
events as a result of undertaking these tests and we believe them to be safe to be used in the 
proposed study population.  
 Any participation in research requires those taking part to deviate from their normal routine and that 
doing so will cause them to experience some inconvenience and this study is no different.  
Participants will already be undertaking spirometry as part of routine clinical treatment. Pulmonary 
function tests require maximum effort and co-operation during repeated attempts over a period of 
time. Such a high degree of effort in a relatively short period of time can result in short term fatigue, 
coughing, breathlessness and short duration discomfort, all of which become more pronounced in 
chest disease patients.  
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The 6-minute test we propose is of a sub-maximal, non-volitional nature, in effect the pulmonary tests 
the participants will be undertaking will be a significantly more intense experience than the proposed 
study tests that we liken to breathing at rest. Participants will have the option to halt study tests at any 
point for any reason, however the level of applied resistive load will be such that in our experience it 
would be extremely unlikely for this to occur.   
There are no obvious risks that will result from participation in this study, and we feel that screening 
measures put in place will further reduce any possible causes of harm. No long term side-effects due 
to participation are envisaged or anticipated. 
13.0 Time-scale 
It is expected that from recruitment of the first participant to completion of testing of the last participant 
will be a period of no longer than 12 months. 
14.0 Dissemination of Results 
Findings of this study will be disseminated verbally at national and international scientific meetings 
and in print in scientific peer-reviewed journals. 
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Appendix I – Study Screening Form 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7)
Breathing Energy Expenditure in Chest Disease  
Patients 
Study Screening Form 
 
  1. Inclusion Criteria  
 
  FEV1 _______   pFEV1 ________ 
  FVC _______    pFVC ________ 
  FEV1/FVC _______% 
  GOLD Status 
 
  Current Medication 
  • 
  • 
  • 
  • 
    
  Date of last COPD exacerbation  _________       (more than 12 months?    Yes  /  No) 
 
  Capable of Providing informed Consent       Yes / No 
 
  Able to attend study investigation sessions      Yes / No 
 
  Willing for GP to be informed of participation in study    Yes / No 
 
  Willing to take part in all study measurements      Yes / No 
 
   
  2. Exclusion criteria 
 
  Any history of severe disease co-morbidity?      Yes / No 
 
  Any other serious medical condition?       Yes / No 
 
  Any prescribed medication?         Yes / No 
  (unless associated with COPD disease status) 
 
  Pregnancy?          Yes / No / NA 
 
  Unable to complete 6MWD ?        Yes / No 
V 
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Appendix II – Study Information Sheet 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Breathing Energy Expenditure in Chest Disease Patients 
Study Information Sheet  —  Part 1 
 
You are being invited to take place in a research study, before you decide to participate, it is  
Important for you to read the following information, to understand why the research is being  
undertaken and what is involved. Ask us if there is anything that is not clear or if you would like 
more information. Take time to decide whether you wish to take part. 
What is the purpose of this study 
There are many different tests that measure how your lungs work, many of these require a lot of 
effort and can leave you feeling breathless. We are interested in developing a new technique that 
assesses the endurance capacity of your lungs and how much energy it takes, whilst you are 
breathing in a more relaxed manner. 
 
Why have I been asked to participate? 
You have been asked to participate as you have been referred to the lung function clinic at the 
Royal Glamorgan Hospital. We will be asking approximate 30 other people like yourself to take 
part as well. We think you will be able to complete all the study assessments 
 
Do I have to take part? 
No, taking part is voluntary. It is up to you to decide whether or not to take part. If you do decide 
to take part we will ask you to sign a consent form and give you a copy of this information sheet 
and the consent form to keep.  
 
What will happen to me if I  take part? 
During your visit to the Department of Respiratory Medicine at the Royal Glamorgan hospital for  
assessment of your lung function you will be asked if you want to take part in the study. We will 
answer any questions you may have about the study.  There will only be 1 session as part of 
this study that should take approximately 30-40 minutes to complete. 
 
What will I have to do if I take part? 
If you agree to enter the study you will undertake some breathing tests whilst sitting down. 
These tests are simple to complete and we think you will be able to complete them. 
Department of Respiratory  
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What are the possible disadvantages and risks of taking part? 
During the breathing tests you may become breathless, however this should not last long and will 
soon pass. The breathing tests will be similar to those which you will be doing as part of your visit to 
the lung function clinic. 
 
What are the possible benefits of taking part? 
There are no direct benefits to you from taking part. We hope that study findings will help increase 
our understanding of chest disease and may help in the development of future treatments and care. 
 
What if there is a problem?  
Any complaint about the way in which you have been dealt with during the study or any possible 
harm you might suffer will be addressed. The detailed information on this is given in part 2 of the 
information sheet. 
 
Will my taking part in this study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled in  
confidence. The details are included in part 2 of this information sheet. 
 
Part 2 
What will happen if I don’t want to carry on with the study? 
If you decide to take part you are still free to withdraw at any time. If you decide not to take part you 
do not have to give a reason, nobody will be upset and the standard of care you receive will not be  
affected. 
 
What if there is a problem?  
If you are harmed by taking part in this research project, there are no special compensation  
arrangements. If you are harmed by someone's negligence, then you may have grounds for a legal  
action but you may have to pay for it. Regardless of this, if you wish to complain, or have any  
concerns about any aspect of the way you have been approached or treated during the course of 
this study, the normal National Health Service complaints mechanisms will be available to you. 
 
Will my taking part in this study be kept confidential? 
Yes. You will be anonymised and assigned a study number which will mean you can’t be identified 
in the study results. Additionally if you consent to take part in the research your medical records 
may be inspected by members of the study research team. Your name will not be disclosed outside 
the hospital although, with your permission, your GP will be informed you will be taking part. 
 
 LXXV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
What will happen to the results at the end of the research study? 
The results of the study will be presented to local, national and international medical meetings. The 
results will also be reported in a medical journal, you will not be identified in any of these reports. 
 
Who is organizing and funding this research? 
This study is being led by Dr Paul Neill and sponsored by the Cwm Taf NHS trust. We will not  
receive any payments or funding for including you in this study. 
 
Who has reviewed the study? 
This study has been looked at by an independent group of people, called a Research Ethics  
Committee to protect your safety, rights, wellbeing and dignity. This study has been reviewed and 
given a favorable opinion by the South East Wales Research Ethics Committee. It has also been 
reviewed by the University of Glamorgan and Cwm Taf NHS Trust. 
 
Where can I get independent advice about taking part in research? 
INVOLVE is a national advisory group funded by the Department of Health which aims to  
promote and support active public involvement in NHS, public health and social care research  
INVOLVE was established to promote public involvement in research in order to improve the way 
research is prioritized and commissioned undertaken communicated and used. You can contact  
INVOLVE by: Tel: 02380 651 088, e-mail:admin@invo.org.uk, Post: Involve, Wessex House  
Eastleigh, Hampshire, S050 9FD. 
 
Who do I contact now? 
You will be contacted by a study investigator on arrival at the Lung Function clinic at the Royal 
Glamorgan Hospital, who will ask if you wish to take part. Remember you do not have to take part 
and may withdraw at any time. If you would like to contact a member of the research team to ask 
any questions regarding the study you can conatct Dr Paul Neill (Tel 01443 443 443 ex 3544). 
 
Thank you for taking the time to read the information sheet 
Version 3.2 May 2008 
TP 
 LXXVI 
Appendix III - STUDY CONSENT FORM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
STUDY CONSENT FORM 
 
Cent re Number: 
Study Number: 
Patient Identification Number for this trial: 
 
Title of Project: ‘Breathing Energy Expenditure in Chest Disease  
Patients’. 
                Please initial box 
 
1. I confirm that I have read and understand the information sheet dated May 2008 for 
the above study. I have had the opportunity to consider the information, ask  
2. questions and have these answered satisfactorily.  
   
2.    I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical or legal rights being affected.
  
 
3. I understand that relevant sections of my medical notes and data collected during  
  the study may be looked at  by individuals from regulatory authorities of from the  
  NHS trust where it is  relevant to my taking part in this research. I give permission  
  for these individuals to have access to my records.  
 
4.  I agree to my GP being informed of my participation in the above study  
              
5.  I agree to take part in the above study.       
 
 
 
 
Name of Participant  _____________            Date ___/____/____     Signature ______________ 
   
 
Name of Researcher ______________          Date ___/____/____     Signature ______________ 
 
 
 
1 copy to CRF, 1 copy to be given to participant, 1 copy to 
patients GP, Original to patients notes 
 
V3 .2 May 2008 
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Appendix IV    GP Letter 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dear Dr     
 
Re:  
 
Address:   
 
Your patient is taking part in a pilot study to investigate breathing energy expenditure in 
chest disease patients using a new method of generating constant resistive breathing 
loads. 
 
If you have any questions please do not hesitate to contact Dr Paul Neill at the Department 
of Respiratory Medicine tel: 01443 443 443 ext 3544.               . 
 
 
Many thanks 
 
Yours sincerely 
 
 
 
 
 
Dr Paul Neill    Tom Powell 
 
 
 
 
 
 
 
V1 November 2007 
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Appendix V Study Questionnaires 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MRC DYSPNOEA SCALE 
 
 
Subject ID _____   Date ___/____/____ 
 
 
1, “I only get breathless with strenuous exercise” 
 
 
 
 2, “I get short of breath when hurrying on the level or up a slight hill” 
 
 
3,  “I walk slower than people of the same age on the level because of  
 Breathlessness or have to stop for breath when walking at my own pace  
 on the level”  
 
 
 
4,  “I stop for breath after walking 100 yards or after a few minutes on the  
 level” 
 
 
 
5,  “ I am too breathless to leave the house” 
 
 
 
 
 
 
 
 
 
 
 
 
 
MRC dyspnea score V1 November 2007 TP 
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ST.GEORGE’S RESPIRATORY QUESTIONAIRE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Study Number: 
 
 
 
  Date: 
 
 
  Symptom Score: 
 
  Activities Score: 
 
  Impact Score: 
 
  Total Score: 
 
V2 May2008 
Department of Respiratory  
Medicine 
Cwm Taf NHS Trust 
  
  
 University of Glamorgan 
Faculty of Health, Sport and Science 
  
 
Dr Paul Neill  
Tel: 01443 443 443 ext.3544 
E-mail: Paul.Neill@pr-tr.wales.nhs.uk 
  Tom Powell  
Tel: 01443 483084 
E-mail: tpowell@glam.ac.uk 
  
 LXXX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Version 2 May 2008 
Part 1 
 
 
 
 
 
 
 
 Most 
days 
a 
week 
Several 
days a 
week 
A few 
days a 
month 
Only with 
chest 
infections 
Not 
at 
all 
1.Over the last month, I have 
coughed: 
     
2. Over the last month, I have 
brought up phlegm (sputum): 
     
3. Over the last month, I have had 
shortness of breath: 
     
4. Over the last month, I have had 
attacks of wheezing: 
     
 
5. During the last year, how many 
severe or very unpleasant attacks of 
chest trouble have you had: 
 
More than 3 attacks……………………. 
3 attacks………………………………… 
2 attacks………………………………… 
1 attack………………………………….. 
no attacks………………………………. 
6. How long did the worst attack of 
chest trouble last: (go to question 7 if 
you had no severe attacks) 
A week or more………………………… 
3 or more days…………………………. 
1 or 2 days………………………………. 
Less than a day………………………… 
7. Over the last year, in an average 
week, how many good days (with 
little chest trouble) have you had: 
None…………………………………….. 
1 or 2……………………………………. 
3 or 4…………………………………….. 
nearly every day………………………… 
every  day……………………………….. 
8. If you have a wheeze, is it worse in 
the morning: 
Yes……………………………………… 
No……………………………………….. 
 
These are questions about how much chest trouble you have had over the last 
month of the year. 
 
Please mark the appropriate box by filling in the box with a thick pencil line. 
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How would you describe your chest condition: 
the most important problem I have………………………………. 
 
causes me quite a lot of problems……………………………….. 
 
causes me a few problems……………………………………….. 
 
causes no problems……………………………………………….. 
 
If you ever had paid employment, please mark one of these: 
 
my chest trouble made me stop work………………………….. 
 
my chest trouble interferes with my work or made me change my work……. 
 
My chest trouble does not affect my work……………………… 
 
SECTION 2 
Questions about what activities usually make you feel breathless.  Please mark 
each question TRUE (T) or FALSE (F) as applies to you these days: 
            
sitting or lying still…………………………………………….. 
 
getting washed or dressed………………………………….. 
 
walking around the home…………………………………… 
 
walking outside on the level………………………………… 
 
walking up a flight of stairs…………………………………. 
 
walking up hills………………………………………………. 
 
playing sports or games……………………………………. 
 
SECTION 3 
Some more questions about your cough and breathlessness.   
Please mark each questions TRUE (T) or FALSE (F) as applies to you these 
days: 
    
my cough hurts………………………………………………. 
 
my cough makes me tired………………………………….. 
 
I am breathless when I talk…………………………………. 
 
I am breathless when I bend over………………………….. 
 
my cough or breathing disturbs my sleep…………………. 
 
I get exhausted easily………………………………………… 
T      F 
T      F 
PART 2 
Please mark the appropriate box by filling in the box with a thick pencil line 
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SECTION 4 
Questions about other effects that your chest trouble may have on you. 
Please mark each question TRUE (T) or FALSE (F) as applies to 
 you these days: 
 
my coughing or breathing is embarrassing in public……… 
  
my chest trouble is a nuisance to my family, friends or neighbours…. 
 
I get afraid or panic when I cannot get my breath…………. 
 
I feel that I am not in control of my chest problems……….. 
 
I do not expect my chest to get any better…………………. 
 
I have become frail or an invalid because of my chest……. 
 
exercise is not safe for me……………………………………. 
 
everything seems too much of an effort……………………… 
 
SECTION 5 
Questions about your medication.  If you are receiving no medication 
go straight to Section 6. 
 
my medication does not help me very much………………… 
 
I get embarrassed using my medication in public…………... 
 
I have unpleasant side effects from my medication………… 
my medication interferes with my life a lot…………………… 
  T       F 
   T      F 
SECTION 6 
These are questions about how your activities might be affected by 
your breathing.  Please mark each question TRUE (T) or FALSE (F) 
which  
you think applies to you because of your breathing. 
 
I take a long time to get washed or dressed………………….  
 
I cannot take bath or shower, or I take a long time………….. 
 
I walk slower than other people, or I stop for rests…………. 
 
jobs such as housework take a long time, or I have to stop for rests 
 
if I walk up one flight of stairs, I have to go slowly or stop…… 
 
if I hurry or walk fast, I have to stop or slow down…………… 
 
my breathing makes it difficult to do such as 
walk up hills, carrying things up stairs, light gardening 
such as seeding, dance, play bowls or play golf…………….. 
 
   T      F 
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SECTION 6 (cont…) 
my breathing makes it difficult to do things such as 
carry heavy loads, dig the garden or shovel snow, 
jog or walk at 5 miles per hour, play tennis or swim…………. 
 
my breathing makes it difficult to do things such as 
very heavy manual work, run, cycle, swim fast 
or play competitive sports………………………………………. 
 
SECTION 7 
We would like to know how your chest usually affects your daily life.  
Please mark each question TRUE (T) or FALSE (F) which you  
think applies to you because of your chest trouble: 
 
I cannot play sport or games…………………………………… 
 
I cannot go out for entertainment or recreation………………. 
 
I cannot go out of the house to do the shopping……………… 
 
I cannot do housework…………………………………………… 
 
I cannot move far from my bed or chair………………………… 
 
Here is a list of other activities that your chest trouble may prevent you 
doing: (You do not have to tick these, they are just to remind you of 
ways in which your breathlessness may affect). 
 
•  going for walks or walking the dog  •  doing things at home or in the  
•  sexual intercourse    garden 
•  going out to church, or place of entertainment 
•  going out in bad weather or into smoky rooms 
•  visiting family or friends or playing with children 
 
Please write in any  important activities (such as those above or others) 
that your chest trouble may stop you doing: 
 
…………………………………………………………………………………………
…………………………………………………………………………………………
Now, would you mark the bracket below (only one) which you think best 
describes how your chest affects you: 
It does not stop me doing anything I would like to do…………… 
 
It stops me doing one or two things I would like to do………….. 
 
It stops me doing most of the things I would like to do…………. 
 
It stops me doing everything I would like to do………………….. 
     T       F 
        T      F 
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